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ABSTRACT 
The purpose of the dissertation was to characterize the adaptive changes in 5-
HT 1A receptors induced by repeated injections of 5-HT uptake inhibitors. Hormones 
released in response to 5-HT1A agonists were used as markers to determine the function 
of hypothalamic 5-HT1A receptors. The density of 5-HT1A receptors, their coupling to 
G proteins and the levels of Gi and G0 proteins were examined. Daily injections of 5-
HT uptake inhibitor fluoxetine for three weeks significantly reduced the ACTH, 
corticosterone and oxytocin responses to the 5-HT1A agonists 8-0H-DPAT and 
ipsapirone. In contrast, daily injections of desipramine or acute injection of fluoxetine 
did not alter the hormone responses to 5-HT1A agonists. Fluoxetine injections did not 
reduce the affinity or density of 5-HT1A receptors in the hypothalamus. An examination 
of the time-course of the effect of fluoxetine and paroxetine revealed that both drugs 
produce a gradual reduction in the ACTH, corticosterone and oxytocin responses to 8-
0H-DPAT. The reduction in hormone responses to 8-0H-DPAT appeared after three 
days and reached a maximum after seven to fourteen daily of injections. No change 
was observed in the density of 5-HT1A receptors and in their G protein coupling in the 
hypothalamus or in other brain regions after daily injections of fluoxetine or paroxetine. 
The time course of both drugs in reducing the hypothalamic level of Gi3 proteins was 
similar and parallel to the time course of the decrease in the hormone responses to 8-
xv 
OH-DPAT. This similarity suggests that the reduction in the level of Gi3 proteins may 
be involved in the desensitization of hypothalamic 5-HT1A receptors. In conclusion, our 
results suggest that prolonged blockade of 5-HT uptake sites, but not of norepinephrine 
uptake sites, produces a delayed and gradual desensitization of hypothalamic 5-HT1A 
receptors. This desensitization may be mediated by alterations in signal transduction 
mechanisms of 5-HT1A receptors in the hypothalamus. 
xvi 
CHAPTER I 
INTRODUCTION 
Selective serotonin (5-HT) reuptake inhibitors (SSRI's), such as fluoxetine 
(Prozac®), fluvoxamine (Luvox®), paroxetine (Paxil®), sertraline (Zoloft®) and 
citalopram are widely used to treat affective disorders, including depression, 
premenstrual disorder, obsessive compulsive disorder, bulimia/anorexia nervosa and 
anxiety (Advokat and Kutlesic, 1995; Wong et al.1995; Lam et al.1995; Tollefson et 
al.1994; Lecrubier, 1993; Sternlicht, 1993). Serotonin reuptake is the principal process 
responsible for terminating the action of 5-HT at post-synaptic receptors. By inhibiting 
the uptake of 5-HT into the nerve terminals, SSRI's act to increase the 5-HT 
concentration in the synaptic cleft. However, since there is a delay of about 14-21 days 
in clinical improvement after the initiation of SSRI administration, the therapeutic 
effects of these drugs may be mediated by adaptive changes in serotonergic 
neurotransmission, initiated by the inhibition of 5-HT uptake sites (Blier and de 
Montigny, 1994; Montgomery, 1994; Briley and Moret, 1993; Richelson, 1991). It has 
been suggested that dysfunction of 5-HT1A receptor systems may contribute to the 
etiology of affective disorders (Lesch et al.1992c; Lesch et al.1991b; Lesch, 1991). 
Furthermore, it has been hypothesized that somatodendritic 5-HT1A receptors are 
involved in the delay of the onset of clinical improvement after treatment with SSRI's 
(Gardier et al.1996; Briley and Moret, 1993). Therefore, studying the effect of 5-HT 
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uptake inhibitors on the 5-HT1A receptor system can contribute to the understanding and 
improvement of the therapeutic effects of 5-HT uptake inhibitors. 
5-HT IA receptors can be classified into somatodendritic 5-HT IA receptors 
(autoreceptors) and postsynaptic 5-HT1A receptors. Somatodendritic 5-HT1A 
autoreceptors are located on serotonergic perikarya in the dorsal and median raphe 
nuclei in the midbrain (Le Poul et al.1995; Kreiss and Lucki, 1992). These 5-HT1A 
autoreceptors function as a negative feedback mechanism. Activation of 5-HT1A 
autoreceptors in the raphe decreases the firing rate of 5-HT neurons and, subsequently, 
reduces 5-HT release from their nerve terminals in the forebrain (Kreiss and Lucki, 
1995; Kreiss and Lucki, 1992). Postsynaptic 5-HT1A receptors are widely distributed 
in the brain and are located on neurons that are innervated by serotonergic pathways 
(Khawaja, 1995; Kung et al.1995; Wright et al.1995). The function of postsynaptic 5-
HT1A receptors is related to the function of target cells. For example, activation of 5-
HT1A receptors in the hypothalamus increases the secretion of ACTH, corticosterone 
and oxytocin (Fletcher et al.1996; Critchley et al.1994a; Van de Kar and Brownfield, 
1993; Gilbert et al.1988a; Bagdy and Makara, 1994; Bagdy and Kalogeras, 1993). 
Therefore, hormone responses to 5-HT1A agonists can be used as a peripheral marker 
of the functional status of hypothalamic 5-HT1A receptor systems. Somatodendritic 5-
HT1A receptors are more sensitive to 5-HT1A agonists than the postsynaptic 5-HT1A 
receptors. The doses of 5-HT1A agonists (such as 8-0H-DPAT, ipsapirone or 
buspirone) that activate somato-dendritic autoreceptors to suppress the firing rate of 
dorsal raphe neurons are about 10-fold lower (Hjorth and Magnusson, 1988; Sprouse 
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and Aghajanian, 1988; Aghajanian et al.1990), than the doses that activate post-synaptic 
hypothalamic 5-HT1A receptors and increase the secretion of hormones such as ACTH 
(Pan and Gilbert, 1992) or oxytocin (Bagdy and Kalogeras, 1993). 
Several investigators have hypothesized that long-term exposure to 5-HT uptake 
inhibitors will first desensitize somatodendritic 5-HT1A autoreceptors, leading to 
increase release of 5-HT in the forebrain, and subsequently desensitize postsynaptic 5-
HT1A receptors (Le Poul et al.1995; Bel and Artigas, 1992; Blier and Bergeron, 1995; 
Blier and de Montigny, 1994). Inhibition of 5-HT uptake sites results in an increase 
of concentration of 5-HT in the synaptic cleft, thereby activating 5-HT1A receptors. 
Since 5-HT1A autoreceptors are more sensitive to the increase of 5-HT concentration 
than postsynaptic 5-HT1A receptors, the 5-HT1A autoreceptors are predominantly 
activated after administration of 5-HT uptake inhibitors. The activation of 5-HT1A 
autoreceptors will decrease the firing rate of 5-HT neurons and subsequently reduce the 
release of 5-HT from serotonergic nerve terminals (Arborelius et al.1995; Gartside et 
al.1995). Therefore, although forebrain 5-HT uptake sites are still blocked during this 
period, the concentration of 5-HT in forebrain synaptic clefts would not be increased. 
Following repeated administration of SSRI's, somatodendritic 5-HT1A receptors are 
desensitized by consistent increase of 5-HT concentration in the presynaptic cleft of 5-
HT neurons. The desensitization of somatodendritic 5-HT1A autoreceptors would 
eventually free 5-HT neurons; firing would be resumed and 5-HT release would return 
to normal. Since forebrain 5-HT uptake sites are still inhibited by 5-HT uptake 
inhibitors, the concentration of 5-HT in the postsynaptic cleft would increase and induce 
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desensitization of postsynaptic 5-HT1A receptors, such as hypothalamic 5-HT1A 
receptors. If this hypothesis is correct, then repeated injections of fluoxetine would 
produce a delayed and gradual reduction in the function of hypothalamic 5-HT1A 
receptors. Several investigators have provided evidence that 5-HT uptake inhibitors 
first produce inhibition of the firing rate of 5-HT neurons and decrease the release of 
5-HT in the forebrain, followed by desensitization of somatodendritic 5-HT1A 
autoreceptors in the dorsal raphe nucleus as early as 3 days after administration of 5-HT 
uptake inhibitors (Le Poul et al.1995). However, very little is known regarding the 
onset of desensitization of postsynaptic 5-HT1A receptors after repeated injections of 5-
HT uptake inhibitors. 
5-HT1A receptors are coupled to G0 and/or Gi proteins (Raymond et al.1993; 
Fargin et al.1991; Sprouse and Aghajanian, 1988; Emerit et al.1990). Somatodendritic 
5-HT1A autoreceptors in the raphe nuclei are coupled to G0 proteins, which increase the 
opening of K+ channels (Sprouse and Aghajanian, 1988). Activation of 5-HT1A 
receptors that are coupled to Gi proteins inhibits the activity of adenylyl cyclase and 
consequently decrease the intracellular concentration of cAMP (cyclic adenosine 
monophosphate) (Varrault et al.1994). 5-HT lA receptors have high affinity for Gi 
proteins with the rank order of affinity being Gi3 > Gil > Gi2 > G0 proteins (Raymond 
et al.1993). Most of the studies having investigated the coupling of 5-HT1A receptors 
to G proteins, however, were conducted in cells in culture transfected with expressing 
cloned 5-HT1A receptors and G proteins. Little is known about specific G proteins that 
are involved in specific 5-HT1A receptor-mediated functions in vivo. For example, it 
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is still unclear which G proteins mediate 5-HT1A receptor-induced increases of ACTH 
and oxytocin secretion and 5-HT1A receptor-inducted hypothermia. 
The purpose of the present project was to investigate adaptive changes in the 
hypothalamic 5-HT1A receptor systems induced by daily injections of 5-HT uptake 
inhibitors. The hypothesis was that daily injections of 5-HT uptake inhibitors produce 
a delayed and gradual desensitization of the hypothalamic 5-HT1A receptors. This 
desensitization may be mediated by alterations in the signal transduction of 5-HT1A 
receptors. Three specific aims were designed to address the hypothesis. First, to 
examine whether long-term fluoxetine and desipramine influence 5-HT1A receptor 
systems. Fluoxetine is a widely used SSRI, while desipramine is a norepinephrine 
uptake inhibitor and a tricyclic antidepressant. Comparing the effect of fluoxetine with 
desipramine on 5-HT1A receptors allowed us to understand whether the effects of 
fluoxetine are unique to SSRI's. In addition, the effects of acute fluoxetine on the 5-
HT lA receptors were examined in order to determine whether the effects of fluoxetine 
are mediated by the long-term administration. Secondly, the time-course of the effects 
of fluoxetine on 5-HT1A receptor systems was determined. If 5-HT1A autoreceptors play 
a role in the delay of therapeutic effects of SSRI's, daily injections of 5-HT uptake 
inhibitors should produce a delayed, gradual alteration in postsynaptic 5-HT1A receptors 
in the hypothalamus. Finally, I determined whether the effects of fluoxetine on the 5-
HT1A receptors are mediated by the blockade of 5-HT uptake sites by examining the 
time-course of effects of paroxetine on the hypothalamic 5-HT1A receptors and 
comparing these effects with those observed in the fluoxetine study. Paroxetine is 
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another 5-HT uptake inhibitor with a different chemical structure from fluoxetine. It 
has a higher affinity for 5-HT uptake sites, shorter half-life than fluoxetine, and no 
active metabolites (Nemeroff, 1993). Therefore, if the effects of paroxetine on the 5-
HT1A receptors are similar to those induced by fluoxetine, one can conclude that the 
alterations in the 5-HT1A receptors induced by daily injections of fluoxetine or 
paroxetine are mediated by the sustained blockade of 5-HT uptake sites. The following 
biochemical and functional parameters of 5-HT1A receptors examined to achieve these 
aims. 1) Hormone responses to 5-HT1A agonists were used as functional markers of 5-
HT1A receptors. 2) The density of 5-HT1A receptors and their coupling to G proteins 
in the rat brain were measured using homogenate or autoradiographic analysis of 3H-8-
0H-DPAT binding. 3) Gil, Gi2, Gi3 and G0 proteins, which are coupled to 5-HT1A 
receptors, were examined by immunoblots. 
CHAPTER II 
REVIEW OF RELATED LITERATURE 
Serotoner1:ic Systems 
General review of serotonergic systems 
Serotonergic pathways are important neurotransmitter systems in the central 
nervous system. Serotonin neurons, projecting their axons to the forebrain, are located 
in the dorsal and median raphe nuclei and in the ventrolateral B9 cell group in the brain 
stem. The distribution of serotonergic projections from the dorsal and median raphe 
are different. For example, the striatum mainly receives projections from the dorsal 
raphe, while the hippocampus receives projections from the median raphe (Bonvento 
et al.1992; Kreiss and Lucki, 1994). The serotonin neurons in both median and dorsal 
raphe nuclei project to the hypothalamus, cortex and amygdala (Van de Kar and 
Lorens, 1979; Sawchenko et al.1983; Petrov et al.1992). On the other hand, 5-HT 
neurons in the raphe nuclei receive 5-HT input from 5-HT axon collaterals or dendro-
dendritic junctions, which is related to feedback regulation of 5-HT release (Wang and 
Aghajanian, 1978; Wang and Aghajanian, 1977). 
Serotonin neurons synthesize serotonin from tryptophan, an essential amino acid. 
The key enzyme for the synthesis of 5-HT is tryptophan hydroxylase, which converts 
tryptophan to 5-hydroxytryptophan (5-HTP). 5-HTP is decarboxylated to 5-HT by 
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aromatic L-amino acid decarboxylase. Serotonin is then transported to serotonergic 
terminals through axons and stored in vesicles in the nerve terminals. When 5-HT 
neurons are activated, the firing rate of the neurons is increased, resulting in 5-HT 
release from nerve terminals to the synaptic cleft. In the synaptic cleft, 5-HT can bind 
to and stimulate 5-HT receptors, resulting in physiological responses. 5-HT, in the 
synaptic cleft, can also be taken back into the nerve terminal via 5-HT uptake sites (i.e. 
5-HT transporters), which are located on the membrane of nerve terminals. In the 
nerve terminals, 5-HT can be restored in the vesicles or metabolized in the 
mitochondria to 5-HIAA (5-hydroxyindole acetic acid) by monoamine oxidase (MAO). 
5-HT receptors are located on pre- or postsynaptic membranes. To date at least 
fifteen types of 5-HT receptors have been found by receptor-cloning studies (Hoyer et 
al.1994). The 5-HT receptors are classified into 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5 , 
5-HT6 and 5-HT7 receptors (Saxena, 1995; Hoyer et al.1994). Among them, 5-HT1 
receptors are subclassified to 5-HT1A, 5-HTrn, 5-HT10, 5-HTrn, and 5-HT1F receptors. 
5-HT2 receptors are subclassified to 5-HT2A, 5-HT28 and 5-HT2c receptors. 5-HT2A 
(previously 5-HT2) receptors and 5-HT2c (previously 5-HT1c) receptors have similar 
structures and few agonists or antagonists can distinguish between them. However, 5-
HT2c receptors have a higher affinity for 5-HT than 5-HT2A receptors. Also, 5-HT2c 
receptors are abundant in the choroid plexus. 5-HTrn and 5-HT10 receptors are 
autoreceptors. They are located in the nerve terminals and function as feedback 
regulators of 5-HT release. 5-HTrn receptors are found in rodent species, such as rats 
and mice, while 5-HT10 receptors are located in non-rodent mammalian species, such 
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as guinea pig, pig, calf, rabbit, dog, monkey and human. The distribution of 5-HTrn 
and 5-HTrn receptors in the brain is similar. Therefore, it is believed that 5-HTrn and 
5-HT10 receptors play the same role in the different species. Except for 5-HT3 
receptors which are cation channel-ligand gated receptors, all other 5-HT receptors are 
G protein-coupled receptors. 5-HT1 receptors have a high affinity for 5-HT and are 
coupled to Gi proteins, which inhibit adenylyl cyclase. Beside Gi proteins, 5-HT1A 
receptors also couple to G0 proteins that increase opening of potassium channel and 
inhibit the opening of Ca2+ channel. Except for 5-HT2c receptors, 5-HT2 receptors 
have relative lower affinity for 5-HT. Stimulation of 5-HT2 receptors will activate 
phospholipase C and, consequently increase the hydrolysis of inositol phospholipid to 
inositol triphosphate (IP3) and diacylglycerol (DAG). DAG induces Ca2+ mobilization, 
which in tum activates protein kinase C, while IP3 activates calmodulin-dependent 
protein kinase. 5-HT4 , 5-HT6 and 5-HT7 receptors are positively linked to adenylyl 
cyclase. The signal transduction system of 5-HT5 is still unknown. Except for 5-HTrn 
and 5-HT 10 receptors that are located presynaptically, all other 5-HT receptors are 
located on postsynaptic membranes. Thus, their physiological functions are related to 
the function of the target cells. Physiological functions of 5-HTrn, 5-HT1p, 5-HT5 , 5-
HT6 and 5-HT7 receptors remain unknown. These 5-HT receptors were identified from 
cloned cDNA. Due to the lack of selective agonists and antagonists, few studies have 
been reported regarding their distribution and functions in the tissue of intact animals 
or humans. 
In conclusion, serotonergic systems are involved in many regulatory processes 
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and play important roles in maintaining normal life. On the other hand, serotonergic 
systems are very complicated systems and very little is known about the systems. The 
present dissertation is focused on the effects of SSRI's on 5-HT1A receptors. In the 
following review, I will expand the discussion on the 5-HT1A receptor systems. 
5-HT iA receptor systems 
Structure and function 
5-HT1A receptors belong to the G protein-coupled receptor family. Like other 
receptors in this family, 5-HT1A receptors contain seven hydrophobic transmembrane 
domains, which are highly conserved with other G protein-coupled receptors, such as 
B2 adrenergic receptors (Raymond et al.1992). The connections of these seven 
membrane-spanning domains form three extracellular loops (ol-o3) and three 
intracellular loops (il-i3). The N-terminal of 5-HT1A receptors faces the membrane 
surface and the C-terminal is in the cytoplasm. The intracellular features of 5-HT1A 
receptors are similar to other cloned receptors which couple to Gi proteins, such as a 
long i3 loop and a short C terminal tail. These features are different from the receptors 
coupled to Gs or Gq proteins, such as the B2 and 5-HT2A12c receptors, suggesting that the 
i3 loop and C terminus may be involved in the coupling of 5-HT1A receptors to their 
G proteins. Few studies on the function of 5-HT1A receptor domains in term of ligand 
binding and G protein coupling have been reported. Aspartate at positions 82 and 116 
(Asp86 and Asp116), asparagine at position 396 (Asn396) and serine at position 393 (Ser393) 
may be important for ligand binding (Chanda et al.1993; Raymond et al.1992). Asp86 
and Asp116 are located in transmembrane domain II and III respectively and Asn396 and 
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Ser393 are in transmembrane region VII. Except for these residues, the transmembrane 
IV domain may also play a role in the binding of ligands to 5-HT1A receptors (Chanda 
et al.1993). It is interesting that about 70% of amino acids in transmembrane VI of 5-
HT1A receptors are identical to those in B receptors, suggesting that this domain may 
be related to the binding property of B antagonists to 5-HT1A receptors. Although 5-
HT1A receptors do not contain the sequence for phosphorylation by protein kinase A, 
at least 3 potential phosphorylation sites for protein kinase C have been found in the 5-
HT1A receptor. They are located in the i2 and i3 loops. These sequences may be the 
target for protein kinase C and induce a phosphorylation of 5-HT1A receptors, which 
would consequently produce a desensitization of 5-HT1A receptors (Nebigil et al.1995; 
Raymond and Olsen, 1994; van Huizen et al.1993; Raymond, 1991). Furthermore, two 
cysteine residues in the C terminus of 5-HT1A receptors may be palmitoylated, which 
is one of the post-translational modifications that may modify the coupling of receptors 
to their G proteins (Raymond et al.1992). 
5-HT1A receptors have been classified into somatodendritic and postsynaptic 
receptors (Hoyer and Boddeke, 1993; Blier et al.1993a; Blier et al.1993b). The 
somatodendritic 5-HT1A receptors (5-HT1A autoreceptors) are located on serotonin 
neurons in the dorsal and median raphe nuclei and receive serotonergic input from 
recurrent collaterals or from other raphe neurons (Wang and Aghajanian, 1978; Wang 
and Aghajanian, 1977; Sotelo et al.1990). The somatodendritic 5-HT1A receptors 
function as feedback regulators of 5-HT release from nerve terminals. When 5-HT 
neurons are activated, the firing rate of the neurons is increased, resulting in an 
12 
increase of 5-HT release from nerve terminals and recurrent collaterals. The increased 
concentration of 5-HT in the synaptic cleft of serotonin neurons activates 
somatodendritic 5-HT lA receptors. Consequently, the activation of somatodendritic 5-
HT 1A receptors inhibits the firing rate of 5-HT neurons and reduces 5-HT release from 
serotonergic nerve terminals (Hjorth and Sharp, 1991; Hjorth and Magnusson, 1988; 
Bonvento et al.1992). Furthermore, activation of somatodendritic 5-HT1A receptors 
inhibits 5-HT synthesis in 5-HT neurons (Hjorth and Magnusson, 1988; Sharp et 
al.1993). 
Postsynaptic 5-HT1A receptors are located on target cells in most forebrain 
regions. The functions of postsynaptic 5-HT1A receptors are related to the target cells. 
For example, 5-HT lA receptors in the ventromedial nucleus of the hypothalamus (VMN) 
may be involved in sexual behavior (Uphouse et al.1994a; Uphouse et al.1994b; 
Mendelson and Gorzalka, 1986), and 5-HT1A receptors in the hippocampus may play 
a role in the feedback regulation of corticosteroid secretion (Burnet et al.1992; Lopez 
et al.1993; Zhong and Ciaranello, 1995; Chalmers et al.1993). As will be discussed 
later, 5-HT1A receptors in the paraventricular nucleus of the hypothalamus may be 
involved in the regulation of ACTH, corticosterone and oxytocin secretion (Bagdy, 
1995; Bagdy and Makara, 1994). 
The density of 5-HT1A receptors varies among brain regions. The distribution 
of 5-HT1A receptors in the brain has been studied using autoradiographic analysis of 
radioligand binding (Gozlan et al.1995; Khawaja, 1995; Le Poul et al.1995; Frankfurt 
et al.1994; Radja et al.1992; Dillon et al.1991; Hensler et al.1991; Marlier et al.1991; 
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Sijbesma et al.1991; Welner et al.1989; Palacios et al.1987) and immunocytochemistry 
(Kia et al.1996). The hippocampus, septum and dorsal raphe contain the highest 
density of 5-HT1A receptors, while the caudate putamen contains few 5-HT1A receptors. 
Most of the studies on the autoradiography of 5-HT1A receptors have focused on the 
hippocampus and raphe nuclei. Very little is known regarding the distribution of 5-
HT lA receptors in the hypothalamus. A few investigators (Hensler et al .1991 ; Palacios 
et al.1987; Sijbesma et al.1991) have examined the density of 5-HT lA receptors in the 
hypothalamus, but only within a few nuclei, such as the ventromedial nucleus, 
dorsomedial nucleus and lateral hypothalamus. So far, the distribution of 5-HT1A 
receptors in subdivisions of nuclei in the hypothalamus and amygdala has not been 
reported. 
Several studies have compared the map of 5-HT1A receptors and the encoding 
mRNA of 5-HT1A receptors (Miquel et al.1991; Chalmers and Watson, 1991; 
Pompeiano et al.1992; Wright et al.1995; Raghupathi et al.1996). Generally, the 
distribution of 5-HT1A receptors is consistent with their mRNA expression. A recent 
study (Raghupathi et al.1996) showed that inactivation of 5-HT1A receptors by a high 
dose (10 mg/kg), but not by low doses (0.1and1 mg/kg) of EEDQ (N-ethoxycarbonyl-
1,2-ethoxydihydroquinoline) induced an increase of 5-HT1A receptor mRNA within 12 
hours after injection. mRNA levels returned to normal, when the density of the 
receptors recovered. However, the magnitude of the increase of mRN A varied between 
brain regions, whereas reduction of the density of 5-HT1A receptors was similar among 
brain regions. Also, less than 503 inactivation of 5-HT1A receptors did not alter the 
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level of 5-HT1A receptor mRNA. These results suggest that changes in the 5-HT1A 
receptor mRNA may not be an exclusive mechanism of regulation of the density of 5-
HT1A receptors, especially when a modest change in the density of 5-HT1A receptors 
occurs. 
Signal transduction of 5-HT iA receptors 
5-HT1A receptors are G protein-coupled receptors. According to the model 
proposed by Lefkowitz et al. (1976), G protein-coupled receptors exist in high 
(coupled) and low (uncoupled) affinity states with respect to agonists. Agonists only 
bind to receptors in high affinity states, while antagonists bind to both high and low 
affinity state receptors. The coupled receptor-G protein configuration only exists while 
GDP (Guanosine diphosphate) is bound to the a-subunit of the G protein. When an 
agonist binds to receptors, the GDP on the G proteins coupled to the receptors will be 
exchanged with GTP (Guanosine triphosphate) due to changes in the conformation of 
the receptors. The replacement of GDP with GTP on the a-subunit of G proteins 
results in a dissociation of the G proteins from the receptors, which consequently 
switches the receptors from a high affinity-state to a low affinity-state. The dissociated 
G proteins are then further dissociated into a and B'Y subunits. The a subunits activate 
a second messenger system, such as adenylyl cyclase and phospholipase C, which in 
turn activates the effectors and produces a physiological response. The a subunits are 
then inactivated by hydrolysis of the GTP into GDP via its intrinsic GTPase. The 
GDP-bound a subunits will finally reassociate with the fJ'Y subunits and couple to 
receptors. 
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To date, about 20 G proteins have been identified and have been divided into 4 
classes (Hamm and Gilchrist, 1996) based on their a subunit, Gs, Gi, Gq and G12• Gs 
proteins include Gs and G01f proteins. They activate adenylyl cyclase. Gi proteins 
include Gil• Gi2 , Gi3 , G01 , G02 , Gz, Ggust and Gr proteins. Some of them (Gil• Gi2, Gi3 
and Gz) inhibit adenylyl cyclase. G0 proteins increase the opening of potassium 
channels and decrease the opening of calcium (Ca2+) channels. Except for Gz proteins, 
all Gi proteins are pertussis toxin-sensitive, i.e pertussis toxin inactivates the Gi proteins 
via ADP-ribosylation. Most of the Gq proteins (Gq, G11 , G14 and G15) stimulate 
phospholipase C and increase the intracellular concentration of inositol triphosphate and 
diacylglycerol. 
Stimulation of hippocampal 5-HT1A receptors with 5-HT agonists inhibits 
forskolin-stimulated adenylyl cyclase activity (Yocca and Maayani, 1990; De Vivo and 
Maayani, 1986). This inhibitory effect of 5-HT1A receptors can be blunted by pertussis 
toxin, which selectively inactivates Gi and G0 proteins by ADP-ribosylation (Clarke et 
al.1987). These results suggest that hippocampal 5-HT1A receptors are coupled to Gi 
proteins. On the other hand, activation of 5-HT1A autoreceptors in the dorsal raphe 
does not inhibit forskolin-stimulated adenylyl cyclase activity (Yocca and Maayani, 
1990; Clarke et al. 1990; Clarke et al. 1996), but does increase the opening of potassium 
channels, resulting in a hyperpolarization of 5-HT neurons (Sprouse and Aghajanian, 
1988). This inhibitory effect of 5-HT1A agonists on cell firing and 5-HT release can 
also be blocked by pertussis toxin (Innis and Aghajanian, 1987; Innis et al.1988; 
Romero et al.1994). These results suggest that 5-HT1A autoreceptors in the raphe are 
16 
coupled to G0 proteins. From these results, it is believed that 5-HT1A receptors are 
coupled to Gi or G0 proteins. However, it is still unclear which particular Gi or G0 
proteins are coupled to 5-HT1A receptors in specific cells, since at least three Gi and two 
G0 proteins have been identified (Bimbaumer, 1993). Also, it cannot be ruled out that 
other G proteins, such as Gz or Gq proteins could couple to 5-HT1A receptors, since 5-
HT1A receptors are located on different cells and are involved in different functions. 
However, it is difficult to study these questions in intact animals, since living cells are 
very complex and contain several different G proteins. Thus, most molecular biologic 
studies on the G protein-coupling of 5-HT1A receptors are performed using the 
expressional cloned 5-HT1A receptors in a receptor-free cell line that does not naturally 
contain the 5-HT1A receptors. 
Using co-expressed human 5-HT1A receptors and G proteins in Hela and CHO-
Kl cells, Raymond et al. (1993; 1994) found that 5-HT1A receptors have a high affinity 
for Gi and G0 proteins. The rank order of the affinity for 5-HT1A receptors is Gi3 > 
Gi1 > Gi2 > G0 proteins (Raymond et al.1993; Mulheron et al.1994; Bertin et al.1992). 
Gs proteins do not seem to couple to 5-HT1A receptors (Raymond et al.1993; Bertin et 
al.1992; Butkerait et al.1995). These findings are consistent with biochemical and 
electrophysiological results that 5-HT1A receptors are coupled to Gi and/or G0 proteins. 
However, in reconstituted cells, Gz protein, a pertussis toxin-insensitive member of the 
Gi protein family, also strongly increases 3H-8-0H-DPAT binding (Butkerait et 
al.1995), suggesting that Gz proteins may be coupled to 5-HT1A receptors. In addition, 
in different receptor-negative cell lines, transfected 5-HT1A receptors express different 
17 
functions. For example, 5-HT1A receptors transfected into pituitary GH4 cells inhibit 
the activity of adenylyl cyclase, increasing the opening of potassium channels and 
closing calcium channels, but having no effect on phospholipase C. However, in Ltk 
fibroblast cells (L cells), transfected 5-HT1A receptors not only inhibit adenylyl cyclase, 
but also stimulate phospholipase C and increase phosphoinositide turnover (Albert et 
al.1996; Liu and Albert, 1991). Since all responses to 5-HT1A agonists in both cell 
lines can be blocked by pertussis toxin, it is unlikely that 5-HT1A receptors in L cells 
are coupled to Gq proteins. These results suggest that the functions of 5-HT1A receptors 
may vary in different cell environments. However, it should be noted that conditions 
in the cell lines are different from those in living cells. It is still a puzzle how G 
proteins link to 5-HT1A receptors in vivo, since the natural cells are much more 
complicated than cell lines. It is possible that the coupling of 5-HT1A receptors is not 
only dependent on their affinity for G proteins, but also dependent on the relative 
amount of each G protein in the cells (Raymond et al.1993). 
5-HT tA agonists and antagonists 
Several 5-HT1A agonists have been discovered such as 8-0H-DPAT, ipsapirone, 
flesinoxan, gepirone and buspirone (Hoyer et al.1994; Van Wijngaarden et al.1990). 
Among them, 8-0H-DPAT has been considered to be the most selective 5-HT1A agonist 
and is a full agonist for most 5-HT1A receptor-mediated responses. 3H-8-0H-DPAT is 
the most widely used radioactive ligand for examination of 5-HT1A receptors. 
However, several studies have shown that 3H-8-0H-DPAT may bind to both high and 
low affinity 5-HT1A receptors (Butkerait et al.1995). This could be due to the small 
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difference in affinity for 8-0H-DPAT between the high and low affinity-states of 5-
HT1A receptors (Kd=0.7nM vs. Kd=17nM) (Chamberlain et al.1993). Although 
ipsapirone and buspirone are partial 5-HT1A agonists, they have been frequently used 
in research since they can be administered to humans. 
Few 5-HT1A antagonists are available. Most 5-HT1A antagonists, such as NAN-
190 and WAY-100135, also behave as partial agonists (Escandon et al.1994; Cliffe et 
al.1993; Fletcher et al.1993; Gobert et al.1995; Greuel and Glaser, 1992; Claustre et 
al.1991b). Pindolol is a 5-HT1A antagonist and can be used in humans. However, it 
also is a B adrenergic antagonist. So far, the only silent 5-HT lA antagonist is WAY-
100635 (Forster et al.1995; Khawaja et al.1995; Routledge, 1995; Craven et al.1994). 
Recently, several 5-HT1A agonists and antagonists have been discovered, such as 8-0H-
PIPAT (5-HT1A agonist) (Zhuang et al.1993) and p-MPPI (5-HT1A antagonist) (Kung 
et al.1994). However, further studies on their pharmacologic profiles are still 
necessary. 
5-HT1A agonists and antagonists bind to both somatodendritic and postsynaptic 
5-HT1A receptors. However, some of them have a higher affinity for the 
somatodendritic 5-HT1A receptors than for postsynaptic 5-HT1A receptors (Matheson et 
al.1994). For example, the ED50 of azapirones (such as ipsapirone and buspirone) for 
inhibiting the firing rate of 5-HT neurons is much lower than the ED50 for stimulation 
of postsynaptic 5-HT1A receptors (Matheson et al.1994). This may be due to a larger 
receptor reserve for 5-HT1A autoreceptors in the raphe than for postsynaptic 5-HT1A 
receptors in the forebrain (Cox et al.1993; Bohmaker et al.1992). 
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5-HT iA receptor-mediated neuroendocrine responses 
Several 5-HT receptors are involved in the regulation of hormone secretion 
(Tuomisto and Mannisto, 1985; Van de Kar et al.1995b; Van de Kar and Brownfield, 
1993; Van de Kar, 1991 ; Y atham and Steiner, 1993; Murphy et al.1991 ; Fuller, 1992; 
Fuller, 1990). For example, the secretion of ACTH, corticosterone and oxytocin can 
be stimulated by 5-HT1A agonists (Van de Kar and Brownfield, 1993; Van de Kar, 
1991). Stimulation of 5-HT2A;zc receptors will increase plasma levels of ACTH, 
corticosterone, renin, prolactin, oxytocin and vasopressin in a dose-dependent manner 
(Rittenhouse et al.1994; Li et al.1993a; Rittenhouse et al.1993; Van de Kar and 
Brownfield, 1993; Li et al.1992). Also, 5-HT18 and 5-HT3 receptors may be involved 
in the regulation of prolactin secretion (Levy et al.1995). 5-HT1A agonists do not 
stimulate renin and vasopressin secretion under normal conditions. In the present 
review, the effect of 5-HT1A receptors on the regulation of hormone secretion will be 
discussed. 
Most evidence has shown that hormonal regulatory effects are mediated by 
postsynaptic 5-HT lA receptors in the hypothalamus (Przegalinski et al.1989; Gilbert et 
al.1988b). However, the signal transduction pathway of 5-HT1A receptor-mediated 
hormone secretion is still unknown. For example, which G proteins and second 
messengers are involved in 5-HT1A receptor-mediated hormone secretion? How do 
changes in second messengers trigger hormone release? Since 5-HT1A receptors may 
be coupled to Gi or G0 proteins, it is possible that the hormone responses to 5-HT1A 
agonists are inversely related to the activity of adenylyl cyclase. 
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5-HT1A receptor-mediated ACTH and corticosterone secretion 
The secretion of ACTH and corticosterone is regulated by the hypothalamic-
pituitary-adrenocortical axis (HPA axis). The paraventricular nucleus of the 
hypothalamus (PVN) contains parvocellular cells that secrete corticotropin-releasing 
hormone (CRH or CRF). When the parvocellular cells are activated, CRH is released 
into the pituitary portal vessels and travels into the anterior lobe of the pituitary gland 
through the superior hypophyseal artery. In the anterior pituitary (i.e 
adenohypophysis), CRH stimulates adrenocorticotropin (ACTH) release from ACTH 
containing cells (corticotrophs). ACTH then travels to the adrenal gland through the 
circulation, where ACTH stimulates adrenal cortical cells resulting in release of 
corticosterone in rats or cortisol in humans. The HPA axis includes both neurons and 
endocrine cells and spans from the central nervous system to the peripheral adrenal 
gland. It can be expected that the HPA axis will be regulated by both central and 
peripheral factors. 
Several neurotransmitter systems mediate the regulation of ACTH and 
corticosterone release. For example, activation of adrenergic a 1 receptors increases the 
secretion of ACTH and corticosterone (Al-Damluji and Francis, 1993; Levy et al.1994; 
Feldman et al.1995; Radant et al.1992). In addition, stimulation of dopamine D2 
receptors and µ opiate receptors also increases ACTH and corticosterone release (Levy 
et al.1994; Boesgaard et al.1990; Borowsky and Kuhn, 1992). It is worth noting that 
D2 andµ receptors couple to Gi proteins, just as 5-HT1A receptors do. Therefore, it is 
possible that these receptors share common G proteins, and hence, they can interact 
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with each other. Parvocellular cells (CRH cells) receive serotonergic input from dorsal 
and median raphe nuclei (Petrov et al.1992; Liposits et al.1987). Activation of several 
5-HT receptors, such as 5-HT1A, 5-HTrn, 5-HT2Aizc and 5-HT3 receptors, increases 
CRH, ACTH and corticosterone secretion (Fuller, 1995; Fuller, 1992; Fuller, 1990; 
Fuller, 1981; Van de Kar and Brownfield, 1993; Van de Kar, 1991; Chaouloff, 1993). 
Activation of 5-HT1A receptors by 5-HT1A agonists, such as 8-0H-DPAT, 
ipsapirone, buspirone and gepirone, increases plasma ACTH and corticosterone 
concentrations (Cowen et al.1990; Fuller, 1992; Gilbert et al.1988a; Koenig et 
al.1988). The hormone responses to 5-HT1A agonists can be inhibited by 5-HT1A 
antagonists, such as pindolol, spiperone, NAN-190, UH-301, WAY-100135 and WAY-
100635 (Cowen et al.1990; Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et 
al.1994b; Przegalinski et al.1989; Kelder and Ross, 1992; Vicentic et al.1996), but not 
by 5-HTrn, 5-HT2, 5-HT3 and adrenoceptor antagonists (Przegalinski et al.1989). 
Several laboratories (Przegalinski et al.1989; Gilbert et al.1988b) and our preliminary 
data have shown that destruction of 5-HT neurons using 5,7-dihydroxytryptamine (5,7-
DHT) or depletion of 5-HT storage by p-chlorophenylalanine (PCPA) does not reduce 
the ACTH and corticosterone responses to 5-HT1A agonists. These results suggest that 
the ACTH and corticosterone responses to 5-HT1A agonists are exclusively mediated by 
activation of postsynaptic 5-HT1A receptors. However, a study by Bluet Pajot et 
al.(1995) showed that infusing 8-0H-DPAT into the dorsal raphe nucleus slightly 
increases ACTH secretion. Also, in that study, repeated injections of PCPA decreased 
ACTH responses to 8-0H-DPAT. These results suggest that presynaptic 5-HT1A 
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receptors may also be involved in the ACTH response to 8-0H-DPAT. However, no 
other data support these results so far and further confirmation is necessary. 
Hypothalamic 5-HT1A receptors, especially those in the paraventricular nucleus, 
might be involved in the regulation of ACTH secretion (Bagdy and Makara, 1994; 
Bagdy, 1994; Calogero et al.1989). Infusion of 8-0H-DPAT into the PVN significantly 
increases ACTH secretion (Bluet Pajot et al.1995). A lesion in the hypothalamic 
paraventricular nucleus blocks the effect of the 5-HT1A agonist ipsapirone on plasma 
corticosterone concentration (Bagdy and Makara, 1994; Bagdy, 1994). Taken together, 
these results suggest that the ACTH and corticosterone responses to 5-HT1A agonists are 
mediated by postsynaptic 5-HT1A receptors in the hypothalamus. 
A receptor-reserve has been demonstrated for the 5-HT1A receptor-mediated 
increase of plasma ACTH and corticosterone concentrations (Meller and Bohmaker, 
1994; Pinto et al.1994). Irreversible inactivation of 5-HT IA receptors by EEDQ (N-
ethoxycarbonyl-1,2-ethoxydihydroquinoline) shifts the 8-0H-DPAT dose-response 
curves for plasma ACTH and corticosterone to the right. A low dose of EEDQ 
(lmg/kg, sc) (Pinto et al.1994) reduced the density of 5-HT1A receptors by 53%, but 
did not change the hormone responses to 8-0H-DPAT. A high dose of EEDQ (6 
mg/kg, sc) decreased both the potency and efficacy of ACTH and corticosterone 
responses to 8-0H-DPAT (Meller and Bohmaker, 1994). The fractional occupancy of 
5-HT1A receptors required to reach 50% maximal response of ACTH or corticosterone 
is 25% or 5.5% respectively (Meller and Bohmaker, 1994). The effect of EEDQ on 
the hormone responses to 8-0H-DPAT can be prevented by pretreatment with the 5-
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HT1A antagonist pindolol, suggesting that the effect of EEDQ on the ACTH and 
corticosterone responses to 8-0H-DPAT is mediated by 5-HT1A receptors (Meller and 
Bohmaker, 1994). The apparent receptor-reserve for 5-HT1A receptor-mediated ACTH 
and corticosterone may be due to the cascade of the HPA axis. When a hypothalamic 
5-HT1A receptor is stimulated, the signals travel through the HPA axis from the 
hypothalamus, pituitary and adrenal cortical cells. The signals are amplified in each 
step along the pathway, and thus, the response to the 5-HT1A agonist becomes 
amplified. This is consistent with data showing that the corticosterone response has 
more receptor reserve than the ACTH response. 
5-HT1A receptor-mediated oxytocin secretion 
Oxytocin is synthesized by magnocellular cells in the hypothalamic supraoptic 
and paraventricular nuclei. The oxytocin neurons send their axons to the posterior lobe 
of the pituitary gland where they secrete oxytocin into the inferior hypophyseal artery. 
Oxytocin secretion can be regulated by stimulation of either oxytocin cell bodies in the 
hypothalamus or nerve terminals in the posterior pituitary. Several studies indicate that 
noradrenergic and serotonergic neurons are involved in the regulation of oxytocin 
secretion. Noradrenergic projections from neurons in the Al,A2 and A6 cell groups 
stimulate magnocellular cells in the paraventricular nucleus, while C2 noradrenergic 
neurons inhibit the magnocellular cells (Saphier, 1993). Stimulation of a 1 receptors 
increases the secretion of oxytocin (Levy et al.1994; Saphier, 1993). In contrast with 
ACTH, D2 and µ-receptors inhibit the secretion of oxytocin. Injection of the 5-HT 
releasers p-chloroamphetamine (PCA) and d-fenfluramine increase the concentration of 
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plasma oxytocin (Van de Kar et al.1995c; Saydoff et al.1991). The effect of 5-HT 
releasers can be inhibited by the 5-HT uptake inhibitor fluoxetine (Van de Kar et 
al.1995c). Neurons in the dorsal rap he nucleus innervate magnocellular cells in the 
paraventricular nucleus (Saphier, 1991). Furthermore, lesions in the paraventricular 
nucleus, but not in the supraoptic nucleus, by the cell-selective toxin ibotenic acid 
inhibits the oxytocin response to the 5-HT releaser p-chloroamphetamine (PCA) (Van 
de Kar et al. l 995c). These results suggest that serotonin neurons regulate oxytocin 
secretion by stimulating oxytocin neurons in the hypothalamic paraventricular nucleus. 
Bagdy (1993) and our laboratory (Li et al.1993b) have found that activation of 
5-HT1A receptors increases the secretion of oxytocin. 5-HT,A agonists, such as 8-0H-
DPAT and ipsapirone increase the concentration of plasma oxytocin in a dose dependent 
manner (Li et al.1993b; Bagdy and Kalogeras, 1993). Furthermore, the oxytocin 
response to 8-0H-DPAT can be inhibited by the 5-HT,A antagonist NAN-190 and 
WAY-100635 (Vicentic et al.1996; Bagdy and Kalogeras, 1993). A lesion in the 
hypothalamic paraventricular nucleus decreases the effect of ipsapirone on the secretion 
of oxytocin (Bagdy, 1994), suggesting that neurons in the PVN are involved in the 
oxytocin response to 5-HT,A agonists. Unlike the 5-HT,A receptor-mediated ACTH 
response, only a few studies have reported on the oxytocin responses to 5-HT1A 
agonists. The signal transduction mechanism of the 5-HT1A receptor-mediated 
regulation of oxytocin release is still not clear. 
No data regarding receptor reserve for the oxytocin response to 5-HT IA agonists 
have been published so far. An observation by Pinto and Battaglia (unpublished) 
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indicates that less receptor reserve exists for the oxytocin response to 5-HT tA agonists 
than for ACTH. The oxytocin response to 8-0H-DPAT was examined in rats treated 
with different doses of EEDQ, to inactivate receptors in a graded manner. Although 
the Emax of oxytocin response to 8-0H-DPAT was not reduced with a low dose (1 
mg/kg) of EEDQ, the 10 mg/kg dose of EEDQ completely blunted the oxytocin 
response to 8-0H-DPAT. This dose of EEDQ, however, did not completely block the 
8-0H-DPAT-induced increase in plasma levels of ACTH. 
A 5-HT1A receptor-mediated increase of oxytocin secretion occurs in both males 
and females. The physiologic significance of this response is still unknown. Recently, 
an interesting study (Bj6rkstrand et al.1996) found that an antagonist for oxytocin 
receptors inhibited the effects of 8-0H-DPAT on insulin, cholecystokinin and 
somatostatin, suggesting that 5-HT1A receptor-mediated regulation of oxytocin secretion 
may be related to the regulation of other hormones via oxytocin receptors. 
Unlike ACTH and corticosterone, oxytocin is released directly into the 
circulation from nerve terminals of oxytocin containing neurons in the hypothalamus. 
Therefore, the magnitude of the oxytocin response to 5-HT1A receptors will more 
directly reflect the function of 5-HT1A receptors in the hypothalamus than that of ACTH 
and corticosterone responses. 
5-HT tA agonist-induced increase of prolactin secretion may not be mediated by 5-
HT tA receptors 
Prolactin is secreted from the anterior pituitary gland. The secretion of prolactin 
is regulated by the hypothalamus. It is believed that the hypothalamus produces a 
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releasing hormone to stimulate prolactin release. However, no prolactin releasing 
hormone has been found so far. Prolactin secretion is predominantly controlled by 
dopamine. Dopamine is released from the hypothalamus to the pituitary and inhibits 
secretion of prolactin. Therefore, inhibition of dopamine release or blockade of 
dopamine D2 receptors results in an increase in prolactin release. 
Several 5-HT1A agonists, such as 8-0H-DPAT, ipsapirone and buspirone, 
stimulate prolactin secretion (Kellar et al.1992; Gartside et al.1990; Di Sciullo et 
al.1990; Aulakh et al.1988). Our preliminary data showed that destruction of 5-HT 
neurons using icv injection of 5, 7-DHT potentiated the prolactin response to 8-0H-
DPAT, suggesting that postsynaptic 5-HT1A receptors are involved in the 5-HT1A 
agonist-induced increase of prolactin release. In addition, injection of pertussis toxin, 
which inactivates Gi and G0 proteins, or forskolin, an activator of adenylyl cyclase, 
inhibits the prolactin response to 8-0H-DPAT (Van de Kar et al.1995a). These results 
suggest that the prolactin response to 8-0H-DPAT is mediated by Gi proteins, which 
are negatively coupled to adenylyl cyclase. However, the time course and dose 
response of prolactin to 5-HT1A agonists are different from those of ACTH and 
corticosterone (Kellar et al.1992; Gartside et al.1990). The prolactin response to 5-
HT1A agonists can not be inhibited by the 5-HT1A antagonists pindolol (Levy et al.1995; 
Groenink et al.1995; Park and Cowen, 1995) or WAY -100635 (Vicentic et al.1996). 
Furthermore, a surgical lesion in the hypothalamic PVN did not inhibit the prolactin 
response to ipsapirone (Bagdy and Makara, 1994). These results suggest that the 
prolactin response to 5-HT1A agonists may be not mediated by 5-HT1A receptors. 
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Neuroendocrine challenge test 
In conclusion, 5-HT1A receptors are involved in the regulation of the secretion 
of ACTH, corticosterone and oxytocin. Therefore, the magnitude of the hormone 
responses to 5-HT1A agonists can be used as a marker to examine the function of 
hypothalamic 5-HT1A receptor systems. 
As will be discussed below, dysfunction of serotonergic systems may play a role 
in affective disorders. Therapeutic effects of antidepressants may be related to changes 
in the function of 5-HT1A receptors. Since hypothalamic neurons are involved in mood 
change, determination of the function of hypothalamic 5-HT1A receptors will help in the 
diagnosis and monitoring of the therapeutic effects of antidepressants (Van de Kar, 
1989). Hormone responses to 5-HT agonists or releasers can be a useful peripheral tool 
to determine the function of central serotonergic systems. In fact, hormone responses 
to 5-HT agonists or releasers have been used clinically to assess the function of 
serotonergic systems in patients with affective disorders (Cowen et al.1994; Hollander 
et al.1991; Murphy et al.1991; Price et al.1991; Muller, 1990; Asnis et al.1988; Curtis 
and Glitz, 1988). For example, Lesch et al.(Lesch et al.1992c; Lesch, 1991; Lesch et 
al.1991b; Lesch et al.1991c; Lesch et al.1990a; Lesch et al.1990b; Lesch et al.1989) 
examined ACTH and cortisol responses to ipsapirone to assess changes in the function 
of 5-HT1A receptors in depressed patients and the effect of antidepressants on 5-HT1A 
receptors. It is possible that changes in the function of 5-HT receptors occur prior to 
signs of clinical improvement during the treatment of affective disorders. Therefore, 
monitoring the function of 5-HT receptors using a neuroendocrine challenge test may 
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be a valuable tool to give physicians early information, such as whether the patient will 
respond to the treatment. 
Although a neuroendocrine challenge test is a relatively reliable examination 
compared to other peripheral tests, its limitations should be noted. First, most agonists 
(e.g. a 5-HT1A agonist) used as a challenge are not exclusively selective for one type 
of 5-HT receptor (e.g 5-HT1A receptors). These drugs may also influence other 
neurotransmitter receptors (e.g. Dopamine D2 receptors). Therefore, the hormone 
responses to the agonists may not only reflect the function of 5-HT receptors (5-HT1A 
receptors), but also other receptors (D2 receptors). For example, buspirone is a 5-HT1A 
agonist and an antagonist of dopamine D2 receptors. Since dopamine is a predominant 
inhibitory control for prolactin release, the prolactin response to buspirone will mainly 
represent the function of D2 receptors. Secondly, since the pathways for 5-HT 
receptors regulating hormone release are still unknown and each hormone can be 
regulated by several different systems, it is possible that the steady-state of a hormone 
will be changed under different physical conditions, such as illness. In this case, the 
hormone challenge test may not represent the function of 5-HT receptors. To overcome 
these limitations, it is necessary to examine more than one hormone response. Since 
each hormone is regulated by different neurotransmitters, determination of several 
hormones will allow ruling out some of the side effects of agonists or abnormal 
hormone states. 
5-HTlA Receptors and 5-HT Uptake Inhibitors 
5-HT and affective disorders 
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Dysfunction of serotonergic systems is believed to be involved in several 
affective disorders, such as anxiety, depression, obsessive compulsive disorder, 
premenstrual syndrome and seasonal affective disorder (Sandyk, 1992; Shapira et 
al.1994; Eison, 1990; Mann et al.1990; Lesch et al.1992a). There is growing evidence 
regarding the involvement of abnormal serotonergic systems in schizophrenia and 
epilepsy (Rao and Moller, 1994; Holden, 1995; Statnick et al.1996). The evidence 
regarding the involvement of serotonergic systems in affective disorders includes the 
following: 1) Alterations of the concentration of 5-HT induce mood changes. 
Delgado and his colleagues found that depletion of tryptophan, a precursor of 5-HT, 
by a tryptophan-free diet induced a relapse of depressive symptoms in remitted 
depressed patients (Delgado et al.1990). Also, tryptophan depletion worsened 
depressive symptoms in drug-free depressed patients one day after the test (Delgado 
et al.1994). In contrast, tryptophan depletion improved aggressive behavior one day 
after the test (Salomon et al.1994). These results indicate that abnormal serotonin levels 
may trigger mood changes, while the symptoms may be related to adaptive postsynaptic 
changes induced by the alteration of 5-HT (Delgado et al.1994). Consistent with the 
above results, a low 5-HT turnover (low 5-HIAA) in CSF has been found in impulsive 
violence offenders, which may be due to a genetic disorder (Virkkunen et al.1995). To 
determine whether the effect of tryptophan depletion on mood changes is due to a 
decrease of 5-HT release from nerve terminals, Bel and Artigas (1996) recently 
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examined the effect of tryptophan depletion on 5-HT concentration in rat frontal cortex 
using microdialysis. They found that tryptophan depletion significantly reduced 5-HT 
concentration in the frontal cortex of the rats that received fluvoxamine (a 5-HT uptake 
inhibitor) treatment. This result is consistent with the clinical observations. 2) 
Changes in 5-HT receptors have been found in the brain of suicide victims. 5-HT 
uptake sites were decreased and 5-HT1A receptors were increased in the ventrolateral 
prefrontal cortex of suicide victims (Arango et al.1995). Increased 5-HT2Aizc receptors 
in the cortex and amygdala and a low level of 5-HT1 receptors in the hippocampus have 
also been observed in suicides (Cheetham et al.1990; Hrdina et al.1993). However, the 
results from different studies were not consistent. This may be due to the variation in 
populations, sample sources and methods used between the studies. 3) Chronic 
exposure to antidepressants alters 5-HT transmission. The theories on the 
implication of dysfunction of serotonergic systems in the pathogenesis of affective 
disorders were originally based on the therapeutic effects of antidepressants (Shapira 
et al.1994). Most antidepressants alter 5-HT transmission, although the effective sites 
may vary between classes of antidepressants (Owens and Nemeroff, 1994). For 
example, tricyclic antidepressants tend to potentiate the function of postsynaptic 5-HT 
receptors, while SSRI's desensitize presynaptic 5-HT receptors (Blier et al.1987). 4). 
5-HT uptake inhibitors are antidepressants As will be discussed below, 5-HT uptake 
inhibitors are widely used to treat affective disorders. 
Taken together, these observations support the hypothesis that dysfunction of 
serotonergic systems may play a role in the pathophysiology of affective disorders. 
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However, since affective disorders are complicated processes, it is still unclear what 
the mechanisms of affective disorders are in terms of abnormalities of serotonergic 
systems. 
5-HT1A receptors may play a role in the pathophysiology and therapeutics of 
affective disorders (Shapira et al.1994). A few studies observed abnormal functions of 
5-HT1A receptors in patients with affective disorders. However, the observations were 
not consistent between studies. For example, hypothermic, ACTH and cortisol 
responses to ipsapirone were reduced in patients with unipolar depression, suggesting 
a decrease in the function of 5-HT1A receptors in both pre- and postsynaptic sites (Lesch 
et al.1992c; Lesch, 1991; Lesch et al.1990b). However, the results reported by Cowen 
at al. (1994) reveal that hypothermia, but not ACTH and growth hormone responses 
to 5-HT1A agonists buspirone were attenuated in patients with major depression. This 
inconsistency may be due to the differences in population or type of the depression. 
However, it should be noted that a dysfunction of 5-HT IA autoreceptors was consistently 
observed in both major and unipolar depressed patients. Although several mutated 5-
HT1A receptor genes have been found, none of them is correlated with depression 
(Erdmann et al.1995; N akhai et al.1995; Xie et al.1995). In fact, more convincing 
evidence for existing dysfunction of 5-HT1A receptors in affective disorders comes from 
the involvement of 5-HT1A receptors in the therapy of affective disorders. Several 5-
HT1A agonists are anxiolytics and express antidepressive properties (De Vry, 1995; 
Handley, 1995; Griebel, 1995). Also, some antidepressants, especially 5-HT uptake 
inhibitors (SSRI's), desensitize 5-HT1A receptors (Blier et al.1987; Lesch et al.1991c; 
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Lesch et al.1990a), as will be discussed later. Furthermore, it has been found that 
administration of the 5-HT1A antagonist pindolol, combined with SSRI's, reduced the 
delay in the therapeutic effects of SSRI's (Artigas et al.1994; Blier and Bergeron, 
1995). 
Effects of 5-HT uptake inhibitors on 5-HT1A receptor systems 
Selective serotonin reuptake inhibitors (SSRl's) 
5-HT uptake inhibitors include fluoxetine (Prozac®), fluvoxamine (Luvox®), 
paroxetine (Paxil®), sertraline (Zoloft®) and citalopram. The 5-HT uptake inhibitors, 
especially fluoxetine, are widely used to treat depression, obsessive compulsive 
disorders, bulimia nervosa, panic disorder, obesity and premenstrual syndrome (Wong 
et al.1995; Goldstein et al.1995; Weltzin et al.1994; Advokat and Kutlesic, 1995; 
Eriksson et al.1995; Steiner et al.1995; Woods et al.1993; Goldstein et al.1994a; 
Goldstein et al.1994b; Lam et al.1995). A major advantage of the 5-HT uptake 
inhibitors is that they produce fewer side effects than the tricyclic antidepressants 
(Wong et al.1995; Richelson, 1994). 
5-HT uptake inhibitors do not share common chemical structures, but all have 
a high affinity for 5-HT uptake sites. They have a relatively low affinity for other 
monoamine transporters and receptors (Richelson, 1994; Wong et al.1995). Since the 
chemical structures of the 5-HT uptake inhibitors are different, their pharmacokinetic 
profiles are quite different as well. Among the 5-HT uptake inhibitors, fluoxetine has 
the lowest affinity, while paroxetine has the highest affinity for 5-HT uptake sites 
(Richelson, 1994; Wong et al.1995). In humans, the half-life (t11i.) values for the 5-HT 
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uptake inhibitors range from 15 hours (paroxetine and fluvoxamine) to 1.9 days 
(fluoxetine) after a single dose of administration (Table I). There is no active 
metabolite for paroxetine and fluvoxamine. However, the metabolite of fluoxetine, 
norfluoxetine, has a similar potency for 5-HT uptake sites and a much longer t112 (7 
days) than fluoxetine. Although sertraline has an active metabolite, its activity is only 
10% that of sertraline (Van Harten, 1993). It should be noted that the half-life values 
of the 5-HT uptake inhibitors are usually increased with chronic treatment (Van Harten, 
1993; Goodnick, 1994). Very few studies have been reported regarding the 
pharmacokinetics of 5-HT uptake inhibitors in animals. Caccia et al. (1990) reported 
that the mean elimination half-life (t11z) of a single dose of fluoxetine in rats is about 5 
hours (intravenous) or 7 hours (oral), while the t112 of norfluoxetine is about 15 hours. 
These t112 values are much shorter than those in humans. However, the elimination 
half-life may not reflect the duration of effects of 5-HT uptake inhibitors in terms of 
ability to occupy 5-HT uptake sites. Scheffel et al. (1994) have shown that the t112 
values of the inhibitory effect on 1251-RTI-55 binding (a in vivo radioactive tracer for 
5-HT uptake sites) in the mouse brain are about 35, 7 and 6 hours for fluoxetine, 
sertraline and paroxetine, respectively. 
The doses of 5-HT uptake inhibitors used in animals are determined as the doses 
that prevent 5-HT depletion by the 5-HT releasers PCA or fenfluramine, which enter 
nerve terminals through 5-HT uptake sites (Fuller et al.1978; Fuller and Wong, 1987). 
34 
TABLE I 
PHARMACOLOGIC PARAMETERS OF 5-HT UPTAKE INHIBITORS 
Fluoxetine Paroxetine Fluvoxamine Sertraline Citalopram 
Ki (nM)1 25 1.1 6.2 7.3 2.6 
Ki ratio 20 320 180 190 1500 
(NE: 5-HT)1 
tmax (h)2 6-8 5 5 6-8 2-4 
t112 (human)2'3 
parent compound 1.9 days 10-16 h 15 h 26 h 33 h 
active metabolite 7 days NA NA 62-104 h 
t112 (rat)4,s 
parent compound 5-7 h 3h 
active metabolite 15 h 
Dosage 20-80 20-30 100-300 50-200 
(mg/day)3'6 
NA: No active metabolite 
-: the data are unknown 
1. Nemeroff, 1993; Van Harten, 1993 
2. Van Harten, 1993 
3. Goodnick, 1994 
4. Caccia et al. 1990 
5. Moret and Briley, 1990 
6. Hollister and Claghorn, 1993 
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5-HT1A receptors in the therapeutic effects of SSRl's 
The pharmacologic effects of 5-HT uptake inhibitors are blockade of 5-HT 
reuptake sites, resulting in an increase in the concentration of 5-HT in the synaptic 
cleft. However, like other antidepressants, the clinical improvement is usually observed 
two to three weeks after the onset of treatment with 5-HT uptake inhibitors. This delay 
of the clinical improvement suggests that the therapeutic effects of 5-HT uptake 
inhibitors might not be directly mediated by their acute pharmacologic effects, but are 
due to an adaptive change triggered by the sustained blockade of 5-HT uptake sites. 
It has been hypothesized (Briley and Moret, 1993; Blier and de Montigny, 1994; 
Gardier et al.1996) that 5-HT1A receptors are involved in the delayed onset of 
therapeutic effects of 5-HT uptake inhibitors. The blockade of 5-HT uptake sites by 
5-HT uptake inhibitors leads to an increase in the concentration of 5-HT in the synaptic 
cleft both in the raphe and in postsynaptic brain areas (Fuller, 1994; Rutter and 
Auerbach, 1993). Since somatodendritic 5-HT1A autoreceptors (in the raphe) are more 
sensitive to the alteration of 5-HT concentration in the synaptic cleft than postsynaptic 
5-HT1A receptors (Blier et al.1993a; Hoyer and Boddeke, 1993), the increase in 5-HT 
concentration in the synaptic cleft will first stimulate somatodendritic 5-HT1A 
autoreceptors. The activation of 5-HT1A autoreceptors results in an inhibition in the 
firing rate of 5-HT neurons of the raphe nuclei and consequently, reduces 5-HT release 
from nerve terminals in the forebrain. Thus, initially, the net 5-HT concentration in 
the synaptic cleft of forebrain may not be increased. The decrease in 5-HT release may 
even produce an initial supersensitivity of postsynaptic 5-HT1A receptors (Ceci et 
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al.1993). With repeated administration of 5-HT uptake inhibitors, it is hypothesized 
that the over-stimulation of somatodendritic 5-HT1A autoreceptors by the high 
concentration of 5-HT will produce a desensitization of somatodendritic 5-HT1A 
autoreceptors in the raphe. The desensitization of somatodendritic 5-HT1A autoreceptors 
reduces the responses of serotonin neurons to 5-HT. Consequently, the 5-HT neurons 
will be liberated from the inhibition of firing activity and 5-HT release from 5-HT 
nerve terminals will return to normal or even be increased. Therefore, the 
concentration of 5-HT in the postsynaptic clefts will be increased, resulting in a 
desensitization of postsynaptic 5-HT1A receptor systems. The desensitization of 
postsynaptic 5-HT1A receptors may be implicated in the therapeutic effects of 5-HT 
uptake inhibitors. 
Evidence to support this hypothesis will be discussed below. Most of the 
evidence is focused on somatodendritic 5-HT1A receptors and very few studies have 
investigated the adaptive changes in postsynaptic 5-HT1A receptors. 
1) Inhibition of 5-HT neurons induced by acute injection of 5-HT uptake inhibitors is 
mediated by somatodendritic 5-HT1A autoreceptors. Acute administration of 5-HT 
uptake inhibitors decreases the firing rate of 5-HT neurons in the dorsal and median 
rap he nuclei (Rigdon and Wang, 1991 ; Rutter and Auerbach, 1993; Chaput et al .1988; 
Haj6s et al.1995). This effect can be blocked by the 5-HT1A antagonists pindolol, (S)-
UH-301, WAY-100135, spiperone and WAY-100635 (Arborelius et al.1995; Haj6s et 
al.1995; Gartside et al.1995; Huang and Harlan, 1994), suggesting that 5-HT uptake 
inhibitor-induced reduction in the firing rate of 5-HT neurons is mediated by 5-HT1A 
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autoreceptors. Consistent with the electrophysiological results, it is limited that the 
influence of acute administration of 5-HT uptake inhibitors on extracellular 
concentration of 5-HT in the forebrain, which was measured by microdialysis. 
Depending on the doses of 5-HT uptake inhibitors used, the extracellular 5-HT 
concentration in forebrain regions can be slightly increased (high doses of SSRI's) or 
not changed by systemic injections of 5-HT uptake inhibitors (Fuller, 1994; Gartside 
et al.1995; Gardier et al.1996; Rutter et al.1995; Rutter and Auerbach, 1993; Invernizzi 
et al.1992). Systemic injections of fluoxetine, paroxetine or sertraline (10 mg/kg, ip) 
to rats that received a local perfusion of fluoxetine into the diencephalon to block 5-HT 
uptake in the nerve terminals, significantly decreased the extracellular concentration of 
5-HT in the diencephalon (Rutter et al.1995). This decrease of 5-HT release could be 
reversed by systemic injections of 5-HT1A antagonists, such as WAY-100135 or 
spiperone. Invernizzi et al. (1996) also observed that systemic injection of the 5-HT1A 
antagonist WA Y-100635 potentiated the increase of extracellular 5-HT concentration 
in the frontal cortex induced by an acute injection of fluoxetine. Similar results have 
also been observed in the hippocampus by Hjorth et al. (1994a; 1995). Also, the 
increase of 5-HT concentration in the diencephalon induced by local infusion of 
fluoxetine was twice as high as that induced by systemic injection of fluoxetine (Rutter 
and Auerbach, 1993). Together, these data suggest that acute injections of 5-HT uptake 
inhibitors indirectly activate 5-HT1A autoreceptors on the 5-HT neurons, resulting in an 
inhibition of activity of 5-HT neurons and a decrease in 5-HT release. Furthermore, 
the increase in 5-HT concentration in forebrain regions, induced by 5-HT uptake 
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inhibitors, is much less than that in the raphe nucleus (Gartside et al.1995; Gardier et 
al.1996; Rutter et al.1995). These results suggest that the stimulation of 5-HT1A 
autoreceptors induced by acute injection of 5-HT uptake inhibitors may not be only due 
to the higher sensitivity of 5-HT1A autoreceptors compared with postsynaptic 5-HT1A 
receptors, but also due to a higher 5-HT concentration in the raphe regions than that 
in the forebrain regions. However, it is unknown why activation of 5-HT1A 
autoreceptors does not inhibit the release of 5-HT in the raphe nuclei. 
2) Long-term treatment with 5-HT uptake inhibitors desensitizes 5-HT1A autoreceptors 
in the raphe nuclei. Several studies have demonstrated that chronic treatment with 5-
HT uptake inhibitors reduces the ability of subsequent injections of 5-HT uptake 
inhibitors to decrease 5-HT neuronal activity. Blier et al. (1987; 1988) showed that the 
firing rate of 5-HT neurons was significantly decreased after 2 days of injections with 
the 5-HT uptake inhibitors indalpine, zimelidine or citalopram. However, the firing 
rate of neurons was partially restored after 7 days and returned to normal after 14 days 
of injections of indalpine, zimelidine or citalopram. Repeated injections of fluoxetine, 
paroxetine or cericlamine, a novel 5-HT uptake inhibitor, significantly shifted to the 
right the dose-response curve of 8-0H-DPAT- or ipsapirone-induced inhibition of the 
firing rate of 5-HT neurons in brain stem slices (Le Poul et al .1995; J olas et al .1994). 
This reduction of the effect of 8-0H-DPAT on the firing of 5-HT neurons occurred 
after 3 days of repeated injections (Le Poul et al.1995). These results suggest that 
repeated injections of 5-HT uptake inhibitors desensitize 5-HT1A autoreceptors in 
serotonin neurons. 
39 
Unlike the electrophysiological data, results from microdialysis studies to 
determine the effects of repeated injections of 5-HT uptake inhibitors on 5-HT release 
have not been as consistent (Gardier et al.1996). Bel and Artigas (1993) reported that 
repeated injections of fluvoxamine increased basal level of 5-HT in the frontal cortex, 
but not in the raphe region. The increase in the basal level of 5-HT induced by chronic 
fluvoxamine (2 weeks) was higher than acute fluvoxamine-induced increase of 5-HT 
concentration in the frontal cortex. Also, extracellular 5-HT levels in the frontal cortex 
of chronic fluvoxamine-treated rats were not further increased by a challenge with 
fluvoxamine. Several other investigators (Rutter et al.1994; Kreiss and Lucki, 1995; 
Invernizzi et al.1996; Invernizzi et al.1994) found that repeated injections of fluoxetine 
or citalopram increased baseline concentration of 5-HT in several forebrain regions, 
such as frontal cortex, striatum, hippocampus and diencephalon. When a single dose 
of a 5-HT uptake inhibitor was used as a challenge, the extracellular concentration of 
5-HT in the forebrain increased to a much higher degree in the rats that received 
repeated injections of 5-HT inhibitors than in the control rats. Furthermore, repeated 
injections of 5-HT uptake inhibitors, such as fluoxetine, abolished 8-0H-DPAT-induced 
inhibition of 5-HT release (lnvernizzi et al.1996). Taken together, these results suggest 
that repeated administration of 5-HT uptake inhibitors leads to a desensitization of 5-
HT1A autoreceptors on 5-HT neurons. This desensitization of 5-HT1A autoreceptors 
liberates serotonin neurons from the inhibition of firing activity and consequently, 
increases the concentration of 5-HT in the postsynaptic cleft. However, several studies 
do not support this hypothesis. Hjorth and Auerbach (1994b) reported that chronic 
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citalopram did not reduce the inhibitory effect of 8-0H-DPAT on 5-HT release in the 
frontal cortex and dorsal hippocampus. Also, an increased baseline of hypothalamic 
5-HT in rats chronically treated with citalopram was only observed during 
administration, but not after a 24 hours washout (Moret and Briley, 1996). Although 
Invernizzi et al. (1995) observed a desensitization of 5-HT1A autoreceptors induced by 
chronic fluoxetine, they did not find that chronic citalopram produced desensitization 
of 5-HT1A autoreceptors. These inconsistent results could be due to the different 
experimental procedures, different 5-HT uptake inhibitors used or different brain 
regions examined. 
3) 5-HT1A antagonists shorten the delay of clinical improvement in the 5-HT uptake 
inhibitor therapy. If the hypothesis is correct that activation of 5-HT1A autoreceptors 
plays a role in the delay of the onset of clinical improvement after administration of 5-
HT uptake inhibitors, then, blocking the 5-HT1A autoreceptors with 5-HT1A antagonists 
while administering 5-HT uptake inhibitors should speed the therapeutic effects of 5-HT 
uptake inhibitors. Artigas (1994; 1995) was the first to give depressed patients the 5-
HT1A antagonist pindolol with 5-HT reuptake inhibitors. Two-thirds of the patients 
remitted completely within 1 week. Some of them had taken 5-HT uptake inhibitors 
for at least 6 weeks with no full antidepressant responses before pindolol was added. 
A similar result was also observed by Blier et al (1995). Nine patients with unipolar 
depression and 19 patients with resistant unipolar depression were treated with 5-HT 
uptake inhibitors and pindolol. Most of them achieved clinical improvement within 1 
week. All patients, Except one, remitted within 14 days. Furthermore, Koran et al. 
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(1996) recently reported that pindolol also short the delay of the therapeutic effect of 
5-HT reuptake inhibitors on obsessive compulsive disorder. All of these results support 
the hypothesis that 5-HT1A autoreceptors are involved in the delay of clinical 
improvement during treatment with 5-HT uptake inhibitors. However, it should be 
noted that pindolol is also a B-adrenergic receptor antagonist. It still cannot be ruled 
out that the effect of pindolol in accelerating the therapeutic effect of 5-HT uptake 
inhibitors is due to its B antagonist effect. There were some patients that did not gain 
benefit from the combined pindolol and 5-HT uptake inhibitor treatment. All data, so 
far, have come from clinical trials and the number of cases is still limited. Therefore, 
further studies are necessary. 
4) The effects of chronic 5-HT uptake inhibitors on postsynaptic 5-HT1A receptors. Data 
regarding the effect of 5-HT uptake inhibitors on the function of postsynaptic 5-HT1A 
receptors are limited. Lesch et al.(199lc) reported that long-term treatment with 
fluoxetine reduced the ACTH response to the 5-HT1A agonist ipsapirone in patients with 
obsessive-compulsive disorder. Hensler et al. (1991) showed that repeated injections 
of sertraline or citalopram attenuated the hypothermic response to 8-0H-DPAT, which 
in rats is mediated by postsynaptic 5-HT1A receptors. These results suggest that chronic 
injections of 5-HT uptake inhibitors desensitize postsynaptic 5-HT1A receptors. 
In conclusion, evidence supports the hypothesis that the therapeutic effects of 
SSRI's may be mediated by desensitization of 5-HT1A receptors. However, most studies 
focus on the presynaptic 5-HT1A autoreceptors. Less is known about the effect of 
chronic administration of SSRI's on postsynaptic 5-HT1A receptors. 
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The mechanism of desensitization of 5-HTlA receptors induced by chronic 
administration of 5-HT uptake inhibitors 
The desensitization of 5-HT1A receptors is defined as a reduction in the function 
of 5-HT1A receptor systems. It is still unknown what changes in the components of 5-
HT1A receptor systems contribute to the desensitization. 5-HT1A receptor systems 
include the 5-HT1A receptors, G proteins that are coupled to 5-HT1A receptors, second 
messengers and effectors that couple to the second messenger and determine the 
function of 5-HT1A receptors in the cells. Most studies have investigated the effects of 
chronic 5-HT uptake inhibitors on the 5-HT1A receptors. Recently, some studies on the 
effects of 5-HT uptake inhibitors on G proteins, second messengers and the regulation 
of 5-HT receptors or G proteins have been reported (Newman et al.1992; Jolas et 
al.1994; Lesch and Manji, 1992; Lesch et al.1992b). 
Several studies have shown that repeated injections of 5-HT uptake inhibitors do 
not change the density of 5-HT1A receptors (either pre- or postsynaptic) (Le Poul et 
al.1995; Hensler et al.1991; Jolas et al.1994). Le Poul et al. (1995) reported that 
neither 5-HT1A agonist binding (3H-8-0H-DPAT) nor 5-HT1A antagonist binding (3H-
WA Y-100635) was altered by repeated injections of fluoxetine or paroxetine. These 
results indicate that the total number of 5-HT1A receptors and high affinity state 5-HT1A 
receptors are not changed by repeated injections of 5-HT uptake inhibitors. Hensler et 
al. (1991) found that although repeated injections of sertraline or citalopram attenuated 
the hypothermic response to 8-0H-DPAT, there were no changes in the density of 5-
HT1A receptors as measured by autoradiographic analysis of 3H-8-0H-DPAT binding. 
In contrast, Welnet et al. (1989) reported that repeated injections of fluoxetine for 21 
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days decreased the density of 5-HT1A receptors in the dorsal raphe but not in the 
hippocampus. Also, Klimek et al. (1994) reported that citalopram, but not fluoxetine, 
enhances the density of 5-HT1A receptors in the hippocampus. 
Since repeated injections of 5-HT uptake inhibitors may not change the density 
of 5-HT1A receptors or the changes only occur in specific nuclei, it is possible that the 
desensitization of 5-HT1A receptors induced by 5-HT uptake inhibitors is mediated by 
alterations of the signal transduction systems of 5-HT1A receptors. Newman, et al. 
(1992) have found that chronic exposure to fluoxetine reduces 5-HT-induced inhibition 
of forskolin-stimulated adenylyl cyclase in rat hippocampus. In contrast with the 
observation, repeated injections of cericlamine (a new 5-HT uptake inhibitor) for 14 
days did not reduce the 8-0H-DP AT-induced inhibition of forskolin-stimulated adenylyl 
cyclase, although the forskolin-induced activity of adenylyl cyclase was increased in the 
chronic cericlamine treated rats (Jolas et al.1994). No study has examined changes in 
the coupling of 5-HT1A receptors to their G proteins, although Le Poul et al. (1995) 
indicated that the ratio of 5-HT1A agonist and antagonist binding is not altered by 
repeated injections of 5-HT uptake inhibitors. Their data suggest that repeated injections 
of 5-HT uptake inhibitors do not alter the coupling of 5-HT1A receptors to their G 
proteins. No data regarding changes in the levels of G proteins induced by repeated 
injections of 5-HT uptake inhibitors have been reported, although some investigators 
have studied the effects of tricyclic antidepressants on the levels of G proteins in several 
brain regions (Lesch et al.1991a; Lesch and Manji, 1992) and in glial cells (Chen and 
Rasenick, 1995b). Lesch et al. (1992b; 1992) examined the changes in Gs, Gil• Gi2 , G0 , 
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G and G 12 rnRN A expression after repeated administration of a low dose of fluoxetine q 
for 21 days. Their results indicate that fluoxetine increases G12 rnRNA in the frontal 
cortex, Gq rnRNA in the neostriatum and Gi2 and G0 rnRNA in the midbrain. No 
change in the G protein rnRNA was detected in the hypothalamus and hippocampus. 
These results suggest that chronic administration of 5-HT uptake inhibitors may change 
the level of G proteins. All together, these results suggest that the desensitization of 
5-HT1A receptors, induced by repeated injections of 5-HT uptake inhibitors, may not 
be due to changes in the density of 5-HT1A receptors and their coupling to G proteins 
in the steady state. It is possible that the desensitization of 5-HT1A receptors is 
mediated by alterations in the components of the signal transduction system, such as the 
level of G proteins and activity of adenylyl cyclase, resulting in dynamic changes in the 
signal transduction system of 5-HT1A receptors in the neurons. Furthermore, the 
regulation of 5-HT1A receptors and/or G proteins, for example by phosphorylation or 
palmitoylation (Wedegaertner et al.1995; Ross, 1995; Milligan et al.1995), could play 
a role in producing the desensitization of 5-HT1A receptors. Several studies have 
demonstrated that phosphorylation of 5-HT1A receptors induces their desensitization 
(Nebigil et al.1995; Raymond and Olsen, 1994; van Huizen et al.1993; Raymond, 
1991). Some of these studies have shown that the phosphorylation of 5-HT1A receptors 
may be mediated by protein kinase A and/or protein kinase C (Raymond and Olsen, 
1994; Raymond, 1991). Others suggest that the phosphorylation of 5-HT1A receptors 
may be mediated by other mechanisms but not by protein kinase C (Nebigil et al.1995; 
van Huizen et al.1993; Claustre et al.1991a). Mann et al. (1995) reported that repeated 
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injections of fluoxetine (5 mg/kg) for 21 days significantly decreased the activity of 
protein kinase C in the cortex and hippocampus. Therefore, it is unlikely that the 
desensitization of 5-HT1A receptors, induced by repeated injections of 5-HT uptake 
inhibitors, is due to the phosphorylation by protein kinase C. So far, no study has been 
reported regarding the effects of 5-HT uptake inhibitors on the palmitoylation of 5-HT1A 
receptors, although there are some studies on palmitoylation of G proteins (Milligan et 
al.1995; Ross, 1995; Wedegaertner et al.1995; Degtyarev et al.1994). Taken together, 
the mechanism of desensitization of 5-HT1A receptors, induced by chronic 5-HT uptake 
inhibitors, is still unclear. Specifically, no studies have reported on the time-course of 
the effect of 5-HT uptake inhibitors on the 5-HT1A receptor system, including changes 
in the 5-HT1A receptors, their signal transduction system, and 5-HT1A receptor-mediated 
physiological functions. 
CHAPTER III 
MATERIALS AND METHODS 
Animals 
Male Sprague-Dawley rats (225-275 g) were purchased from Harlan Sprague 
Dawley Inc. (Indianapolis, IN). The rats were housed two per cage in a lighting (12 
hr light/dark; lights on at 7 A.M), humidity and temperature-controlled room. Food 
and water were available ad lib. All procedures were conducted in accordance with the 
NIH Guide for the Care and Use of Laboratory Animals as approved by the Loyola 
University Institutional Animal Care and Use Committee. 
Drugs and Reagents 
Fluoxetine was a gift from Eli Lilly and Company (lndianapolis,IN). 
Desipramine was purchased from Sigma Chemical Co (St. Louis, MO). Paroxetine was 
a gift from Smith-Kline Beecham. 8-0H-DPAT was purchased from Research 
Biochemicals Inc (Natick, MA). Ipsapirone was a gift from Miles Laboratories, 'Inc. 
(West Haven, Connecticut). All the drugs were dissolved in saline and injected in a 
volume of 2 ml/kg for antidepressants and 1 ml/kg for 8-0H-DPAT and ipsapirone. 
ACTH antiserum was purchased from lgG Corp (Nashville, TN). ACTH (1-39) 
standards were obtained from Calbiochem (San Diego CA). Bovine serum albumin and 
aprotinin were purchased from Sigma Chemical Co. (St. Louis, MO). Normal rabbit 
46 
47 
serum and goat anti-rabbit-')'-globulin were purchased from CalBiochem (San Diego, 
CA). 1251-ACTH was obtained from INCSTAR (Stillwater, MN). Corticosterone 
antiserum was purchased from ICN Biochemicals (Irvine, CA). Ultima Gold 
scintillation fluid was purchased from Packard Instrument Co., Inc. (Downers Grove, 
IL). acetone (Spectranalyzed A-19) and petroleum ether were obtained from Fisher. 
3H-corticosterone, 1251-oxytocin and 3H-8-0H-DP AT were purchased from DuPont-NEN 
(Boston, MA) at a specific activity of 129 Ci/mmol for the fluoxetine study and 135 
Ci/mmol for the paroxetine study. Gpp(NH)p was purchased from Sigma Chemical 
Co. (St. Louis, Mo). Recombinant a-subunits of G protein immunoblot standards were 
purchased from Calbiochem (San Diego, CA). Anti Gi112 (AS/7) and anti G0 (GC/2) 
sera were purchased from Du-Pont NEN. Anti Gi3 serum was purchased from Upstate 
Biotechnology Inc. (Lake Placid, NY). Rabbit peroxidase-anti peroxidase was purchased 
from Organon Teknika Co (Durham, NC). The chemiluminescence substrate solution 
LumiGlo was obtained from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, 
MD). NP-40 (Nonidet P-40 or lgepal CA-630) was purchased from Sigma Chemical 
Co. (St. Louis, Mo). 
Biochemical Determinations 
Radioimmunoassays 
Plasma ACTH radioimmunoassay 
ACTH radioimmunoassay was performed in an un-extracted plasma samples 
using an ACTH antiserum. The sequence recognition of the antiserum is the 5-18 
segment of ACTH. This antiserum does not significantly recognize a-MSH, /j-MSH, 
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,6-endorphin, ,6-lipotropin, ACTH 11-24, or ACTH 1-16-amide. ACTH (1-39) was 
used as standards. In this double antibody radioimmunoassay, samples and standards 
were incubated with the ACTH antibody (final dilution 1:30,000, 223 total binding) 
at 4 °c for 24 hr in a 0. 01 M phosphosaline buffer (PBS, pH 7. 6) containing 1 % bovine 
serum albumin, 0.025 M EDTA, 0.53 normal rabbit serum and 25 KIU/ml aprotinin. 
1251-ACTH (2000 cpm) was added and incubated for 24 hr at 4°C in a total volume of 
0.3 ml. The second antibody (goat anti-rabbit-)'-globulin) was added at a final dilution 
of 1 :50 and incubated overnight at 4°C. After 1.5 ml of cold PBS was added, the tubes 
were then centrifuged at 15,000 x g 4°C for 40 min. The radioactivity of the pellet was 
counted for 5 min by a Micromedic 4/200 plus 'Y counter and analyzed from a standard 
curve using a RIA-AID computer program (Robert Maciel Associates, Arlington, MA). 
The sensitivity of the assay is 0.25 pg/tube and the intra- and inter-assay variations are 
4.23 and 14.6% respectively. 
Plasma corticosterone radioimmunoassay 
Corticosterone radioimmunoassay was performed on un-extracted plasma samples 
in which corticosterone-binding proteins had been denatured by boiling, as previously 
described (Van de Kar et al.1985). The assay is based on procedures and antiserum 
(final dilution 1:11,200, 463 total binding) from ICN Biochemicals (Irvine, CA). 
Briefly, plasma (2 or 5 µl) and standard (0-5 ng/tube) were incubated with sodium 
phosphate buffer (0.05 M pH 7.0) containing 0.16 M NaCl, 0.015 M sodium azide and 
2 3 gelatin at 70° C for 20 min to denature plasma proteins. After the tubes were 
cooled to room temperature, 0.1 ml antibody (1 :5600 dilution) and radioactive 3H-
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corticosterone tracer (about 6,000 - 7 ,000 cpm) were added to the tubes. The tubes, 
with a total volume of 0. 7 ml, were then incubated at 4° C overnight. To separate the 
bound from the free tracer, 0.2 ml of cold Dextran T 70-charcoal suspension was added 
to the tubes, mixed and incubated at 4°C for 10 min. The tubes was then centrifuged 
at 15,000 x g, 4°C for 20 min. The supernatants were decanted into scintillation vials 
and 5 ml of Ultirna Gold scintillation fluid was added to each vial. The radioactivity 
of 3H-corticosterone was counted by a Hewlett Packard MINAXY scintillation courter 
for 2.5 min. The sensitivity of this assay is 0.02 ng/tube, and the intra- and inter-assay 
variabilities are 4. 5 % and 11. 9 % respectively. 
Plasma oxytocin radioimmunoassay 
Oxytocin assay was performed by a method modified from Keil ( 1984). Plasma 
was first extracted before it was used in the radioirnrnunoassay. Briefly, rat plasma (1 
ml) was mixed with 2 ml cold acetone (Spectranalyzed) and centrifuged at 2000 rpm, 
4°C for 30 min. The supernatant was then added to 5 ml cold petroleum ether and 
mixed immediately. After centrifugation at 2000 rpm, 4°C for 15 min. the top layer 
was aspirated and discarded. The remaining solution was dried by blowing air into the 
tubes in ice. The dried extract was then dissolved in 1 ml assay buffer (0.05 M 
phosphate buffer pH 7.4, containing 0.125 % bovine serum albumin, 0.01 % sodium 
azide, 0.001 M EDTA) and was used for the oxytocin radioirnrnunoassay. This assay 
is a double-antibody assay. The plasma extract (20 or 200 µl) and oxytocin standard 
(0-1 ng) were incubated with 0.1 ml rabbit anti-oxytocin serum (1 :50,000 dilution) in 
a total volume of 0.4 ml assay buffer for 24 hours at 4°C. 1251-oxytocin (3,000 cpm, 
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0.1 ml) was then added to the tubes and incubated for 72 hours at 4°C. To the tubes 
was then added 0.1 ml goat anti-rabbit )'-globulin (1: 12.5 dilution), followed by 0.1 ml 
normal rabbit serum (1: 120 dilution). After incubation for 24 hours, the tubes were 
centrifuged at 15,000 x g, at 4°C for 20 min. The supernatant was decanted and the 
radioactivity of the pellet was counted for 5 min by a Micromedic 4/200 plus 'Y counter 
and analyzed from the standard curve using the RIA-AID computer program (Robert 
Maciel Associates, Arlington, MA). The concentration of plasma oxytocin was 
calculated with a correction factor based on the recovery of the extraction. 
Radioligand binding assay 
Homoi:enate radiolii:and bindint: assays for 5-HT1A receptors in hypothalamus, 
midbrain and frontal cortex 
Tissue preparation 
Hypothalamic, midbrain and frontal cortical homogenates were prepared 
according to the protocol of Leonhardt et al. (1992). Briefly, frozen tissues were 
placed in a minimum of 25 volumes of ice cold 50 mM Tris-HCl (pH 7.7, 25°C) 
containing 0.5 mM EDTA and 10 mM MgS04 and homogenized using a Tekmar 
Tissumizer (2 x 5 sec). The homogenate was centrifuged at 37 ,000 x g for 15 min at 
4°C. The pellet was resuspended in 30 volumes of buffer, homogenized, incubated at 
37°C for 15 min and then centrifuged at 37 ,000 x g for 10 min. Tissue was then 
washed and centrifuged once more. The tissue for 3H-paroxetine binding was washed 
for 8 times to remove excess fluoxetine. Finally, the pellet was resuspended to a 
volume of 30 mg wet wt./ml in cold 50 mM Tris-HCl (pH 7.7) containing 0.5 mM 
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EDTA and 10 mM MgS04 . The protein concentration of the homogenate was 
measured according to Lowry et al. ( 1951). 
3H-8-0H-DPAT binding 
The 3H-8-0H-DPAT binding assay was used to determine 5-HT1A receptors in 
the hypothalamus, midbrain and frontal cortex. Briefly, hypothalamic (1.5 mg wet 
tissue/tube), midbrain (3 mg wet tissue/tube) or frontal cortical (3 mg wet tissue/tube) 
homogenates were incubated with 1 ml Tris buffer (50 mM, pH 7.7) containing 10 mM 
MgS04 , 0.5 mM EDTA, 10 µM pargyline, 0.02% ascorbate acid and 3H-8-0H-DPAT 
(159.5 Ci/mmol, 1 mCi/ml, New England Nuclear) in a concentration of 0.75-6.0 nM, 
at room temperature for 1 hr. Non-specific binding was defined in the presence of 1 
µM 8-0H-DPAT. The reaction was stopped by immediate filtration over Whatman 
GF/C filters and washed three times with 5 ml of a 50 mM Tris buffer (pH 7.7). The 
radioactivity of the filters was counted in 5 ml scintillation liquid at 56 % efficiency. 
Scatchard analysis was applied for calculation of the Kd and Bmax of 3H-8-0H-DPAT 
labelled 5-HT1A receptors. 
3H-5-HT binding for 5-HT1A receptors 
3H-5-HT was used to determine 5-HT1A receptors in the frontal cortex. Briefly, 
6 mg (wet wt.) of frontal cortex was incubated with 0.75 - 6.0 nM 3H-5-HT in 2 ml 
50 mM Tris buffer (pH 7.7, 25°C), containing 10 mM MgS04, 0.5 mM EDTA, 0.02% 
ascorbate and 10 µM pargyline for 60 min at room temperature. Non-specific binding 
was defined in the presence of 1µM8-0H-DPAT. The content of the assay tubes was 
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filtered, washed and analyzed as described for the 3H-8-0H-DPAT binding assay. 
3H-paroxetine binding for 5-HT uptake sites 
A 3H-paroxetine saturation assay (Battaglia et al.1987) was used to examine 5-
HT uptake sites. The tissue homogenate was incubated for 30 minutes at 37°C and 
further washed a 8 times in 40 volumes of Tris buffer (pH 7.7, 50 mM Tris, 120 mM 
NaCl, 5 mM KCl), followed by centrifugation at 37,000 g at 4°C to wash out fluoxetine 
and desipramine from the tissues. Preliminary data from our laboratory have indicated 
that inadequate washes of the tissue resulted in an apparent increase in K0 for 3H-
paroxetine binding, due to fluoxetine remaining bound to the tissue. However, 
following 8 washes, as described above, no significant differences were observed 
between vehicle and fluoxetine pretreated rats. After a final wash, the pellet was 
resuspended to a volume of 30 mg wet wt/ml in 50 mM Tris buffer (pH 7. 7) containing 
120 mM NaCl and 5 mM KCI. 3H-paroxetine (20.3 Ci/mmol, 1 mCi/ml, Du Pont 
NEN, Boston, MA) in concentrations of 0.01-0.4 nM was incubated at room 
temperature with midbrain homogenates (1.5 mg tissue/tube) in 5 ml of 50 mM Tris 
buffer (pH 7.7), containing 120 mM NaCl and 5 mM KCl, at room temperature for 2 
hrs. Non-specific binding was defined in the presence of 1 µM citalopram. The 
reaction was stopped by immediate filtration over Whatman GF/C filters and the filters 
were washed three times with 5 ml of a 50 mM Tris buffer (pH 7. 7). The radioactivity 
of the filters was counted in 5 ml scintillation liquid at 56 % efficiency. The Bmax and 
Kd of the 5-HT uptake sites were calculated using Scatchard analysis. 
Autoradiographic analysis of 3H-8-0H-DPAT binding 
Procedure 
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The brains from the rats that received saline-challenge were cut into 15 µm 
coronal sections using a cryostat at -21°C. The sections were thaw-mounted on 
chromalum/gelatin coated slides and stored at -20°C. Sections were collected from the 
following levels: frontal cortex (Bregma +3.70 mm), medial hypothalamus (Bregma -
1.80 mm), caudal hypothalamus (Bregma -3.14 mm) and midbrain (Bregma -7.8 mm) 
according to the atlas of Paxinos & Watson (1986). Sections from these levels were 
used for autoradiographic analysis. 
The autoradiographic assay for 3H-8-0H-DPAT- labeled 5-HT1A receptors was 
performed as described by Pazos and Palacios (1985). Briefly, after a preincubation 
in the assay buffer (containing 0.17 M Tris, 4 mM CaCl, 10 µM pargyline and 0.01 % 
ascorbic acid, pH 7.6), slide mounted sections were incubated with 3H-8-0H-DPAT (2 
nM) at room temperature for 1 hour. This concentration of 3H-8-0H-DPAT is equal 
to its Kd in hypothalamic homogenates (Li et al.1993b). Non-specific binding was 
defined in presence of the 10-6M 5-HT. Gpp(NH)p-induced inhibition of 3H-8-0H-
DPAT binding was examined by incubating the slides in the presence of 10-5M 
Gpp(NH)p. After washing the slides twice with Tris buffer at 4 °C for 5 min, the slides 
were dipped in cold H20 and then blow-dried immediately. They then were exposed 
to tritium-sensitive Hyperfilm-3H for either 2 months or 2 weeks (for sections 
containing a high density of the binding sites). A set of 3H microscales (Amersham) 
was exposed to each film together with the slides to calibrate the optical density into 
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fmol/mg tissue equivalent. 
The films were developed by a Kodak developing procedure for X-ray films. 
Films were placed in a Kodak Developer D-19 for 5 min, followed by 30 sec in Kodak 
Indicator Stop Bath solution. Then, the films were transferred into Kodak Fixer for 5 
min and subsequently placed in a running water bath for 10 min followed by 5 min in 
a water bath containing Kodak Photo-Flo 200. The films were then air-dried. 
Data analysis 
Autoradiograms were analyzed densitometrically using the NIH image analysis 
program for Macintosh computers. The gray scale density readings were calibrated to 
fmol/mg tissue equivalent using the [3H]microscales. Brain regions were identified 
according to the atlas of Paxinos and Watson (1986), as shown in Fig.10. The layers 
of the cortex were identified according to the atlas of Zilles ( 1985). The density of 3H-
8-0H-DPAT binding in each brain region was measured and expressed as fmol/mg 
tissue equivalent. An area outside of the section was measured as the background of 
the film, which was subtracted from each measurement in the section. Specific 3H-8-
OH-DPAT binding sites in each brain region were determined by subtracting the non-
specific binding sites from the total binding sites in each region. The percent of 
Gpp(NH)p-induced inhibition was calculated using the equation below: 
fmol/mg tissue equivalentsp - fmol/mg tissue equivalentopp(NH)p 
3 of inhibition - x 100 % 
fmol/mg tissue equivalentsp 
In this equation, fmol/mg tissue equivalentsp represents the specific 3H-8-0H-DPAT 
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binding in the absence of Gpp(NH)p; fmol/mg tissue equivalentapp(NH)p represents the 
specific binding in the presence of Gpp(NH)p. 
The data for a brain region of each rat represents the mean of four adjacent 
brain sections. 
Immunoblot analysis of G proteins 
Membrane preparation 
The membranes of the hypothalami, midbrains and frontal cortices were 
prepared as described by Sternweis ( 1984) and Okuhara ( 1996). Briefly, the tissues 
were homogenized in 1ml50 mM Tris buffer, pH 7.4 containing 150 mM NaCl, 10% 
sucrose and 0.5 mM phenylmethanesulfonyl fluoride (PMSF; added immediately before 
homogenization), using a Tekmar tissumizer at a speed of 13,500 rpm for about 10 
seconds. After centrifugation at 20,000 x g, 4°C for 60 minutes, pellets were re-
suspended in 50 µl (for the hypothalamus), or 200 µl (for the midbrain and frontal 
cortex) of 20 mM Tris buffer, pH 8 containing 1 mM ethylenediamine tetraacetic acid 
(EDTA), 100 mM NaCl, 1 % sodium cholate and 1 mM dithiothreitol to solubilize the 
membrane proteins. The re-suspended homogenates were incubated and shaken at 4°C 
for 1 hour, followed by centrifugation at 100,000 x g, 4°C for 60 minutes. The 
supernatants were used for G protein measurements. Protein concentrations in the 
supernatant were measured according to Lowry (1951) using bovine serum albumin as 
a standard. The protein concentrations in the supernatant were: 1.7-2.2 µglµl for the 
hypothalamus; 2.0-3.5 µglµl for the midbrain; and 1.6-2.3 µglµl for the frontal cortex. 
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Quantification of G proteins 
The solubilized proteins (10-35 µg protein) were resolved by SDS-
polyacrylamide gel electrophoresis, using gels containing 0.1 3 sodium dodecyl sulfate 
(SDS), 12% acrylamide/bisacrylamide (30:0.2), 4 M urea and 375 mM Tris, pH 8.4 
(Mullaney and Miligan, 1990). Two samples from each treatment group (i.e. control, 
fluoxetine 3 days, fluoxetine 7 days, etc.) were loaded on each gel. Each sample was 
repeatedly measured on three independent gels. The proteins were then 
electrophoretically transferred to nitrocellulose membranes. The membranes were 
incubated in a solution containing 5 3 non-fat dry milk, 0.05 3 NP40, 50 mM Tris and 
150 mM NaCl, pH7.4, and were then washed. The membranes were incubated with 
polyclonal antisera for Gi112 (AS/7, 2500 dilution), Gi3 (Anti-GiaJ• 1 :2000 dilution) and 
G0 (GC/2, 1 :2000 dilution) at 4°C overnight. The membranes were then incubated with 
a secondary antibody (goat anti-rabbit serum 1: 10,000) for 60 minutes. Following 4 
washes with 0.05% NP40 in 50 mM Tris and 150 mM NaCl, the membranes were 
incubated with rabbit peroxidase-antiperoxidase (1: 10,000) for 1 hour. After several 
washes, the membranes were incubated with the chemiluminescence substrate solution 
(LumiGlo) for 1 minute and then exposed to Kodak x-ray film for 10-40 seconds. 
Data analysis 
Films were analyzed densitometrically using the NIH image analysis program 
for Macintosh computers. The gray scale density readings were calibrated using 
transmission step wedge standard (Stouffer Graphic Arts Equipment Co., South Baend, 
IN). The integrated optical density (IOD) of each band was calculated as the sum of 
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optical densities of all the pixels within the area of the band outlined. An area adjacent 
to the G protein bands was used to calculate the background optical density of the film. 
The IOD for the film background was subtracted from the IOD for each band. The 
resulting IOD for each G protein band was then divided by the amount of protein 
loaded on the corresponding lane. The IOD/ µg protein values obtained from treated 
rats were divided by the mean IOD/ µg protein values obtained from control rats in 
same gel to determine the relative amounts of the G proteins. The data for each rat 
were the means obtained from the three gels. Samples from 6-8 rats were measured 
for each treatment group. 
Characterization of antisera 
Recombinant mouse Gil• Gi2 , Gi3 and G0 standards (obtained from CalBiochem) 
were used to identify the G protein bands and characterize the specificity of antisera. 
As Fig.1 shows, Gil protein can be separated from Gi2 protein under our electrophoretic 
conditions. Therefore, we were able to use an antiserum which recognizes both Gi1 and 
Gi2 proteins (AS/7), to measure these Gi proteins independently. Gi3 and G0 proteins 
were not detected with the AS/7 antiserum. Anti Gi3 serum recognizes at least three 
bands between 39-45 kd. The Gi3 standard co-migrated with the highest molecular 
weight band. Therefore, we measured this band as the Gi3 protein. This Gi3 antibody 
did not detect Gi1 , Gi2 or G0 proteins. GC/2, an anti G0 serum, was found to be 
selective for G0 protein and did not detect Gil, Gi2 and Gi3 proteins (Fig. 1). 
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AS/7 
~ 45 kDa 
-- - ~ 32.6 kDa 
Gi1 Hyp Go Gi3 Gi1 Gi2 + Gi2 
Anti Gi3 ~ 45 kDa 
~ 32 .6 kDa 
Gi3 
G;3 
Hyp Go G;, G,2 + Hyp 
Fi2ure 1. Characterization of antibodies against Gi., Gi2, Gu and G0 proteins 
used in immunoblots. The top panel demonstrates the specificity of AS/7 antibody for 
the Gi1 and Gil proteins: The lanes from left to right contain: recombinant Gi1 protein, 
recombinant Gi2 protein, recombinant Gi1 plus Gi2 proteins, hypothalamic extract, 
recombinant G0 protein, and recombinant Gi3 protein. The bottom panel demonstrates 
the specificity of the UBI Gi3 antibody. The lanes from left to right contain: 
recombinant Gi3 protein, hypothalamic extract plus recombinant Gi3 protein, 
hypothalamic extract, recombinant G0 protein, recombinant Gil , and recombinant Gi2 
protein. 
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Statistics 
The data from the hormone analyses were extrapolated from standard curves 
using the RIA-AID computer program (Robert Maciel Associates, Arlington, MA). 
The data are presented as group means and the standard errors of the means (S.E.M.). 
The data from the hormone assays were analyzed by a two-way analysis of variance 
(ANOVA) and the data obtained from radioligand binding for the density and affinity 
of 5-HT1A receptors and 5-HT uptake sites or from immunoblots for G proteins were 
analyzed by one-way ANOVA. Group means were compared by Newman-Keuls' or 
Duncan's multiple range test as indicated in the text (Steel and Torrie, 1960). A 
computer program (NWA STATPAK, Portland,OR) was used for all the statistical 
analyses. 
CHAPTER IV 
LONG-TERM FLUOXETINE, BUT NOT DESIPRAMINE, PRODUCES A 
DESENSITIZATION OF HYPOTHALAMIC 5-HTIA RECEPTORS 
Summary 
The present studies determined whether the hypothalamic 5-HT1A receptor 
systems are modified by chronic exposure to antidepressants. Hormone responses to 
the 5-HT1A agonists 8-0H-DPAT and ipsapirone were used as marker to evaluated the 
function of 5-HT1A receptors after long-term exposure to two antidepressants, the 5-HT 
uptake inhibitor fluoxetine and the norepinephrine uptake inhibitor desipramine. In 
addition, the effects of long-term exposure to fluoxetine and desipramine on the density 
and affinity of 5-HT1A receptors in the hypothalamus, midbrain and cerebral cortex 
were examined. Male rats received fluoxetine (10 mg/kg ip), desipramine (5 mg/kg 
ip) or saline injections once daily for 21 days. 8-0H-DPAT (0-500 µg/kg sc), or 
ipsapirone (0-5 mg/kg, ip) were administered 18 hours after the final antidepressant 
injection and 15 minutes before sacrifice. 8-0H-DPAT and ipsapirone significantly 
increased plasma ACTH, corticosterone and oxytocin concentration in a dose-dependent 
manner. Chronic injections of fluoxetine inhibited the ACTH, corticosterone and 
oxytocin responses to 8-0H-DPAT or ipsapirone, suggesting reduced 5-HT1A receptor 
function. In contrast, chronic injections of desipramine did not alter the hormone 
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responses to either 8-0H-DPAT or ipsapirone. The density and affinity of 5-HT1A 
receptors in the frontal cortex or hypothalamus were not altered by either fluoxetine or 
desipramine. However, a decrease in the Bmax of 5-HT1A receptors in the midbrain 
was observed after chronic fluoxetine, but not desipramine. No change in the 5-HT 
uptake sites was observed after either antidepressant. To verify that the observed 
effects require prolonged exposure to fluoxetine, rats received a single injection of 
fluoxetine (10 mg/kg, ip), 3 hours before the injection of 8-0H-DPAT (0-500 µglkg 
sc). Acute fluoxetine did not reduce any of the hormone responses to 8-0H-DPAT. 
In conclusion, the results suggest that chronic, but not acute exposure to fluoxetine 
produces a desensitization of hypothalamic 5-HT1A receptors. This effect is not seen 
in rats chronically exposed to desipramine. The mechanism of the effects of chronic 
fluoxetine on 5-HT1A receptor mediated hormone responses is not likely due to reduced 
density of 5-HT1A receptors, because no changes were observed in 3H-8-0H-DPAT 
binding in hypothalamus and cortex. It could be due to changes in signal transduction 
system of 5-HT1A receptors. Furthermore, it can not be ruled out that fluoxetine 
injections alter the density of 5-HT1A receptors in specific nuclei of the hypothalamus. 
Introduction 
The present studies examined hormone responses to two 5-HT1A agonists, 8-0H-
DPAT and ipsapirone, to assess the effect of two antidepressants, fluoxetine and 
desipramine on 5-HT1A receptor function. Several antidepressants are 5-HT uptake 
inhibitors with lower affinity for norepinephrine or dopamine uptake sites ( e. g 
fluoxetine, sertraline, paroxetine) (Beasley et al.1992; Levy and Van de Kar, 1992; 
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Perry and Fuller, 1992; Wong et al .1990; Bolden-Watson and Richelson, 1993; Fuller 
et al.1991). Other antidepressants, such as desipramine, are norepinephrine uptake 
inhibitors with low affinity for serotonin uptake sites (Richelson, 1991). Regardless of 
the acute pharmacologic profiles of these antidepressants, the mechanisms of their 
antidepressant effects remain unclear, particularly because they have to be administered 
for at least 2-3 weeks before clinical improvement can be observed (Richelson, 1991). 
Alterations in 5-HT IA receptors have been suggested to contribute to the clinical 
improvement observed after long-term exposure to antidepressants (Lesch et al.1991c; 
Meltzer, 1990; Richelson, 1991; Newman et al.1992; Stockmeier et al.1992). To 
determine whether changes in 5-HT1A receptor systems occur commonly after chronic 
exposure to two classes of antidepressants, in the present study we compared the effect 
of chronic fluoxetine and desipramine on the function of 5-HT1A receptors in the 
hypothalamus. 
Hormone responses to challenges with selective 5-HT agonists can be used as 
indices of the function of serotonin receptors, both in humans and experimental animals 
(Van de Kar, 1989). Activation of 5-HT1A receptors increases the secretion of ACTH, 
corticosterone and oxytocin (Kelder and Ross, 1992; Van de Kar, 1991; Jorgensen et 
al.1992; Van de Kar and Brownfield, 1993; Brownfield et al.1992). 8-0H-DPAT is 
a selective 5-HT1A agonist (Van Wijngaarden et al.1990; Hoyer and Schoeffter, 1991) 
that has been shown to increase the secretion of oxytocin, ACTH and corticosterone by 
activating 5-HT1A receptors (O'Donnell and Grealy, 1992; Calogero et al.1990; Fuller 
and Snoddy, 1990; Bagdy et al. 1989; Calogero et al.1989; Koenig et al.1987; Gilbert 
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et al.1988a; Vicentic et al.1996). Ipsapirone is a partial 5-HT IA agonist. Like 8-0H-
DPAT, ipsapirone increases ACTH, corticosterone and oxytocin secretion by activating 
hypothalamic 5-HT,A receptors (Lesch et al.1991c; Cowen et al.1990; Gilbert et 
al.1988a; Bagdy, 1995; Bagdy, 1994; Bagdy and Makara, 1994). However, the two 
5-HT,A agonists have different chemical structures and thus, they may have different 
side effects. Since ipsapirone and 8-0H-DPAT have a common pharmacological effect 
on 5-HT1A receptors, the common neuroendocrine profiles obtained with these two 5-
HT,A agonists are most likely mediated by activation of 5-HT1A receptors. 
In the present studies, we examined the neuroendocrine responses to the 5-HT,A 
agonists, 8-0H-DPAT and ipsapirone, after chronic exposure to fluoxetine or 
desipramine. To examine the mechanism of the changes in the 5-HT,A receptor 
systems induced by the antidepressants, we also measured the affinity and density of 
5-HT1A receptors in the hypothalamus, midbrain and cerebral cortex as well as the 
affinity and density of 5-HT uptake sites. Furthermore, we compared the effects of 
chronic fluoxetine on the hormone response to 8-0H-DPAT with that of acute treatment 
with fluoxetine, to determine whether the effects of fluoxetine on the function of 5-HT,A 
receptors require long-term treatment. 
Experimental Protocol 
The rats for the chronic experiment were pretreated with either fluoxetine ( 10 
mg/kg ip), desipramine (5 mg/kg ip) or saline once daily for 21 days. These doses 
were observed by de Montigny and Aghajanian (1978) to alter the response of rat 
forebrain neurons to 5-HT. Furthermore, treatment with these doses has resulted in up-
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regulation of 5-HT2 receptors in the hypothalamus (Li et al.1993a). 8-0H-DPAT (50, 
200, 500 µglkg sc), or ipsapirone ( 1, 2, 5 mg/kg ip) or saline were administered 18 
hours after the last injection of the antidepressants. The rats were sacrificed by 
decapitation 15 minutes following injection of the 5-HT1A agonists or saline. Trunk 
blood was collected in centrifuge tubes containing 0.5 ml of a 0.3 M EDTA (pH 7.4) 
solution. The frontal cortex, hypothalamus and midbrain were dissected immediately 
after decapitation and frozen in liquid nitrogen. Tissues were stored at -70°C until the 
measurement of 5-HT1A receptors and 5-HT uptake sites. In the acute experiment, the 
rats received a single dose of saline or fluoxetine (10 mg/kg ip) 3 hours before injection 
of 8-0H-DPAT. The doses of 8-0H-DPAT in the acute experiment were the same as 
those in the chronic experiment. 
Plasma was stored at -70°C until assayed for plasma hormone levels. Plasma 
ACTH, corticosterone and oxytocin concentrations were measured by 
radioimmunoassay (see Chapter III). The affinity and density of 5-HT1A receptors in 
the hypothalamus, midbrain and frontal cortex were examined by 3H-8-0H-DPAT 
binding or 3H-5-HT binding assays. In addition, affinity and density of 5-HT uptake 
sites in the midbrain were determined by 3H-paroxetine binding (see Chapter Ill for 
details). 
Results 
Both 8-0H-DPAT and ipsapirone increased plasma ACTH, corticosterone and 
oxytocin concentrations in a dose-dependent manner (Fig. 2, 3, 5). Repeated injections 
of fluoxetine, but not desipramine, significantly inhibited the 8-0H-DPAT-induced 
65 
increase of plasma ACTH levels (Fig. 2). This inhibition was observed at the 50 µglkg 
dose of 8-0H-DPAT in fluoxetine pretreated rats (Newman Keuls' test P < 0.01). 
Consistent with the ACTH response to 8-0H-DPAT, chronic fluoxetine, but not 
desipramine, inhibited the ipsapirone-induced increase of plasma ACTH concentration 
(Fig. 2). Chronic fluoxetine significantly reduced the ACTH response to the 5 mg/kg 
dose of ipsapirone (P < 0.01). A single injection of fluoxetine did not significantly 
alter the ACTH response to 8-0H-DPAT (Fig. 4). 
Similar to the ACTH response, chronic fluoxetine, but not desipramine, shifted 
the corticosterone dose response curve of 8-0H-DPAT to the right, but did not change 
the maximal response. A significant inhibition of the corticosterone response by 
chronic fluoxetine was observed at the lowest dose (50 µg/kg) of 8-0H-DPAT (P< 
0.05, Newman Keuls' test, Fig. 3). Two-way ANOVA revealed no significant effect 
of the antidepressants on the ipsapirone-induced increase of plasma corticosterone 
concentration. However, a significant inhibition by fluoxetine was observed at the 2 
mg/kg dose of ipsapirone (Duncan's multiple range test, P < 0.01). In contrast, a 
single injection of fluoxetine potentiated the corticosterone response to the lowest dose 
(50 µg/kg sc) of 8-0H-DPAT (Fig. 4). No significant difference was observed in the 
corticosterone responses to any dose of ipsapirone after long-term treatment with 
desipramine (Fig. 3). 
Chronic fluoxetine, but not desipramine, inhibited the effect of 8-0H-DPAT on 
oxytocin secretion as seen by a parallel right-shift in the dose response curves (Fig. 5). 
The lower doses of 8-0H-DPAT (50 and 200 µglkg sc) produced significantly lower 
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effects on plasma oxytocin in fluoxetine treated rats (Newman Keuls' test, P < 0.05). 
Chronic fluoxetine, but not desipramine, also reduced the oxytocin responses to 
ipsapirone. Two-way ANOV A showed a significant interaction between the effect of 
the antidepressants and ipsapirone on plasma oxytocin concentration (F<6.79i=3.062, P 
< 0.01). Furthermore, Duncan's multiple range test indicated that chronic fluoxetine 
significantly inhibited the effect of ipsapirone (5 mg/kg) on plasma oxytocin (P < 
0.01). Chronic desipramine did not affect the ipsapirone-induced increase in plasma 
oxytocin concentration. As can be seen in Figures 5, acute injection of fluoxetine did 
not inhibit the oxytocin responses to the same doses of 8-0H-DPAT. 
As can be seen in Table II, repeated injections of fluoxetine and desipramine did 
not significantly alter the density of 5-HT1A receptors in the hypothalamus and frontal 
cortex. However, chronic fluoxetine, but not desipramine, decreased the density of 3H-
8-0H-D PAT-labeled 5-HT1A receptors in the midbrain. Neither fluoxetine nor 
desipramine altered the affinity of 3H-8-0H-DPAT binding in any brain region. Also, 
long-term injections of the antidepressants did not change the density and affinity of 3H-
paroxetine-labeled 5-HT uptake sites in the midbrain. 
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Figure 2 Effect of chronic exposure to fluoxetine or desipramine on ACTH 
responses to 8-0H-DPAT (top) or ipsapirone (bottom). The data represent mean± 
S.E.M of eight to nine rats per group. Two way ANOVA: Main effect of 
antidepressants: F<2•80>=3.058, P<0.053(top); F<2•82>= 3.8664, P<0.05 (bottom); Main 
effect of 8-0H-DPAT: F<3•80>=27.56 P<0.01 (top); Main effect of ipsapirone: 
F<3.82>=29.33 P<0.01 (bottom); Interaction between antidepressants and 5-HT agonists: 
F<6•80>=2.597 P<0.05 (top); F<6.82>=2.6918 P<0.05 (bottom). *Significant difference 
from the saline challenged group, P < 0. 01. + significant difference from the saline 
pretreatment group (injected with the same dose of 5-HT1A agonists), P < 0.05 
(Duncan's multiple range test). 
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Figure 3. Effect of chronic exposure to fluoxetine or desipramine on the 
corticosterone response to 8-0H-DPAT (top) or ipsapirone (bottom). The data 
represent mean ± S.E.M of eight to nine rats per group. Two way ANOVA: Main 
effect of antidepressants: F<2.83)=0.912, NS (top); F<2•82)=1.8731, NS (bottom); Main 
effect of 8-0H-DPAT: F<3•83)=29.40 P<0.01 (top); Main effect of ipsapirone: 
F<3•82)=18.0487 P<0.01 (bottom); Interaction between antidepressants and 5-HT 
agonists: F<6•83)=2.262 P<0.0452 (top); F<3•82)=1.1089 NS (bottom). * Significant 
difference from the saline challenged group P < 0. 05; + significant difference from 
the saline pretreatment group (injected with the same dose of 5-HT1A agonists), P < 
0.05 (Duncan's multiple range test). 
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Fia=ure 4. Effect of a single injection of fluoxetine on ACTH (top) and 
corticosterone (bottom) responses to 8-0H-DPAT. The data represent mean ± 
S.E.M of eight to nine rats per group. Two way ANOV A: Main effect of 
antidepressants: Fcl,58)=0.267, NS (top); Fcl,58)=4.940, P<0.03 (bottom); Main effect 
of 8-0H-DPAT: Fc3,58l=52.49 P<0.01 (top); Fc3,58l=27.363 P<0.01 (bottom); 
Interaction between antidepressants and 8-0H-DPAT: F(3,s8)= 1.119 NS (top); 
Fc3,58)=2.0225 NS (bottom). * Significant difference from the saline (0 dose of 8-0H-
DPAT) group, P<0.05; +significant difference from the saline pretreatment group 
(injected with the same dose of 8-0H-DPAT), P<0.05 (Newman Keuls' test). 
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Figure 5. Effect of chronic exposure to fluoxetine or desipramine on the 
oxytocin response to 8-0H-DPAT (top) or ipsapirone (bottom). The data represent 
mean ± S.E.M of eight to nine rats per group. Two way ANOVA: Main effect of 
antidepressants: F(2.s4>= 14.429, P < 0.001 (top); F<2•79>=2.618 NS (bottom); Main effect 
of 8-0H-DPAT: F<3•84>=120.73 P<0.001 (top); Main effect of ipsapirone: 
F<3.79>=17.7837 P<0.001 (bottom); Interaction between antidepressants and 5-HT 
agonists: F<6•84>=1.998 P<0.0749 (top); F<6•79>=3.0617 P<0.01 (bottom).* Significant 
difference from the saline challenge group P < 0. 05; + significant difference from 
the saline pretreatment group (injected with the same dose of 5-HT1A agonists), P < 
0.05 (Duncan's multiple range test). 
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Figure 6. Effect of a single injection of fluoxetine on the oxytocin response 
to 8-0H-DPAT. The data represent mean ± S.E.M of eight to nine rats per group. 
Two way ANOVA: Main effect of antidepressant: F(1,5s)=5.2487 P<0.026; Main 
effect of 8-0H-DPAT: F<3•58l=96.959 P<0.001; Interaction between antidepressants 
and 8-0H-DPAT: F<3•58l= 1.214 NS. *Significant difference from the saline (0 dose of 
8-0H-DPAT) group, (Newman Keuls' test). 
TABLE II 
CHANGES IN BMAX OF 5-HT1A RECEPTORS INDUCED BY CHRONIC 
EXPOSURE TO FLUOXETINE AND DESIPRAMINE 
Bmax 
(finol/Ing protein) 
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Saline Fluoxetine Desipramine 
3ff-8-0H-DPAT binding 
Hypothalainus 196.8 ± 21.89 212.3 ± 29.6 211.1 ± 21.9 
(100%) (107.9%) (107.2%) 
Mid brain 82.19 ± 3.95 64.98 ± 2.71 * 77.7 ± 3.23 
(100%) (79.0%) (94.53) 
Frontal cortex 160.3 ± 8.5 150.7 ± 9.3 155.1 ± 11.5 
(100%) (93.7%) (96.7%) 
3H-5-HT binding 
Frontal cortex 158.0 ± 9.0 134.8 ± 11.9 149.0 ± 16.8 
(100%) (85.3%) (94.3%) 
3H-naroxetine binding 
Mid brain 650.3 ± 26.7 640.2 ± 30.3 615.2 ± 37.1 
(100%) (98.4%) (94.63) 
The data represent Inean ± S.E.M of eight rats per group. 
The nuinbers in parentheses indicate percent of the control group. 
TABLE III 
CHRONIC FLUOXETINE OR DESIPRAMINE DOES NOT CHANGE THE 
AFFINITY OF 5-HT1A RECEPTORS AND 5-HT UPTAKE SITES 
Kd 
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Saline Fluoxetine Desipramine 
3H-8-0H-DPAT bindin2 (nM} 
Hypothalamus 1.88 ± 0.2 2.39 ± 0.3 2.03 ± 0.3 
Midbrain 1.32 ± 0.06 1.39 ± 0.12 1.56 ± 0.13 
Frontal cortex 0.94 ± 0.1 0.87 ± 0.05 0.91 ± 0.04 
3H-5-HT bindin2 (nM} 
Frontal cortex 2.0 ± 0.2 1.83 ± 0.12 1.73 ± 0.27 
3H-naroxetine bindin2 (,UM} 
Midbrain 60.1± 2.5 72.0 ± 4.8 58.7 ± 4.0 
The data represent mean ± S.E.M of eight rats per group. 
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Discussion 
The present results suggest that chronic exposure to fluoxetine produces a 
desensitization of hypothalamic 5-HT1A receptors. In contrast, chronic injections of 
desipramine, or an acute injection of fluoxetine do not produce desensitization of the 
5-HT1A receptors. These data suggest that the effects of chronic fluoxetine on the 5-
HT1A receptor systems are adaptive changes induced by chronic inhibition of 5-HT 
uptake. Such reduction in the function of 5-HT1A receptors could be due to down-
regulation of 5-HT1A receptors. However, the inhibitory effects of chronic fluoxetine 
on hormone responses to 5-HT iA agonists were not accompanied by a significant 
reduction in the affinity or density of 5-HT1A receptors in the hypothalamus or frontal 
cortex. These reduced hormone responses are due to unknown mechanisms, possibly 
alterations in the signal transduction mechanisms, or in the second messenger systems 
of 5-HT1A receptors. On the other hand, it cannot be ruled out that the desensitization 
of 5-HT1A receptors induced by chronic fluoxetine is due to changes in the density of 
5-HT1A receptors in specific hypothalamic nuclei, which cannot be detected by the 
radioligand binding assay in homogenates. 
8-0H-DPAT is a selective 5-HT1A agonist with a high affinity for 5-HT1A 
receptors (pKi = 8.7) (Hoyer and Schoeffter, 1991) and low affinity for other 5-HT 
receptor subtypes (5-HTrn pKi = 5.75; 5-HT1c pKi = 5.1; 5-HT2 pKi < 5; 5-HT3 pKi 
< 5; 5-HT uptake pKi = 6.25) (Van Wijngaarden et al.1990). Several studies have 
demonstrated that 8-0H-DPAT increases the secretion of ACTH, corticosterone and 
oxytocin by activating 5-HT1A receptors (Cowen et al.1990; Gilbert et al.1988a; Koenig 
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et al.1987; Bagdy and Kalogeras, 1993; Li et al.1993 b; Vicentic et al.1996). 
Ipsapirone is a partial 5-HT1A agonist. Like 8-0H-DPAT, ipsapirone increases ACTH, 
corticosterone and oxytocin secretion by activating hypothalamic 5-HT iA receptors 
(Lesch et al.1991c; Cowen et al.1990; Gilbert et al.1988a; Bagdy, 1995; Bagdy, 1994; 
Bagdy and Makara, 1994). These two 5-HT1A agonists, ipsapirone and 8-0H-DPAT, 
have a common pharmacological effect on 5-HT1A receptors, despite different chemical 
structures. Therefore, the common neuroendocrine profiles obtained with these two 5-
HT1A agonists are most likely mediated by activation of 5-HT1A receptors. Our 
observation that chronic exposure to fluoxetine inhibits the ACTH and corticosterone 
responses to the 5-HT lA agonists is consistent with observations by Lesch et al. (Lesch 
et al .1991 c). They reported that chronic exposure of humans to fluoxetine inhibited the 
ACTH response to ipsapirone (Lesch et al.1991c). These results suggest that chronic 
exposure to fluoxetine results in desensitization of 5-HT1A receptors both in rats and in 
humans. 
In the present studies, the inhibitory effects of chronic fluoxetine on the oxytocin 
and ACTH responses to ipsapirone were only observed at a dose of 5 mg/kg and were 
not as clear as those observed with 8-0H-DPAT. This could be due to the relatively 
low doses of ipsapirone used in the study. In addition, ipsapirone has a higher efficacy 
for autoreceptors on the 5-HT neurons in the midbrain than for postsynaptic 5-HT1A 
receptors in the forebrain (Aghajanian et al.1990; Sprouse and Aghajanian, 1988). 
Since the regulation of hormones is mainly mediated by hypothalamic postsynaptic 5-
HT 1A receptors (Gilbert et al.1988b), it is possible that ipsapirone has lower efficacy 
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than 8-0H-DPAT in stimulating hormone release. Bagdy and Kalogeras (1993) 
observed that plasma oxytocin concentrations were elevated to a higher level by 8-0H-
DPAT (0.2 mg/kg, iv) than by ipsapirone (2 mg/kg, iv). However, ipsapirone can be 
administered to humans and although is not as useful as 8-0H-DPAT, a challenge with 
ipsapirone still has diagnostic value to determine the function of the 5-HT1A receptor 
system. 
The present studies are the first to examine the influence of 5-HT1A receptors on 
oxytocin secretion. Our results show that 8-0H-DPAT dose-dependently increases 
plasma oxytocin concentration. Note the similarities in the dose-response curves for 
plasma ACTH and oxytocin concentrations. Considering the selectivity of 8-0H-DPAT 
for 5-HT1A receptors (Van Wijngaarden et al.1990), and the dose-dependent effect, the 
data suggest that the 8-0H-DPAT-induced increase in oxytocin secretion is mediated 
by 5-HT1A receptors. Chronic fluoxetine, but not desipramine, produced an inhibition 
as observed by a parallel shift to the right in the oxytocin dose-response curve. This 
inhibition of the oxytocin response resembles the inhibition of the ACTH response to 
8-0H-DPAT, supporting the hypothesis that alterations in 5-HT1A receptor function 
might be responsible for this phenomenon. 
Since the 5-HT1A agonist-induced hormone responses are directly mediated by 
activation of cells in the hypothalamus, the lack of change in hypothalamic 5-HT1A 
receptors after chronic fluoxetine suggests that the decrease of hormone responses to 
8-0H-DPAT by chronic fluoxetine is not due to a reduction in the density or affinity 
of 5-HT1A receptors. Alternatively, since we have measured receptors in the whole 
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hypothalamus, there could be changes in specific nuclei in the hypothalamus or in other 
brain regions which could be responsible for the altered hormone responses to 8-0H-
DPAT. Newman et al. (1992) showed that chronic injections of fluoxetine decreased 
the function of 5-HT1A receptor systems as measured by the 5-HT-induced inhibition 
of forskolin-stimulated adenylyl cyclase activity in the hippocampus. Also, 5-HT1A 
receptor-mediated hypothermia is decreased after long-term exposure to citalopram and 
sertraline (Hensler et al.1991) or after electroconvulsive shocks (Stockmeier et al.1992). 
These observations suggest that antidepressants produce functional changes in 5-HT1A 
receptors which are not due to alteration in ligand recognition sites. Thus, it is possible 
that the desensitization of 5-HT1A receptors induced by chronic fluoxetine is due to a 
dysfunction of the signal transduction system linked to 5-HT1A receptors in the 
hypothalamus. 
An alternative explanation would be that chronic fluoxetine reduces the content 
of corticotropin releasing factor (CRF), ACTH or oxytocin. This is not likely because 
chronic exposure to the same doses of fluoxetine and desipramine potentiated the ACTH 
and oxytocin responses to DOI, a 5-HT2Aizc agonist (Li et al.1993a). These data 
suggest that the reduced hormone response to the 5-HT1A agonists is due to reduced 5-
HT tA receptor function rather than due to reduced hypothalamic or pituitary content of 
releasing factors or hormones. 
Although chronic exposure to fluoxetine did not alter the density of 5-HT1A 
receptors in the hypothalamus and frontal cortex, we observed a reduction of the 
density of 5-HT1A receptors in the midbrain after repeated injections of fluoxetine. 
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Since 5-HT neurons are located in the dorsal and median raphe nuclei in the midbrain, 
the 3H-8-0H-DPAT-labeledreceptors in the midbrainprobably mainly represent 5-HT1A 
autoreceptors. Therefore, this result supports the hypothesis that blockade of 5-HT 
uptake sites will desensitize 5-HT1A autoreceptors. These data are consistent with the 
autoradiographic observations by Welner et al. (Welner et al.1989). However, several 
other investigators did not observe changes in the 5-HT1A receptors in the raphe nuclei 
(Le Poul et al.1995; Hensler et al.1991; Jo las et al.1994). 
Most evidence suggests that hormone regulation is mediated by hypothalamic 
postsynaptic 5-HT1A receptors (Kelder and Ross, 1992; Gilbert et al.1988b). For 
example, depletion of 5-HT stores with PCPA does not reduce the ACTH response to 
8-0H-DPAT (Gilbert et al.1988b). Therefore, the reduction in the density of 5-HT1A 
receptors, in the midbrain might not be directly related to the inhibitory effect of 
chronic fluoxetine on the hormone responses to 5-HT1A agonists. Neither fluoxetine nor 
desipramine could alter the density and affinity 5-HT uptake sites in the midbrain, 
suggesting that the 5-HT nerve terminals in the midbrain are intact. Therefore, the 
reduction of 5-HT1A receptors in the midbrain, by fluoxetine, is not likely due to 
neurotoxic effects of fluoxetine. The lack of alterations in 5-HT uptake sites is 
consistent with other reports (Cheetham et al.1993; Dewar et al.1993). 
In conclusion, chronic exposure to fluoxetine resulted in a desensitization of 
hypothalamic 5-HT1A receptors. This effect was not observed in rats chronically 
injected with desipramine or in rats that received a single injection of fluoxetine. Also, 
this effect was opposite from the effect that chronic fluoxetine has on 5-HT2A12c receptor 
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function. The mechanism whereby chronic fluoxetine alters the 5-HT1A receptor-
mediated hormone responses is still unclear and it may result from changes in the signal 
transduction or second messenger systems. 
CHAPTER V 
TIME-COURSE OF FLUOXETINE-INDUCED DESENSITIZATION OF 
HYPOTHALAMIC 5-HT1A RECEPTORS 
Summary 
We examined the time-course of fluoxetine-induced desensitization of 5-HT1A 
receptors in the hypothalamus. Our previous studies indicated that daily injections of 
the 5-HT uptake inhibitor and antidepressant drug fluoxetine for 21 days produced 
desensitization of hypothalamic 5-HT1A receptors, without altering their density or 
affinity. This desensitization was evident from a reduced ability of the 5-HT1A agonist 
8-0H-DPAT to elevate plasma levels of ACTH, corticosterone and oxytocin. In the 
present study, we further studied the time-course of the desensitization of hypothalamic 
5-HT1A receptors induced by repeated injections of fluoxetine. To begin to examine the 
mechanism of 5-HT1A receptor desensitization, the density of 5-HT1A receptors in 
specific hypothalamic nuclei was examined using autoradiographic analysis of 3H-8-0H-
DPAT binding. Furthermore, the coupling of 5-HT1A receptors to their G proteins was 
studied by examining Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding. 
Finally, levels of Gi and G0 proteins in the hypothalamus, midbrain and frontal cortex 
were determined using immunoblots. Daily injections of fluoxetine (10 mg/kg/day) for 
3, 7, 14 or 22 days gradually shifted to the right the dose-response curve of the effects 
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of 8-0H-DPAT on plasma ACTH, corticosterone and oxytocin. This was particularly 
evident from the inhibition of the hormone responses to the low (50 µg/kg sc) dose of 
8-0H-DPAT. Fluoxetine reduced the maximal elevation in plasma oxytocin but not 
ACTH and corticosterone after injection of higher (200 and 500 µg/kg sc) doses of 8-
0H-DPAT. An examination of the time-course revealed a partial reduction of the 
ACTH and oxytocin responses to 8-0H-DPAT (50 µg/kg sc) after 3 days and a 
maximal reduction of all hormone responses after 14 days of fluoxetine injections. 
After 14 days of fluoxetine, the ACTH and oxytocin responses to the 50 µg/kg dose of 
8-0H-DPAT were virtually blocked. Repeated injections of fluoxetine did not alter the 
density of 5-HT1A receptors and did not reduce their coupling to G proteins in any brain 
region. This result suggests that the desensitization of 5-HT1A receptors induced by 
repeated injections of fluoxetine is not due to changes in the density of 5-HT1A receptors 
in the hypothalamus. On the other hand, the hypothalamic levels of Gil and Gi3 proteins 
were significantly reduced after 7 and 14 days of fluoxetine injections. The levels of 
G0 and Gi2 proteins in the midbrain were significantly decreased after 3 days and 
remained reduced for the duration of fluoxetine injections. Fluoxetine did not reduce 
the concentrations of Gi or G0 proteins in the frontal cortex at any time. The similarity 
in time-course between fluoxetine-induced reductions in hormone responses to 8-0H-
DP AT and the reduction in hypothalamic levels of Gi1 and Gi3 proteins suggests that the 
reduction hypothalamic levels of Gi3 and/or Gi1 proteins plays a role in the gradual 
desensitization of 5-HT1A receptors induced by fluoxetine. Furthermore, the earlier 
onset of decreased levels of G0 proteins in the midbrain may be involved in the reported 
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desensitization of somatodendritic 5-HT1A autoreceptors in the raphe nuclei, after three 
daily injections of fluoxetine (Le Poul et al.1995). In conclusion, repeated injections 
of fluoxetine produce a delayed and gradual desensitization of hypothalamic 5-HT1A 
receptors. The mechanism of desensitization of hypothalamic 5-HT1A receptors may 
involve decreased levels of Gil and Gi3 proteins, but not a change in the density of 5-
HT IA receptors. 
Introduction 
Our previous studies demonstrated that daily injections of fluoxetine for three 
weeks reduce the ACTH and oxytocin responses to two different 5-HT1A agonists, 8-
0H-DPAT and ipsapirone. A single injection of fluoxetine did not inhibit the hormone 
responses to 8-0H-DPAT. These results suggest that adaptive mechanisms are 
triggered by fluoxetine which lead to the desensitization of hypothalamic 5-HT1A 
receptors. The present study was designed to determine the time-course of fluoxetine-
induced desensitization of 5-HT1A receptor systems. The desensitization of 
hypothalamic 5-HT1A receptors was determined functionally from the reduction in 
hormone responses to the 5-HT1A agonist 8-0H-DPAT. 
Because no changes were observed in the density and affinity of 3H-8-0H-
DPAT-labelled 5-HT1A receptors in the hypothalamic homogenate, we hypothesized that 
the desensitization of hypothalamic 5-HT1A receptors may be due to alterations in their 
signal transduction mechanisms, or due to changes in the density of 5-HT1A receptors 
in specific hypothalamic nuclei. In the present study, we determined the time-course 
of effect of fluoxetine on the G proteins that are coupled to 5-HT1A receptors and on 
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the density of 5-HT1A receptors in hypothalamic nuclei and other brain regions. The 
signal transduction of 5-HT1A receptors was evaluated by examining the levels of Gi and 
G0 proteins which may be coupled to the 5-HT1A receptors. In addition, the degree of 
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding was used to determine the 
coupling of 5-HT1A receptors to their G proteins. The density of 5-HT1A receptors in 
hypothalamic nuclei was examined by autoradiographic analysis of 3H-8-0H-DPAT 
binding. 
5-HT1A receptors are G protein-coupled receptors. According to the model 
proposed by Lefkowitz et al. (1976), G protein-coupled receptors exist in high 
(coupled) and low (uncoupled) affinity states with respect to agonists. In general, the 
low affinity of agonists for the uncoupled state of receptors precludes labeling of these 
receptors by radiolabeled agonists. The coupled receptor-G protein configuration only 
exists while GDP is bound to the a-subunit of the G protein. In the presence of an 
agonist, GDP will be exchanged with GTP on the a-subunit of G proteins, resulting in 
dissociation of the G proteins from the receptors and a return of the receptors to the 
low affinity-state. Gpp(NH)p is a non-hydrolyzable GTP analog, that binds irreversibly 
to G proteins and dissociates them from their receptors. In the case of 5-HT1A 
receptors, in the presence of Gpp(NH)p, the high affinity-state 5-HT1A receptors will 
be converted into the low-affinity state, resulting in inhibition of the binding of an 
agonist, such as 8-0H-DPAT. Therefore, the percent inhibition of 3H-8-0H-DPAT 
binding, in the presence of Gpp(NH)p, represents the percent of 5-HT1A receptors that 
are coupled to their G proteins. In the present studies, we determined the degree of 5-
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HT IA receptors coupling in nuclei of the hypothalamus and in other brain regions by 
examining the inhibition of 3H-8-0H-DPAT binding with Gpp(NH)p. 
5-HT1A receptors are subclassified into somatodendritic and postsynaptic 
receptors. Somatodendritic 5-HT1A autoreceptors are located on 5-HT neurons in the 
raphe nuclei and function as feedback regulators of serotonergic neurotransmission. 
Activation of 5-HT1A autoreceptors will inhibit the firing-rate of 5-HT neurons and 
consequently, decrease 5-HT release from nerve terminals. Postsynaptic 5-HT1A 
receptors are distributed in most forebrain neurons. The function of postsynaptic 5-
HT1A receptors depends on the function of the target neurons. Activation of 5-HT1A 
receptors in the hypothalamic paraventricular nucleus increases the secretion of 
corticotropin releasing hormone (CRH), leading to increased release of ACTH and 
corticosterone and also increases the secretion of oxytocin (Fletcher et al.1996; 
Critchley et al.1994a; Van de Kar and Brownfield, 1993; Gilbert et al.1988a; Bagdy 
and Makara, 1994; Bagdy and Kalogeras, 1993). Other physiological roles for 5-HT1A 
receptors in this limbic brain area include food intake, mood changes and sexual 
behaviors (Uphouse et al.1994b). Therefore, it is important to know the distribution 
of 5-HT1A receptors in the different regions of the hypothalamus. While 
autoradiographic information exists on the distribution of 5-HT1A receptors in several 
brain regions, little has been known regarding the distribution of 5-HT1A receptors in 
nuclei of the hypothalamus. In the present study, we measured the effect of repeated 
injections of fluoxetine on the density of 5-HT1A receptors in hypothalamic nuclei and 
other brain regions using an autoradiographic analysis of 3H-8-0H-DP AT binding. This 
85 
study not only investigated whether repeated injections of fluoxetine induce a down-
regulation of 5-HT1A receptors in specific hypothalamic nuclei, but also provided a map 
of the distribution of 5-HT1A receptors in the hypothalamus and in several other brain 
regions. 
5-HT1A receptors are coupled to G0 and/or Gi proteins (Raymond et al.1993; 
Fargin et al.1991; Sprouse and Aghajanian, 1988; Emerit et al.1990). Somatodendritic 
5-HT1A autoreceptors in the raphe nuclei are coupled to G0 proteins, and lead to an 
increase in the opening of K+ channels (Sprouse and Aghajanian, 1988). Activation of 
5-HT1A receptors that are coupled to Gi proteins will inhibit the activity of adenylyl 
cyclase and, consequently, decrease the intracellular concentration of cAMP (Varrault 
et al.1994). 5-HT1A receptors have a high affinity for Gi proteins; the rank order of 
affinity is Gi3 > Gi1 > Gi2 > G0 proteins (Raymond et al.1993). In the present study, 
the effects of repeated injections of fluoxetine on the levels of Gi1, Gi2 , Gi3 and G0 
proteins in the hypothalamus, midbrain and frontal cortex were examined using 
immunoblot analysis. 
Experimental Protocol 
Rats received daily injections of fluoxetine ( 10 mg/kg, ip) for 3, 7, 14 or 22 
days. A control group received saline for 22 days. Eighteen hours after the last 
injection, the rats received a challenge injection of 8-0H-DPAT (0, 50, 200 or 500 
µglkg, sc) and were decapitated 15 minutes after the injection of 8-0H-DPAT. Trunk 
blood was collected in centrifuge tubes containing 0.5 ml of 0.3M ethylenediamine 
tetraacetic acid (EDTA; pH 7.4). After centrifugation at 2,500 rpm, 4°C for 15 min, 
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the plasma aliquots were stored at -70°C for hormone assays. The brains were 
collected for autoradiographic analysis of 3H-8-0H-DPAT binding or were dissected 
and the hypothalami, midbrains and frontal cortices were stored at -7CJ'C for 
immunoblot analysis of G proteins (see Chapter III for detail). 
Plasma ACTH, corticosterone and oxytocin concentrations were measured by 
radioimmunoassay as detailed in Chapter III. 
Results 
Hormone responses to 8-0H-DPAT 
8-0H-DPAT increased plasma ACTH concentrations in a dose-dependent manner 
(Fig. 6). The ACTH response to the 50 µg/kg dose of 8-0H-DPAT was significantly 
decreased by repeated injections of fluoxetine (Top panel of Fig. 6). This reduction 
appeared within 3 days (p < 0. 05) and reached a maximal reduction after 14 daily 
injections of fluoxetine (p < 0. 01, bottom panel of Fig. 6). Also, fluoxetine injections 
for 22 days significantly reduced the ACTH response to the higher dose (200 µg/kg sc) 
of 8-0H-DPAT. However, repeated injections of fluoxetine did not alter the maximal 
ACTH response to the highest dose of 8-0H-DPAT (500 µg/kg). 
Consistent with the ACTH data, 8-0H-DPAT also increased plasma 
corticosterone levels in a dose dependent manner (Fig. 7). The corticosterone response 
to the 50 µg/kg dose of 8-0H-DPAT was not significantly reduced after 3 daily 
injections but started to be significantly reduced after 7 daily injections of fluoxetine 
(bottom panel of Fig. 7). The maximal corticosterone response to high doses of 8-0H-
DPAT was not influenced by repeated injections of fluoxetine. 
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8-0H-DPAT significantly increased plasma concentrations of oxytocin in a dose-
dependent manner (Fig. 8). The dose-response curve of oxytocin was significantly 
shifted to the right after 3 days of fluoxetine injections (Fig. 8, top panel). The 
reduction of the oxytocin response to the 50 µg/kg dose of 8-0H-DPAT was maximal 
after 14 days of fluoxetine injections (Fig. 8 bottom panel). The oxytocin responses 
to all three doses of 8-0H-DPAT were decreased by fluoxetine. However, the degree 
of inhibition by fluoxetine was greater in the rats challenged with the 50 µg/kg dose of 
8-0H-DPAT than in the rats that received higher doses (200 or 500 µg/kg) of 8-0H-
DPAT. 
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Fi1mre 7. Daily injections of fluoxetine inhibit the effect of 8-0H-DPAT on 
plasma ACTH. Top: dose-response curves; Bottom: time-course of the reduction 
observed with a 8-0H-DPAT dose of 50 µg/kg sc. The data represent mean± S.E.M. 
of 8-12 rats per group. Two way ANOVA: Main effect of fluoxetine: F(4 , 160)=2.69996 
P <0.05; Main effect of 8-0H-DPAT: F(3, 160)=95.554 P < 0.001; Interaction between 
fluoxetine and 8-0H-DPAT: F(12, 160)=4.836 P<0.001. *Significant difference from 
the saline (0 dose of 8-0H-DPAT) group, P < 0.05; +Significant difference from the 
saline (0 dose of fluoxetine) group, P<0.05 (Newman Keuls' multiple range test) 
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Figure 8. Daily injections of fluoxetine inhibit the effect of 8-0H-DPAT on 
plasma corticosterone. Top: dose-response curves; Bottom: time-course of the 
reduction observed with a 8-0H-DPAT dose of 50 µg/kg sc. The data represent mean 
± S.E.M. of 8-12 rats per group. Two way ANOVA: Main effect of fluoxetine: F<4• 
133)= 1.461 NS; Main effect of 8-0H-DPAT: F<3• 133)=85.245 P <0.001; Interaction 
between fluoxetine and 8-0H-DPAT: F<12. 133l=2.14 P<0.05. *Significant difference 
from the saline (0 dose of 8-0H-DPAT) group, P<0.05; +Significant difference 
from the saline (0 dose of fluoxetine) group, P<0.05 (Newman Keuls' multiple range 
test) 
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Fi1:ure 9. Daily injections of fluoxetine inhibit the effect of 8-0H-DPAT on 
plasma oxytocin. Top: dose-response curves; Bottom: time-course of the reduction 
observed with a 8-0H-DPAT dose of 50 µg/kg sc. The data represent mean± S.E.M. 
of 8-12 rats per group. Two way ANOVA: Main effect of fluoxetine: F<4• 150)=23.5 
P<0.001; Main effect of 8-0H-DPAT: F(3, 150)=274.5 P<0.001; Interaction between 
fluoxetine and 8-0H-DPAT: Fc12, 150)=3.974 P<0.001. *Significant difference from 
the saline (0 dose of 8-0H-DPAT) group, P<0.05; +Significant difference from the 
saline (0 dose of fluoxetine) group, P<0.05 (Newman Keuls' multiple range test) 
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Autoradiographic analysis of 3H-8-0H-DPAT binding 
A high density of 5-HT1A receptors was observed in several nuclei of the 
hypothalamus and amygdala as well as in the hippocampus, dorsal raphe nucleus and 
in several layers of the frontal cortex (Figures 10 and 11). In the hypothalamus, the 
density of 5-HT1A receptors was markedly different among several nuclei, with 
differences of ten-fold between the highest and lowest densities in the regions measured 
(Table IV and Fig. 10). For example, the density of 5-HT1A receptors in the lateral 
hypothalamic area was 6.8 ± 0.8 (fmol/mg tissue equivalent) while the density in the 
central sub-division of the ventromedial nucleus was 62.8 ± 4.1 (fmol/mg tissue 
equivalent; p < 0.01). In the ventromedial nucleus, the central sub-division contained 
the highest density of 5-HT1A receptors while the ventrolateral sub-division of the 
ventromedial nucleus contained a significantly higher density of 5-HT1A receptors than 
the dorsomedial subdivision of the ventromedial nucleus (38.0 ± 2.0 vs 29.1 ± 2.7, 
fmol/mg tissue equivalent; P<0.05; Table IV). The density of 5-HT1A receptors in the 
parvocellular sub-division of the paraventricular nucleus (14.0 ± 1.8 fmol/mg tissue 
equivalent) was not significantly different from that in the magnocellular region (9.1 ± 
1.4; fmol/mg tissue equivalent; Table IV) but both were significantly higher than the 
lateral hypothalamic area (p < 0.05). The density of 5-HT1A receptors in the 
dorsomedial hypothalamic nucleus was significantly higher than the density in the two 
sub-divisions of the paraventricular nucleus. The lateral hypothalamic area contained 
the lowest density of 5-HT1A receptors in the hypothalamus. 
A very high density of 5-HT1A receptors was found in the hippocampal CAl and 
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dentate gyms (Fig. 11 and Table IV), in the dorsal raphe nucleus, and layers 5 and 6 
of the frontal cortex (Fig. 11 and Table IV). Great differences in density of 5-HT1A 
receptors were observed in the amygdala. A low density of 5-HT1A receptors was 
observed in the central amygdaloid nucleus (13.3 ± 2.3 fmol/mg tissue equivalent) and 
the posterior part of the lateral amygdaloid nucleus (16.9 ± 2.5 fmol/mg tissue 
equivalent), while a high density was observed in the basomedial amygdaloid nucleus 
(65.5 ± 4.1 fmol/mg tissue equivalent). In the cortex, the lowest density of 5-HT1A 
receptors was observed in layers 1-3 of the parietal cortex, while high densities were 
observed in layers 5 and 6 of the cingulate and frontal cortices (Table IV). 
Table IV shows the effects of repeated injections of fluoxetine on specific 3H-8-
0H-D PAT binding in several brain regions. No change was observed in the density 
of 3H-8-0H-DPAT-labelled 5-HT1A receptors binding sites in any brain regions after 
daily injections of fluoxetine. 
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Medial hypothalamus Caudal hypothalamus 
Fi1rnre 10. Autoradiogram of 3H-8-0H-DPAT binding and Gpp(NH)p-
induced inhibition of 3H-8-0H-DPAT binding in the hypothalamus. Medial 
hypothalamus (left column) and caudal hypothalamus (right column) were examined. 
The top panel represents the total 3H-8-0H-DPAT binding; the middle panel represents 
3H-8-0H-DPAT binding in the presence of Gpp(NH)p (1Q-5M); the bottom panel 
represents non-specific binding defined by 3H-8-0H-DPAT binding in the presence of 
10-6M of 5-HT. Abbreviations: ABL: Basolateral amygdaloid nucleus; ABM: 
Basomedial amygdaloid nucleus; AC: Central amygdaloid nucleus; AHN: Anterior 
hypothalamic nucleus; ALP: Lateral amygdaloid nucleus, posterior region; AM: Medial 
amygdaloid nucleus; CAl-3: Field CAl, CA2 and CA3 of ammon's horn in the 
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hippocampus; DG: Dentate gyrus (hippocampus); DMH: Dorsomedial hypothalamic 
nucleus; LH: Lateral hypothalamic area; PAR 1: Parietal cortex, area 1; PVNm: 
Paraventricular hypothalamic nucleus, magnocellular region; PVNp: Paraventricular 
hypothalamic nucleus, parvocellular region; VMHC: Ventromedial hypothalamic 
nucleus, central region; VMHDM: Ventromedial hypothalamic nucleus, dorsomedial 
region; VMHVL: Ventromedial hypothalamic nucleus, ventrolateral region 
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Midbrain Frontal cortex 
Fi1:ure 11. Autoradiogram of 3H-8-0H-DPAT binding and Gpp(NH)p-
induced inhibition of 3H-8-0H-DPAT binding in the midbrain (left column) and 
frontal cortex (right column). The top panel represents the total 3H-8-0H-DPAT 
binding; the middle panel represents 3H-8-0H-DPAT binding in the presence of 
Gpp(NH)p (1Q-5M); the bottom panel represents non-specific binding defined by 3H-8-
0H-DPAT binding in the presence of 10-6M of 5-HT. Abbreviations: CG3:Cingulate 
cortex, area 3; DR:Dorsal raphe; Fr2:Frontal cortex, area 2; MR:Medial raphe 
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Table IV 
REPEATED INJECTIONS OF FLUOXETINE DO NOT ALTER THE 
DENSITY OF 5-HT1A RECEPTORS 
Brain regions Nuclei 
Cortex 
Fr2 layer 1-3 
layer 5 
layer 6 
---------------------------
CG3 layer 1-3 
layer 5 
layer 6 
---------------------------
PARl layer 1-3 
layer 4 
layer 5-6 
Hypothalamus PVNm 
PVNp 
AHN 
LH 
VMHDM 
VMHC 
VMHVL 
DMH 
Amygdala AC 
APL 
ABL 
ABM 
AM 
Density of 3H-8-0H-DPAT - labeled 5-HT1A receptors 
(fmol/mg tissue equivalent) 
Saline 3 days 7 days 14 days 22 days 
26.2± 1.3 25.0± 1.5 25.0±2.5 25.2±1.9 26.8±2.5 
79.3±4.5 78.4±4.7 79.6±4.2 77.9±3.5 84.6±4.0 
64.1±4.7 61.8±5.4 64.9±4.4 62.3±3.8 68.7±4.4 
~-------------------------------------------------------
44.3 ±5.8 41.1 ±5.4 42.4±5.3 42.2±3.4 48.5±2.5 
65.3±6.7 65.8±8.2 65.9±7.2 65.4±5.1 70.2±3.4 
57.4±5.1 57.2±7.0 58.1±5.81 57.4±3.4 61.7±3.7 
~----------------------------------------------------
13.5±2.0 14.7±1.8 13.6± 1.8 16.2±1.1 15.0± 1.6 
28.8± 1.3 26.9±2.2 28.1±1.8 29.5±3.0 31.0±2.0 
46.5±2.0 42.4±3.1 42.6±3.3 42.9±5.2 46.5±2.9 
9.1±1.4 8.0±1.0 10.4± 1.4 9.6±1.4 10.9±1.3 
14.0± 1.8 14.2±1.1 16.5±1.6 15.2±1.1 15.8± 1.2 
18.5±2.0 18.6±0.9 20.8±1.9 20.5±1.5 21.3±1.3 
6.8±0.8 6.1±0.7 6.5±1.1 6.3±0.4 7.2±0.7 
29.1±2.7 24.1±1.1 28.7±1.8 28.2±2.1 27.7±1.3 
62.8±3.6 54.9±5.3 58.0±3.7 57.3±7.0 54.3±3.6 
38.0±2.0 32.3±3.4 33.5±1.7 34.5±3.8 31.1±2.9 
22.4±2.6 19.7±2.1 21.1±1.0 18.4±0.8 18.1±1.1 
13.3±2.3 13.2±1.9 13.3±2.5 14.7±1.6 14.7±1.9 
16.9±2.5 16.8±1.4 16.5±2.3 16.9±1.7 17.8±2.9 
32.2±3.2 28.2± 1.1 31.7±1.4 29.1±2.0 31.1±3.1 
65.5±4.1 57.3±4.5 65.3 ±3.3 61.1±6.5 62.5±4.3 
39.4±2.1 36.0±2.2 41.1±1.9 38.0±4.2 38.3±2.4 
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TABLE IV-Continued 
Density of 3H-8-0H-DPAT - labeled 5-HTlA receptors 
(fmol/mg tissue equivalent) 
Brain regions Nuclei Saline 3 days 7 days 14 days 22 days 
Hippocampus CAl 103.6±7.1104.5±6.4 114.6±8.2 114.9±8.4 117.6±5.8 
CA2 19.5±1.3 19.0±1.0 19.9±1.3 22.4±2.3 19.5±1.7 
CA3 49.0±3.0 44.9±5.5 51.3±3.7 47.9±6.0 48.2±5.2 
DG 126.4±9.7 127.0±6.7 135.1±8.2129.2±7.2133.8±4.5 
Mid brain DR 79.2±5.5 59.6±8.3 79.7±4.3 66.0±6.8 80.1±4.9 
MR 35.5±3.9 25.9±3.9 35.4±3.4 23.3 ±3.0 24.1±3.8 
The data represent mean ± S.E.M. of 5-6 rats per group. 
ABL: 
ABM: 
AC: 
AHN: 
ALP: 
AM: 
CAl-3: 
CG3: 
DG: 
DMH: 
DR: 
Fr2: 
LH: 
MR: 
PAR 1: 
PVNm: 
PVNp: 
VMHC: 
VMHDM: 
VMHVL: 
Basolateral amygdaloid nucleus 
Basomedial amygdaloid nucleus 
Central amygdaloid nucleus 
Anterior hypothalamic nucleus 
Lateral amygdaloid nucleus, posterior region 
Medial amygdaloid nucleus 
Field CAl, CA2 and CA3 of ammon's horn in the hippocampus 
Cingulate cortex, area 3. 
Dentate gyms (hippocampus) 
Dorsomedial hypothalamic nucleus 
Dorsal raphe 
Frontal cortex, area 2 
Lateral hypothalamic area 
Medial raphe 
Parietal cortex, area 1 
Paraventricular hypothalamic nucleus, magnocellular region 
Paraventricular hypothalamic nucleus, parvocellular region 
Ventromedial hypothalamic nucleus, central region 
Ventromedial hypothalamic nucleus, dorsomedial region 
Ventromedial hypothalamic nucleus, ventrolateral region 
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Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding 
Gpp(NH)p inhibited 3H-8-0H-DPAT binding in all brain regions examined 
(Figures 10 and 11). However, the degree of inhibition varied from 143 to 853 
between several brain regions (Fig. 12). For example, Gpp(NH)p produced 853 
inhibition of 3H-8-0H-DPAT binding in the central nucleus of the amygdala, but only 
173 inhibition in the dorsal raphe nucleus (Fig 12). In the hypothalamus, the greatest 
inhibition was observed in the dorsomedial nucleus ( 61 3), while the lowest degree of 
inhibition was observed in the central sub-division of the ventromedial nucleus (143; 
see Fig. 12). In the paraventricular nucleus, a greater inhibition was observed in the 
parvocellular sub-division ( 41 % ) than in the magnocellular sub-division (20. 7 % ) 
(Fig.10, 12). 
As Table V shows, fluoxetine did not alter the Gpp(NH)p-induced inhibition of 
3H-8-0H-DPAT binding in any brain region after the daily injections. 
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Figure 12. Degree of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT 
binding varies between brain regions. The data are represented as mean ± S.E.M. 
The abbreviations are the same as listed in Table V. 
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TABLE V 
REPEATED INJECTIONS OF FLUOXETINE DO NOT ALTER THE PERCENT 
OF G PROTEIN - LINKED 5-HT1A RECEPTORS 
Brain regions Nuclei % Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT 
Saline 3 days 7 days 14 days 22 days 
Cortex 
Fr2 layer 1-3 35.8±3.5 33.7±6.7 34.3±5.8 33.4±7.1 31.8±3.3 
layer 5 21.2±2.1 20.8±4.5 15.3±3.8 22.1±2.9 25.4±4.7 
------------------~'!Y-~E-~- 24.2±2.2 18.6±3.8 17.3±3.6 24.1±2.2 28.2±5.3 ~--------------------------------------------------------
CG3 layer 1-3 31.1 ±2.2 25.3±0.7 18.6±5.8 32.5±7.7 35.2±7.0 
layer 5 30.0±2.0 25.6±3.1 21.2±5.0 34.4±3.9 35.7±3.1 
------------------~'!Y-~E-~- 21.3±2.6 21.2±3.2 19.4±5.8 27.5±3.0 32.6±3.0 ~------------------------------------------------------
PAR 1 layer 1-3 42.9±7.6 50.7±6.7 40.2±6.4 49.0±4.3 46.7±4.9 
layer 4 34.7±4.8 35.7±2.0 28.4±2.1 33.5±3.3 38.7±3.5 
layer 5-6 34.3±4.5 35.8±2.6 27.9±2.8 29.0±4.8 36.8±3.6 
Hypothalamus PVNm 41.0±7.7 32.7±8.3 42.7±8.2 28.4±8.1 33.1 ±8.2 
PVNp 20.7±7.7 27.3±5.8 31.0±5.7 30.7±6.5 33.5±4.6 
AHN 19.1±7.4 30.4±4.7 29.4±4.8 33.6±4.8 32.6±4.2 
LH 22.6±5.6 30.7±7.6 31.3±4.7 36.2±7.4 41.4±5.9 
VMHDM 25.0±3.9 26.2±4.1 21.1 ±4.5 26.6±4.8 18.3±1.3 
VMHC 14.3±5.5 27.7±5.6 19.0±4.7 17.4±7.3 16.3±4.8 
VMHVL 35.6±4.8 40.7±5.5 37.8±5.7 36.7 ±5.8 35.6±5.4 
DMH 61.4+5.6 61.0+3.0 57.7+5.2 56.2+2.8 52.4±2.3 
Amygdala AC 85.5±3.5 85.0±1.3 85.4± 1.9 88.2±0.7 85.0±0.9 
ALP 54.1±3.5 56.9±1.9 59.2±3.8 66.0±3.8 54.2±2.7 
ABL 44.8±3.6 44.4±5.4 46.0±4.7 42.8±2.5 40.1 ±5.4 
ABM 28.4±3.1 31.9±4.3 33.7±2.9 27.6±6.1 32.6±2.8 
AM 30.0+5.1 36.2+4.9 35.9+4.9 31.3±6.4 33.5+4.4 
102 
TABLE V-continued 
Brain regions Nuclei % Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT 
Saline 3 days 7 days 14 days 22 days 
Hippocampus CAI 20.0±4.0 I2.8±6.0 I7.I ±2.8 13.8±2.2 22.2±3.6 
CA2 39.6±3.8 39.I±4.I 38.4±4.2 35.4±6.0 41.0±5.6 
CA3 23.6±4.7 28.I ±5.I 25.4±6.8 23. I ±6.2 35.8±5.5 
DG 21.0±1.7 20.6±3.6 23.5 ±5.3 20.7±4.5 31.0±3.3 
Mi db rain DR I7.4±4.3 I2.6±7.4 21.3±4.I 26.9±2.4 25.6±3.8 
MR 43.7+4.9 47.7+4.5 55.4+3.3 34.2+2.3 38.6+5.5 
The data represent mean ± S.E.M. of 5-6 rats per group. 
ABL: 
ABM: 
AC: 
AHN: 
ALP: 
AM: 
CAI-3: 
CG3: 
DG: 
DMH: 
DR: 
Fr2: 
LH: 
MR: 
PAR 1: 
PVNm: 
PVNp: 
VMHC: 
VMHDM: 
VMHVL: 
Basolateral amygdaloid nucleus 
Basomedial amygdaloid nucleus 
Central amygdaloid nucleus 
Anterior hypothalamic nucleus 
Lateral amygdaloid nucleus, posterior region 
Medial amygdaloid nucleus 
Field CAI, CA2 and CA3 of ammon' s horn in the hippocampus 
Cingulate cortex, area 3. 
Dentate gyms (hippocampus) 
Dorsomedial hypothalamic nucleus 
Dorsal raphe 
Frontal cortex, area 2 
Lateral hypothalamic area 
Medial raphe 
Parietal cortex, area I 
Paraventricular hypothalamic nucleus, magnocellular region 
Paraventricular hypothalamic nucleus, parvocellular region 
Ventromedial hypothalamic nucleus, central region 
Ventromedial hypothalamic nucleus, dorsomedial region 
Ventromedial hypothalamic nucleus, ventrolateral region 
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G,, subunits in hypothalamus, midbrain and frontal cortex 
The G protein a-subunits Gil• Gi2 , Gi3 and G0 were examined in the 
hypothalamus, midbrain and frontal cortex using immunoblots. Figure 13 presents 
examples of Gi1, Gi2 and Gi3 proteins in the hypothalamus and midbrain. The levels of 
Gi1 and Gi3 proteins were significantly decreased in the hypothalamus of rats that 
received injections of fluoxetine for 7 and 14 days (Fig. 14A, 14C). The level of G0 
proteins in hypothalamus was only significantly reduced in rats that received fluoxetine 
injections for 7 days (Fig. 14D). The level of Gi2 proteins in the hypothalami of rats 
that received injections of fluoxetine was not significantly different from those that 
received injections of saline (Fig 14B). The levels of G0 and Gi2 proteins in the 
midbrain were significantly decreased after 3 days of fluoxetine injections and remained 
below control levels for the duration of fluoxetine exposure (Fig. 15). The levels of 
Gi1 and Gi3 proteins in the midbrain were not significantly reduced by injections of 
fluoxetine (Fig. 15). Gi or G0 protein levels were not reduced in the frontal cortex of 
rats that received injections of fluoxetine (Table VI). 
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Fia=ure 13. Example of immunoblots of G proteins in brain regions from rats 
that received daily injections of fluoxetine. Top panel: Gi1 and Gi2 proteins in the 
hypothalamus; middle panel: Gi3 proteins in the hypothalamus; bottom panel: G0 
proteins in the midbrain. The lanes from left to right contain membrane extracts from 
brain regions of rats that received: vehicle, fluoxetine for 3 days, fluoxetine for 7 days, 
fluoxetine for 14 days and fluoxetine for 22 days. 
' 
........ 
0 
I... 100 
a. 
CJ"l 
:::L 8 0 
""' 0 
0 60 
0 
I... 
........ 
c 
0 
u 
40 
20 
105 
Hypothalamus 
0 3 7 14 22 
Days of fluoxetine 
B. Gi2 
........ 
0 
I... 
a. 1 20 
~ 100 
""' 0 80 
0 
0 
I... 
........ 
c 
0 
u 
60 
40 
20 
0 3 7 14 22 
Days of fluoxetine 
::: C. Gi3 
........ 
0 
I... 
a. 
cri 
::t 
""' 0 
0 
100 
80 
60 
0 40 
I... 
........ 
c 
0 20 
u 
-0 
* * 
0 3 7 14 22 
0 
I... 
a. 1 00 '""" 
cri 
:::t 
""' 0 0 
80 ,_ 
60 '""" 
0 40 ..... 
I... 
........ 
c 
0 20 ..... 
u 
* 
-0 
0 L-.CC::CL..J:CID1-.m:CIL..CCID1-.m:CIL--
0 3 7 14 22 
Days of fluoxetine Days of fluoxetine 
Figure 14 (See next page for figure legend) 
106 
Figure 14. Fluoxetine reduces the levels of G proteins in the 
hypothalamus. The data represent mean ± S.E.M. of 6-8 rats per group. A. 
Level ofGi1 proteins, One way ANOVA: F<4• 31>=3.197, P<0.05 B. Level ofGi2 
proteins. One way ANOVA: F<4. 33>=0.4276, NS. C. Level of Gi3 proteins. One 
way ANOVA: F<4• 33> = 2.8079; P < 0.05. D. Level of G0 proteins. One way 
ANOVA: F<4• 35>=5.316, P<0.01. 
* Significant difference from the vehicle group, P <0.05 (Duncan's multiple range 
test) 
NS: No significant difference from the vehicle group. 
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Figure 15. Fluoxetine reduces the levels of G proteins in the midbrain. 
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi1 proteins, 
One way ANOVA: Fc4• 35>=0.9818, NS; B. Level of Gi2 proteins. One way 
ANOVA: Fc4.31)=2.827, P=0.05 . C. Level of Gi3 proteins. One way ANOVA: Fc4• 
35> = 1.1669; NS . D. Level of G0 proteins. One way ANOVA: F<4. 34>=6.56, 
P<0.01. 
*Significant difference from the vehicle group, P<0.05 (Newman Keuls' multiple 
range test). 
NS: No significant difference from the vehicle group. 
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TABLE VI 
DAILY INJECTIONS OF FLUOXETINE DO NOT ALTER LEVELS OF G-
PROTEINS IN THE FRONTAL CORTEX 
Saline 3 Days 7 Days 14 Days 22 Days 
93.1 ± 9.9 117.6±10.0 113.3±10.4 118.1±15.1 113.1±12.7 
102.4±10.6 99.5±10.5 123.7±21.1 94.7±11.1 128.1±26.3 
101.8± 5.5 120.8±16.0 157.5±28.1 133.9±22.6 133.9±26.0 
99.8± 6.4 99.6±12.0 85.9± 9.4 102.2± 9.4 110.7±18.7 
The data represent means ± S.E.M. of the a subunits, expressed as % of the 
integrated optical density of the immunoblots/ µg protein. The data were obtained 
from 6-8 rats per group. 
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Discussion 
The present results indicate that repeated injections of fluoxetine produce a 
delayed and gradual desensitization of hypothalamic 5-HT1A receptors. This 
desensitization is unlikely due to down-regulation of 5-HT1A receptors in the 
hypothalamus or due to changes in the coupling of 5-HT1A receptors to their G proteins. 
The results of the present study demonstrate a similarity in time-course between the 
fluoxetine-induced reduction in hypothalamic levels of Gi proteins and the fluoxetine-
induced inhibition of neuroendocrine responses to a challenge with the 5-HT,A agonist 
8-0H-DPAT. This similarity in time-courses suggests that hypothalamic Gil or Gi3 
proteins may play a role in fluoxetine-induced desensitization of hypothalamic 5-HT1A 
receptors. The delay in desensitization of hypothalamic 5-HT tA receptors might 
underlie the delayed onset of therapeutic effects of fluoxetine and other 5-HT uptake 
inhibitors. 
Hormone responses to 8-0H-DPAT 
We used the changes in magnitude of elevation of plasma levels of ACTH, 
corticosterone and oxytocin, after injection of several doses of 8-0H-DPAT, as 
indicators of desensitization of hypothalamic 5-HT1A receptors. 8-0H-DPAT increases 
plasma ACTH, corticosterone and oxytocin concentrations by activating hypothalamic 
5-HT1A receptors. The ACTH and corticosterone responses to 8-0H-DPAT can be 
inhibited by the 5-HT1A antagonists pindolol, spiperone, or WAY-100635 (Pan and 
Gilbert, 1992; Gilbert et al.1988a; Critchley et al.1994a; Koenig et al.1987; 
Przegalinski et al.1989) and the oxytocin responses to 8-0H-DPAT also can be 
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inhibited by NAN-190 and pindolol (Bagdy and Kalogeras, 1993). We have recently 
observed that the 5-HT1A antagonist WAY-100635 (1 mg/kg, sc) blocks the effects of 
8-0H-DPAT (50 µg/kg, sc) on plasma levels of ACTH, corticosterone and oxytocin 
(Vicentic et al.1996). The location of the 5-HT1A receptors that stimulate the secretion 
of ACTH and oxytocin is likely in the hypothalamic paraventricular nucleus because 
injection of pindolol into the hypothalamic paraventricular nucleus inhibits the ACTH 
response to injection of 8-0H-DPAT into the same site (Pan and Gilbert, 1992). 
Mechanical destruction of the hypothalamic paraventricular nucleus also inhibits the 
ACTH, corticosterone and oxytocin responses to ipsapirone, a partial 5-HT1A agonist 
(Bagdy and Makara, 1994). These data suggest that the ACTH and oxytocin responses 
to 8-0H-DPAT are mediated by hypothalamic 5-HT1A receptors and can be used as 
markers for the functional status of hypothalamic 5-HT lA receptor systems. 
The present observations of fluoxetine-induced desensitization of hypothalamic 
5-HT1A receptors are consistent with our previous observations (Chapter IV), that daily 
injections of fluoxetine for 21 days produce a shift to the right in the dose-response 
effects of 8-0H-DPAT on plasma ACTH, corticosterone and oxytocin. In the present 
study, we further demonstrated that the desensitization of hypothalamic 5-HT IA 
receptors require at least 3 days of injections of fluoxetine. This delayed desensitization 
of hypothalamic 5-HT1A receptors resembles the therapeutic delay seen in clinical 
studies and is different from the rapid desensitization (less than 24 hours) after a single 
injection of 8-0H-DPAT and other 5-HT1A agonists (Kelder and Ross, 1992). The 
difference between the SSRI's and the 5-HT1A agonists could be due to the fact that 5-
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HT1A agonists can immediately and directly activate post-synaptic 5-HT1A receptors. 
In contrast, 5-HT uptake inhibitors need to overcome the inhibitory influence of 
somatodendritic 5-HT1A autoreceptors before they can induce an increase in the synaptic 
concentration of 5-HT in the hypothalamus, which in tum can activate post-synaptic 5-
HT1A receptors. Therefore, the present results support the hypothesis that 
somatodendritic 5-HT1A receptors play a role in the delayed clinical improvement after 
onset of treatment with 5-HT uptake inhibitors. 
A difference was observed between the effect of fluoxetine on ACTH and 
oxytocin responses to 8-0H-DPAT. ACTH showed no reduction in the maximal 
response to 8-0H-DPAT while oxytocin showed a reduction in the maximal responses 
to 8-0H-DPAT. This difference can be explained by the fact that a larger receptor 
reserve exists for the 5-HT1A receptor-mediated ACTH and corticosterone responses, 
than for the oxytocin response to 8-0H-DPAT (Meller and Bohmaker, 1994; Pinto et 
al.1994). 
Autoradiogram of 3H-8-0H-DPAT binding 
The present studies provide autoradiographic data on the distribution of 5-HT1A 
receptors in sub-regions of hypothalamic nuclei. While several studies have used 
autoradiographic analyses to examine other regions in the brain (Khawaja, 1995; Le 
Poul et al.1995), few studies have examined the hypothalamus in the detail reported 
herein. In studies from other laboratories, only a few nuclei were examined (Frankfurt 
et al.1994; Hensler et al.1991; Pompeiano et al.1992; Palacios et al.1987). In the 
present study, several sub-divisions of hypothalamic nuclei were examined. The highest 
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density of 5-HT1A receptors in the hypothalamus was found in the ventromedial nucleus 
(VMH). This observation is in agreement with studies using an antibody against the 5-
HT tA receptor, autoradiography or in situ hybridization for the mRN A coding for this 
receptor, (Wright et al.1995; Kia et al.1996; Frankfurt et al.1994; Hensler et al.1991; 
Frankfurt et al.1993). Differences in the density of 5-HT1A receptors in the three sub-
divisions of the VMH (central, dorsomedial and ventrolateral) may be related to the 
differences between males and females in the interaction between 5-HT1A receptors and 
gonadal steroids with respect to sexual behavior (Uphouse et al.1994a; Uphouse et 
al.1994b; Coirini et al.1992; Mendelson and Gorzalka, 1986). Physiological studies 
indicate that activation of 5-HT1A receptors on neurons in the VMH activates their 
potassium conductance (Newberry, 1992). 
The density of 5-HT1A receptors in the paraventricular nucleus (PVN) was lower 
than that in the surrounding tissue. The PVN can be roughly divided into parvocellular 
and magnocellular sub-regions. The parvocellular cells secrete corticotropin releasing 
hormone (CRH), which then stimulates the secretion of ACTH from the anterior 
pituitary gland. Serotonergic nerve terminals make direct synaptic contact with these 
CRH cells (Liposits et al.1987). There are more serotonergic terminals innervating 
parvocellular CRH cells than magnocellular cells. Furthermore, oxytocin containing 
cells receive a higher innervation than vasopressin containing cells (Sawchenko et 
al.1983). Parvocellular cells in the PVN contain a higher density of 5-HT1A receptors 
than magnocellular cells which contain oxytocin and vasopressin. Activation of 5-HT1A 
receptors can stimulate the secretion of ACTH and oxytocin, but not vasopressin 
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(Bagdy and Kalogeras, 1993; Li et al.1993b; Van de Kar and Brownfield, 1993; 
Vicentic et al.1996). Thus, the observation of a very low density of 5-HT1A receptors 
in the magnocellular cells in the lateral wing of the PVN is in agreement with the 
neuroendocrine data. 
In addition to the hypothalamus, we determined the distribution of 5-HT1A 
receptors in nuclei of the amygdala, regions in the hippocampus, raphe nuclei and 
several cortical areas and layers. Neurons in the amygdala are involved in mood 
changes (Deakin, 1996; Handley, 1995; Adolphs et al.1994). Also, the central nucleus 
of the amygdala and hypothalamic paraventricular nucleus receive collateral projections 
from the dorsal raphe nucleus (Petrov et al.1994). It is possible that 5-HT uptake 
inhibitors might also influence 5-HT1A receptors in the amygdala. Therefore, it was 
interesting to know whether repeated injections of fluoxetine would alter the density of 
5-HT1A receptors and their coupling to G proteins. The hippocampus contains a very 
high density of 5-HT1A receptors (Khawaja, 1995; Le Poul et al.1995). Several 
investigators studied the effects of long-term administration of 5-HT uptake inhibitors 
on the hippocampal 5-HT1A receptors (Klimek et al.1994; Newman et al.1992; Hensler 
et al.1991). With respect to the relative distribution of 5-HT1A receptors in 
hippocampal CAI, CA2 and CA3 regions, our results agree with those of other 
investigators (Khawaja, 1995). The cortex was also used as a standard for comparison 
because it has been studied extensively (Burnet et al.1994; Burnet et al.1995; Fanelli 
and Mcmonagle-Strucko, 1992). The cortex receives a different pattern of serotonergic 
inputs than the hypothalamus (Van Bockstaele et al.1993; Petrov et al.1992; Reichling 
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and Basbaum, 1991). This could mean that fluoxetine might not have the same effects 
on the cortex and hypothalamus. In the present studies, the cortex was used as a 
control to test the region-selectivity of the effect of 5-HT uptake inhibitors on 5-HT1A 
receptors and for comparison with other studies. The 5-HT1A receptors in the dorsal 
and median raphe nuclei are known as somatodendritic autoreceptors, involved in auto-
inhibition of the firing of serotonergic neurons. Neurons both in the dorsal and median 
raphe nuclei innervate the hypothalamus. Because changes in the release of 5-HT in 
the hypothalamus are dependent on somatodendritic 5-HT1A autoreceptors, we included 
the dorsal and median raphe in the autoradiographic analysis of the distribution of 5-
HT tA receptors. 
The present data suggest that fluoxetine-induced desensitization of 5-HT1A 
receptors is not due to a reduction in the density of 5-HT1A receptors in the PVN. This 
is consistent with our previous results indicating that chronic injections of fluoxetine do 
not alter the density or affinity of 5-HT1A receptors in whole hypothalamic homogenates 
(Li et al.1994). Furthermore, the lack of changes in the density of 5-HT1A receptors 
in other brain regions is consistent with several investigations from other laboratories 
(Le Poul et al.1995; Hensler et al.1991). 
In the present study, we did not observe reductions in 3H-8-0H-DPAT labeled 
5-HT1A receptors in either the dorsal raphe or median raphe nuclei. This result is 
consistent with other autoradiographic results indicating that chronic 5-HT uptake 
inhibitors do not change the density of 5-HT1A receptors in the dorsal raphe and median 
rap he nuclei (Le Poul et al.1995; Hensler et al. 1991). 
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Autoradiographic analysis of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT 
binding 
The present studies provide the first autoradiographic data on Gpp(NH)p-induced 
inhibition of 3H-8-0H-DPAT binding in the hypothalamus and other limbic brain 
regions. Gpp(NH)p inhibits the binding of 3H-8-0H-DPAT in most brain regions. 
However, the degree of inhibition varies between different brain regions. This 
variation in the degree of inhibition suggests that differential coupling of 5-HT1A 
receptors occurs in different brain regions. 
8-0H-DPAT is a 5-HT1A agonist. One might expect that 3H-8-0H-DPAT, in 
the concentration of 2 nM, would mainly label the high affinity (coupled) state of 5-
HT1A receptors. Therefore, Gpp(NH)p should be able to inhibit most of the binding of 
3H-8-0H-DPAT to 5-HT1A receptors. However, results observed from the present and 
other studies indicate that 3H-8-0H-DPAT binding cannot be completely blocked by 
micromolar concentrations of Gpp(NH)p (Weinstein et al .1995). Butkerait et al. ( 1995) 
found no significant differences between the Bmax of 3H-8-0H-DPAT binding in Sf9 
cells that express 5-HT1A receptors with G proteins and the same cells without G 
proteins. However, the Kd of 3H-8-0H-DPAT binding was significantly higher in the 
absence of G proteins (Kd = 7.2±0.9 nM) than in the presence of G proteins (Kd = 
1.1 ± 0.2 nM). On the other hand, in many brain regions, the binding ratio of the 5-
HT1A agonist 3H-8-0H-DPAT to the antagonist 3H-WAY-100635 was more than 0.5, 
suggesting more than 50 % coupling of receptors (Gozlan et al.1995; Le Poul et 
al.1995; Kulikov et al.1995). This ratio is much higher than the ratio of agonist to 
antagonist binding for other receptors. For example, the binding ratio of the 5-HT2A12c 
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agonist DOI to the 5-HT2A antagonist ketanserin is about 0.2 (i.e. 20% of receptors are 
coupled) (Teiteler et al.1990; Pinto and Battaglia, 1994). The high ratio of 3H-8-0H-
DPAT to 3H-WAY-100635 binding could be due to two possibilities: 1) a larger number 
of 5-HT1A receptors are coupled to G proteins compared with most other receptors; or 
2) 8-0H-DPAT binds to both the high and low affinity states of 5-HT1A receptors. The 
present results and other studies support the latter possibility. This is possible because 
the affinity of 8-0H-DPAT for G protein-coupled 5-HT1A receptors is close (less than 
one logarithm scale) to that for uncoupled 5-HT1A receptors (Chamberlain et al.1993). 
Taken together, these results suggest that 8-0H-DPAT may bind to both high and low 
affinity states of 5-HT1A receptors. The degree of Gpp(NH)p-induced inhibition of 3H-
8-0H-DPAT binding might depend on the ratio of 5-HT1A receptors existing in the high 
and low affinity states in each brain region. 
Repeated injections of fluoxetine did not change the Gpp(NH)p-induced 
inhibition of 3H-8-0H-DPAT binding. The lack of change suggests that no alteration 
occurred in the fraction of coupled 5-HT1A receptors. This conclusion is consistent with 
the results reported by Le Poul et al. (1995) who observed that repeated injections of 
fluoxetine did not change the ratio of 5-HT1A agonist (3H-8-0H-DPAT) to antagonist 
(3H-W A Y-100635) binding. 
Changes in the levels of Gi and G0 proteins induced by repeated injections of 
fluoxetine 
The time-course of the effect of fluoxetine on Gi1 and Gi3 proteins in the 
hypothalamus appears to parallel the reductions in ACTH and oxytocin responses to 8-
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OH-DPAT, suggesting that the desensitization of 5-HT1A receptors may be due to 
decreased levels of Gil and Gi3 proteins. In vitro, both Gi1 and Gi3 proteins are known 
to be coupled to 5-HT1A receptors (Raymond et al.1993). However, the hormone 
responses to 8-0H-DPAT were partly reduced after 3 days of fluoxetine injections, 
while the hypothalamic levels of Gi1 and Gi3 proteins were not significantly reduced 
until 7 days. One explanation for this difference in time-course is that hormone 
responses to 5-HT1A agonists are amplified through linkage via G proteins to the second 
messenger enzymes. Note that the hypothalamic levels of Gi1 and Gi3 proteins after 3 
days of fluoxetine injections were 79.9 ± 6.8% and 82.6 ± 6.1 % respectively. After 
7 days, the hormone responses to 8-0H-DPAT were almost maximally inhibited and 
the hypothalamic levels of Gil and Gi3 proteins were 58.0 ± 7.9% and 71.1 ± 10.43 
respectively and statistically different from the control group. These observations 
suggest that a small change in the levels of G proteins might induce a large change in 
hormone responses. 
The midbrain was examined for changes in G proteins because it contains 
serotonergic neurons in the dorsal and median raphe nuclei. The most salient finding 
is that the reduction in G proteins in the midbrain precedes the reductions of G proteins 
in the hypothalamus and that different G proteins are reduced in the midbrain than in 
the hypothalamus. The levels of G0 and Gi2 proteins in the midbrain were reduced by 
repeated injections of fluoxetine at 3 days and remained low for the duration of the 
injections. Since G0 proteins are coupled to 5-HT1A autoreceptors and probably play 
a role in the feedback inhibition of serotonergic firing (Sprouse and Aghajanian, 1988), 
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the decrease in their levels in the midbrain may be related to the desensitization of 
somatodendritic 5-HT1A autoreceptors. This observation agrees with the hypothesis that 
desensitization of the 5-HT1A autoreceptors in the raphe occurs before the 
desensitization of postsynaptic 5-HT1A receptors. However, one cannot dismiss the 
possibility that the reduction of G0 and Gi2 levels in the midbrain could also influence 
the functions of other neurotransmitter receptors which are known to be coupled to G0 
and Gi proteins. 
Fluoxetine did not change the levels of Gi or G0 proteins in the frontal cortex 
at any time. This is consistent with the results reported by other investigators (Lesch 
and Manji, 1992; Lesch et al.1991a) and suggests that the regulation of the expression 
of these G proteins is region specific. The reason for the difference between brain 
regions is still unclear and deserves further investigation. It may be due to differences 
in the origin of serotonergic projections to frontal cortex versus the hypothalamus 
(Mamounas et al.1991; Willoughby and Blessing, 1987), or to differences in co-
localized peptides in the serotonergic pathways that innervate the cortex and 
hypothalamus (Smith et al.1994; Li et al.1991; Francois-Bellan et al.1992), which could 
differentially modulate the regulation of G proteins. Other antidepressant drugs also 
differentially alter the expression of G proteins. For example, chronic injections of 
imipramine decrease the level of Gi proteins in the hypothalamus and the hippocampus 
but not in the frontal cortex (Lesch and Manji, 1992; Lesch et al.1991a). It is not clear 
if the reduction in Gi and G0 proteins is due to reduced synthesis. Infusion of a lower 
dose of fluoxetine (2.5 mg/kg/day) for 21 days did not alter Gi and G0 mRNA levels 
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in the hypothalamus and midbrain (Lesch and Manji, 1992; Lesch et al.1992b). This 
could mean that fluoxetine does not reduce the synthesis of Gi and G0 proteins and that 
the reduction is due to increased degradation or alterations in post-translational 
modification, such as reduced levels of palmitoylation of the G proteins (McCallum et 
al.1995; Milligan et al.1995; Ross, 1995). On the other hand, this particular study 
(Lesch and Manji, 1992; Lesch et al.1992b) used a lower dose of fluoxetine than the 
dose used in the present experiment and the lower dose might not have produced the 
same reduction in the levels of G proteins observed in the present study. 
It is difficult to reconcile the reduction in the levels of Gi1 and Gi3 in the 
hypothalamus with lack of change in the Gpp(NH)p-induced inhibition of 3H-8-0H-
DPAT binding. It should be noted that Gpp(NH)p-induced inhibition of 3H-8-0H-
DPAT binding is an indicator of a steady state condition of coupled 5-HT1A receptors. 
Therefore, the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding may not 
necessarily represent the dynamic status of agonist-induced coupling and signal 
transduction of 5-HT1A receptors in living cells. In addition, it is possible that a 
decrease in the levels of G proteins will influence the coupling of G proteins to adenylyl 
cyclase, resulting in an alteration in the level of second messenger. 
In summary, the results of the present study suggest that daily injections of 
fluoxetine produce a desensitization of 5-HT IA receptors in the hypothalamus. This 
desensitization occurs gradually and reaches a maximum after 14 days. The mechanism 
of desensitization of hypothalamic 5-HT1A receptor systems may involve decreased 
levels of Gi1 and/or Gi3 proteins. Furthermore, the earlier onset of reductions in 
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midbrain G0 proteins, compared with the decreases of hypothalamic Gi1 and Gi3 
proteins, supports the hypothesis that sustained inhibition of 5-HT transporters first 
desensitizes somatodendritic 5-HT1A autoreceptors in the raphe nuclei and, subsequently 
desensitizes postsynaptic 5-HT1A receptors. 
CHAPTER VI 
REPEATED INJECTIONS OF PAROXETINE PRODUCE A GRADUAL 
DESENSITIZATION OF 5-HT1A RECEPTORS IN THE HYPOTHALAMUS 
Summary 
In the previous studies, we demonstrated that repeated injections of fluoxetine 
produce a delayed and gradual desensitization of 5-HT1A receptors in the hypothalamus 
of male rats. The desensitization of hypothalamic 5-HT1A receptors was evidenced by 
a reduction in hormone responses to 8-0H-DPAT and by reduction in hypothalamic 
levels of Gil and Gi3 proteins which may be coupled to 5-HT1A receptors. However, 
no changes were observed in the density of 5-HT1A receptors or in the coupling of 5-
HT IA receptors to their G proteins. The present study examined the time-course effects 
of paroxetine on hypothalamic 5-HT1A receptors, to study whether the desensitization 
of 5-HT1A receptors is mediated by the sustained blockade of 5-HT uptake sites. Male 
rats were injected with paroxetine (10 mg/kg, ip) once daily for 1, 3, 7 and 14 days. 
Control rats received saline injections for 14 days. Eighteen hours after the last 
injection, the rats were challenged with 8-0H-DPAT (50 and 500 µg/kg, sc) and were 
decapitated 15 min after the injection of 8-0H-DPAT. Repeated injections of 
paroxetine reduced the 8-0H-DPAT-inducedelevation of plasma ACTH, corticosterone 
and oxytocin levels. The ACTH and corticosterone responses to the 50 µg/kg dose of 
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8-0H-DPAT, but not the high dose (500 µg/kg) of 8-0H-DPAT were significantly 
reduced by repeated injections of paroxetine. On the other hand, the oxytocin 
responses to both low and high doses of 8-0H-DPAT were reduced by the repeated 
injections of paroxetine. ACTH and oxytocin responses to 8-0H-DPAT were 
significantly reduced after 3 daily injections of paroxetine. The reduction reached a 
maximum after 7 and 14 daily injections of paroxetine. The corticosterone response 
to 8-0H-DPAT was not significantly reduced until 7 days of paroxetine injections. 
One daily injection of paroxetine did not alter the ACTH and corticosterone responses 
to 8-0H-DPAT. These results suggest that repeated injections of paroxetine produce 
a delayed and gradual desensitization of 5-HT1A receptors in the hypothalamus. The 
desensitization of hypothalamic 5-HT1A receptors require injections of paroxetine for 
more than one days. 
Repeated injections of paroxetine did not alter the density of 5-HT1A receptors 
in any brain region. However, the profile of changes in the levels of Gi and G0 
proteins is somewhat different from that induced by fluoxetine. Injections of paroxetine 
significantly reduced the levels of all four G proteins in the hypothalamus, although the 
reduction in the levels of Gi1 and Gi3 proteins was greater than in Gi2 and G0 proteins. 
The time-course of the reduction in the level of Gi3 proteins in the hypothalamus was 
similar to the time-course of reduced hormone responses to 8-0H-DPAT. The 
hypothalamic level of Gi1 proteins was significantly reduced after one day of paroxetine 
injection and a reduced level of Gil proteins was maintained up to 14 days of injections. 
Unlike fluoxetine, paroxetine significantly reduced the level of Gi2 proteins in the 
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hypothalamus after seven daily injections. The levels of all four G proteins in the 
midbrain were decreased after the injections of paroxetine. Midbrain levels of Gi2 and 
Gi3 proteins were significantly reduced after one daily injection of paroxetine and this 
reduced level was maintained until 14 days of injections. The level of Gil proteins was 
significantly decreased after three daily injections of paroxetine. Similar to fluoxetine, 
paroxetine reduced the level of midbrain G0 proteins after three daily injections. 
Although paroxetine did not alter the levels of Gi3 and G0 proteins in the frontal cortex, 
the levels of Gi1 and Gi2 proteins were significantly decreased in the frontal cortex after 
one day of paroxetine injection. These results suggest that repeated injections of 
paroxetine reduce Gi and G0 proteins in a region-specific manner. Furthermore, the 
differential profiles of the effects of paroxetine and fluoxetine on the levels of G 
proteins suggest that the reductions in the levels of Gi and G0 proteins are not only 
mediated by the blockade of 5-HT uptake sites, but also by side effects of these 5-HT 
uptake inhibitors. In conclusion, these results suggest that repeated injections of 
paroxetine produce a delayed and gradual desensitization of 5-HT1A receptors in the 
hypothalamus. This desensitization is not due to changes in the density of hypothalamic 
5-HT lA receptors. Since the time-course of the effect of paroxetine on the hypothalamic 
level of Gi3 proteins is similar to the time-course of the hormone responses to 8-0H-
DPAT , the reduced Gi3 proteins may be partly involved in the desensitization of 5-
HT 1A receptors. In addition, the consistent effect of paroxetine and fluoxetine on the 
level of G0 proteins in the midbrain suggests that a reduction of the level of G0 proteins 
in the midbrain may play a role in the desensitization of 5-HT1A autoreceptors induced 
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by the repeated injection of 5-HT uptake inhibitors. 
Introduction 
5-HT uptake inhibitors, such as fluoxetine, paroxetine, fluvoxamine and 
sertraline are widely used to treat affective disorders (Wong et al.1995; Goldstein et 
al.1995; Weltzin et al.1994; Advokat and Kutlesic, 1995; Eriksson et al.1995; Lam et 
al.1995). The pharmacologic effect of these drugs is blockade of 5-HT uptake sites. 
Because 5-HT uptake sites are responsible for reuptake of 5-HT from the synaptic cleft 
back into nerve terminals, blockade of 5-HT uptake sites will prolong the activity of 5-
HT and consequently increase the concentration of 5-HT in the synaptic cleft. Since 
the depletion of 5-HT has been hypothesized to be related to the pathology of 
depression, the blockade of 5-HT uptake sites by 5-HT uptake inhibitors should produce 
an immediate therapeutic effect on the treatment of depressed patients. However, the 
clinical application of these antidepressants suggests that the therapeutic effects of 5-HT 
uptake inhibitors may not be exclusively mediated by the blockade of 5-HT uptake sites 
because the clinical improvement is usually achieved 2-3 weeks after the onset of 
treatment. It is believed that the therapeutic effect of 5-HT uptake inhibitors may be 
related to adaptive changes induced by the blockade of 5-HT uptake sites. 
Activation of 5-HT1A autoreceptors may be involved in the delay of the 
therapeutic effects of 5-HT uptake inhibitors. Recently, Studies (Artigas et al.1994; 
Artigas, 1995; Blier and Bergeron, 1995) found that co-administration of the 5-HT1A/B 
adrenergic antagonist pindolol with 5-HT uptake inhibitors reduces the delay of clinical 
improvement in depressed patients. Our studies (Li et al.1996) (See Chapter V) have 
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demonstrated that repeated injections of fluoxetine produce a delayed and gradual 
desensitization of hypothalamic 5-HT1A receptors. To determine whether the effect of 
fluoxetine on the 5-HT1A receptors in the hypothalamus is mediated by blockade of 5-
HT uptake sites, another 5-HT uptake inhibitor paroxetine was used. Paroxetine has 
a chemical structure and pharmacokinetic profile that is different from fluoxetine 
(Nemeroff, 1993; Van Harten, 1993; Goodnick, 1994). For example, paroxetine has 
a 10 fold higher affinity for 5-HT uptake sites than fluoxetine (Bolden-Watson and 
Richelson, 1993; Richelson, 1994). Also, paroxetine has a higher ratio of affinity for 
serotonin/norepinephrine uptake sites than fluoxetine. The pharmacokinetics of 
paroxetine are quite different from those of fluoxetine (Goodnick, 1994; Van Harten, 
1993; Richelson, 1994; Lane et al. 1995). In humans, the half-life of paroxetine (about 
1 day) is much shorter than that of fluoxetine (3-5 days). Paroxetine does not have an 
active metabolite, while fluoxetine has an active metabolite, norfluoxetine, that has a 
long half-life (7-15 days). Also, one can expect that paroxetine will have different side 
effect than fluoxetine because of their different chemical structures. In fact, clinical 
application has shown that the side effects of paroxetine are different from those of 
fluoxetine (Lane et al.1995). However, since both fluoxetine and paroxetine inhibit 5-
HT uptake sites, a common effect of these two drugs would likely be mediated by 
blockade of 5-HT uptake sites. For example, there is no significant difference in their 
therapeutic effects for treatment of depression (Tignol, 1993; Lane et al.1995), 
suggesting that their therapeutic effect is mediated by blockade of 5-HT uptake sites. 
5-HT1A receptors can be classified into somatodendritic and postsynaptic 
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receptors. Somatodendritic 5-HT1A autoreceptors are located on the 5-HT neurons in 
the dorsal and median raphe nuclei in the midbrain. The function of the 5-HT1A 
autoreceptors is feedback regulation of 5-HT release from serotonergic nerve terminals. 
Stimulation of 5-HT1A autoreceptors by 5-HT or 5-HT1A agonists will decrease the firing 
rate of neurons and subsequently reduce the release of 5-HT from nerve terminals. 
Postsynaptic 5-HT1A receptors are distributed in most forebrain regions, such as the 
hippocampus, hypothalamus, amygdala and cortex (Kia et al.1996; Gozlan et al.1995; 
Khawaja, 1995). The postsynaptic 5-HT1A receptors are activated by serotonergic 
inputs from 5-HT neurons and produce physiological responses, which depend on the 
function of the target cells. For example, stimulation of 5-HT1A receptors in the 
hypothalamus will increase the secretion of several hormones, such as ACTH, 
corticosterone and oxytocin. Since plasma hormone concentrations are easy to measure, 
the hormone responses to 5-HT1A agonists can be used as markers of the function of 
hypothalamic 5-HT1A receptors. The magnitude of the hormone response to 5-HT1A 
agonists reflects the function of 5-HT1A receptors in the hypothalamus. 
5-HT1A receptors are G protein-coupled membrane proteins. So far, the 
evidence suggests that 5-HT1A receptors are coupled to Gi or G0 proteins (Butkerait et 
al.1995; Mulheron et al.1994; Fargin et al.1991). Somatodendritic 5-HT1A receptors 
may be coupled to G0 proteins, which increase the opening of K+ channels and 
consequently suppress the activity of 5-HT neurons (Sprouse and Aghajanian, 1988; 
Innis and Aghajanian, 1987; Innis et al.1988). Postsynaptic 5-HT1A receptors have a 
higher affinity for Gi3 and Gi1 proteins than that for Gi2 and G0 proteins (Raymond et 
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al.1993; Mulheron et al.1994; Bertin et al.1992). Stimulation of 5-HT1A receptors that 
are coupled to Gi proteins will inhibit the activity of adenylyl cyclase, resulting in a 
decrease of cAMP in the cells. In the present study, the effect of daily injections of 
paroxetine on the levels of Gi and G0 proteins in the hypothalamus, midbrain and frontal 
cortex were determined to assess the effect of sustained inhibition of 5-HT uptake on 
the signal transduction system of 5-HT1A receptors. 
We have hypothesized here that repeated injections of paroxetine would produce 
a delayed and gradual desensitization of 5-HT tA receptors in the hypothalamus. The 
time-course of the effect of paroxetine on the hormone responses to 8-0H-DPAT was 
examined to assess the function of 5-HT1A receptors in the hypothalamus. To study 
whether the desensitization is mediated by a down-regulation of 5-HT1A receptors, the 
time-course of effect of paroxetine on the density of 5-HT1A receptors in the 
hypothalamus and several other brain regions was determined by autoradiographic 
analysis of 3H-8-0H-DPAT binding. Furthermore, we examined the levels of Gi and 
G0 proteins in the hypothalamus, midbrain and frontal cortex, to determine whether a 
reduction in the signal transduction system of 5-HT1A receptors plays a role in the 
desensitization of 5-HT1A receptors. 
Experimental Protocol 
Male rats were injected with paroxetine (10 mg/kg, ip) once daily for 1, 3, 7 
or 14 days. The control rats received saline injections for 14 days. Eighteen hours 
after the last injection, the rats were challenged with saline or 8-0H-DPAT (50 or 500 
µg/kg, sc) and decapitated 15 min after the injection of 8-0H-DPAT. Trunk blood was 
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collected in centrifuge tubes containing 0.5 ml of 0.3M EDTA (pH 7.4) solution. After 
centrifugation at 2500 rpm, 4°C for 15 min, plasma aliquots were stored at -7D°C until 
they were used for hormone assays. The brains from saline challenged rats were 
quickly and carefully removed and frozen on powdered dry ice until the brains were 
completely frozen. The brains were then wrapped with plastic wrap, parafilm and 
aluminum foil and stored at -70°C until they were sectioned for autoradiography. The 
brains of the other rats were dissected and the hypothalamus, midbrain and frontal 
cortex were stored at -70°C for immunoblots of Gi and G0 proteins. 
Plasma ACTH, corticosterone and oxytocin were measured by 
Radioimmunoassay as described in Chapter III. The density of 5-HT1A receptors in the 
hypothalamus and several other brain regions was analyzed by autoradiography (See 
Chapter III for details). The levels of Gi1, Gi2, Gi3 and G0 proteins were analyzed using 
immunoblots as described in Chapter III. 
Results 
Hormone responses to 8-0H-DPAT 
8-0H-DPAT significantly increased plasma ACTH concentration. Repeated 
injections of paroxetine significantly reduced the ACTH response to the 50 µglkg dose 
of 8-0H-DPAT (top panel of Fig.16). A partial reduction of the ACTH response to 
8-0H-DPAT occurred after 3 daily injection of paroxetine and this inhibition was 
maximal after 7 and 14 days of injections. One daily injection of paroxetine did not 
alter the ACTH response to 8-0H-DPAT (bottom panel of Fig. 16). Repeated 
injections of paroxetine did not decrease the maximal effect of 8-0H-DPAT (500 µg/kg) 
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on ACTH secretion. However, the ACTH response to this high dose of 8-0H-DPAT 
(500 µglkg) was potentiated by the daily injections of paroxetine for 7 days (top panel 
of Fig. 16). 
Figure 17 shows the effect of both 8-0H-DPAT doses (top) and a time-course 
(bottom) of the effect of repeated injections of paroxetine on the corticosterone response 
to 8-0H-DPAT. 8-0H-DPAT significantly increased plasma corticosterone 
concentration. Repeated injections of paroxetine significantly inhibited the 
corticosterone response to the 50 µglkg dose of 8-0H-DPAT. Unlike the ACTH 
response, the reduced corticosterone response to 8-0H-DPAT was statistically 
significant only after 7 daily injections of paroxetine (bottom panel of Fig.17). 
Injections of paroxetine for one or three days did not decrease the corticosterone 
response to 8-0H-DPAT. However, the corticosterone response to the high dose (500 
µglkg) of 8-0H-DP AT was significantly potentiated by repeated injections of paroxetine 
for three days (top panel of Fig. 17). 
As is shown in Figure 18, 8-0H-DPAT significantly increased plasma oxytocin 
concentration. Paroxetine significantly decreased the oxytocin response to both low and 
high doses of 8-0H-DPAT after 3 daily injections. The reduction of the oxytocin 
response to 8-0H-DPAT reached a maximum after 7 and 14 daily paroxetine injections 
(bottom panel of Fig. 18). Injection of paroxetine for 1 day did not reduce the effect 
of 8-0H-DPAT on oxytocin. However, the oxytocin response to the high dose (500 
µglkg) of 8-0H-DPAT was significantly reduced by injection of paroxetine for one day 
(top panel of Fig. 18). 
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Fi2ure 16. Daily injections of paroxetine inhibit the effect of 8-0H-DPAT 
on plasma ACTH. Top: low and high doses of 8-0H-DPAT; Bottom: time-course 
of the reduction observed with an 8-0H-DPAT dose of 50 µglkg sc. The data 
represent mean ± S.E.M. of 8-12 rats per group. Two way ANOVA: Main effect of 
paroxetine: Fc4• 125l=4.945 P<0.001; Main effect of 8-0H-DPAT: Fcz. 125)=108.013 
P< 0.001; Interaction betweenparoxetine and 8-0H-DPAT: Fcs. 125)=9.1176 P <0.001. 
*Significant difference from the saline (0 dose of 8-0H-DPAT) group, P<0.05; 
+ Significant difference from the saline (0 dose of paroxetine) group, P < 0.05 
(Newman Keuls' multiple range test) 
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Fia=ure 17. Daily injections of paroxetine inhibit the effect of 8-0H-DPAT 
on plasma corticosterone. Top: low and high doses of 8-0H-DPAT; Bottom: time-
course of the reduction observed with an 8-0H-DPAT dose of 50 µg/kg sc. The data 
represent mean ± S.E.M. of 8-12 rats per group. Two way ANOVA: Main effect of 
paroxetine: F<4. 123)=2.9577 P<0.001; Main effect of 8-0H-DPAT: F<2• 123)=77.1356 
P<0.001; Interaction between paroxetine and 8-0H-DPAT: F<8. 123)=2.653 P<0.05. 
*Significant difference from the saline (0 dose of 8-0H-DPAT) group, P<0.05; 
+ Significant difference from the saline (0 dose of paroxetine) group, P<0.05 
(Newman Keuls' multiple range test) 
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Figure 18. Daily injections of paroxetine inhibit the effect of 8-0H-DPAT 
on plasma oxytocin. Top: low and high doses of 8-0H-DPAT; Bottom: time-course 
of the reduction observed with an 8-0H-DPAT dose of 50 µg/kg sc. The data 
represent mean ± S.E.M. of 8-12 rats per group. Two way ANOVA: Main effect of 
paroxetine: Fc4• 122>=12.8076 P<0.001; Main effect of 8-0H-DPAT: Fc2, 122)=401.5 
P<0.001; Interaction between paroxetine and 8-0H-DPAT: Fc8, 122)=3.82 P<0.01. 
*Significant difference from the saline (0 dose of 8-0H-DPAT) group, P<0.05; 
+ Significant difference from the saline (0 dose of paroxetine) group, P < 0.05 
(Newman Keuls' multiple range test). 
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Autoradiographic analysis of 3H-8-0H-DPAT binding 
Autoradiographic analysis of 3H-8-0H-DPAT binding was used to examine the 
effect of paroxetine on the density of 5-HT1A receptors. The time course of the effect 
of repeated injections of paroxetine on the density of 5-HT1A receptors was determined 
in several nuclei in the hypothalamus, amygdala, hippocampus and dorsal and median 
raphe nuclei as well as several layers of the cortex. As shown in Table VII, the 
distribution of 5-HT1A receptors varies among brain regions, which is consistent with 
that seen in the previous study (Chapter V). Like fluoxetine, paroxetine did not alter 
the density of 5-HT1A receptors in any brain regions after daily injections (Table VII). 
Levels of Gi and G0 proteins in the hypothalamus, midbrain and frontal cortex 
The effects of repeated injections of paroxetine on the levels of Gi1, Gi2 , Gi3 and 
G0 proteins were determined using immunoblots. The four G proteins were 
differentially influenced in the hypothalamus, midbrain and frontal cortex by repeated 
injections of paroxetine. 
Repeated injections of paroxetine significantly reduced the levels of all four G 
proteins in the hypothalamus, although the reduction in the levels of Gil and Gi3 proteins 
was greater than that of Gi2 and G0 proteins (Fig. 19). The level of Gu proteins was 
significantly reduced after one day of paroxetine injection and the reduced level of Gi1 
proteins was maintained until 14 days of injections (Fig.19A). Paroxetine significantly 
decreased the level of Gi3 and G0 proteins after 3 days of injections (Fig. 19C, D). The 
low level of Gi3 proteins was maintained until 14 daily injections of paroxetine (Fig. 
19C), while the level of G0 proteins returned to normal levels after 14 days of injections 
135 
(Fig. 19D). The time-course of the effect of paroxetine on the level of Gi3 protein was 
similar to the time-course in reducing the hormone responses to 8-0H-DPAT. The 
level of Gi2 proteins was significantly decreased only after 7 daily paroxetine injections 
(Fig. 19B). 
As shown in Fig. 20, the levels of all four G protein were decreased in the 
midbrain after daily injections of paroxetine. The levels of Gi2 and Gi3 proteins were 
significantly reduced after one day of injection of paroxetine and the reduced level was 
maintained until 14 days of injections (Fig. 20B, C). The level of Gn proteins was 
significantly decreased after 3 days of injections of paroxetine (Fig. 20A). Paroxetine 
reduced the level of G0 proteins in the midbrain after 3 and 7 daily injections (Fig, 
20D). 
Although paroxetine did not alter the levels of Gi3 and G0 proteins in the frontal 
cortex, the levels of Gi1 and Gi2 proteins were significantly decreased in the frontal 
cortex after injection of paroxetine for one day (Fig. 21A,B). 
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TABLE VII 
REPEATED INJECTIONS OF PAROXETINE DO NOT ALTER THE DENSITY 
OF 5-HT1A RECEPTORS AT ANY BRAIN REGION 
Brain regions Nuclei Density of 3H-8-0H-DPAT - labeled 5-HT1A receptors 
Cortex 
Fr2 
Saline 1 days 3 days 7 days 14 days 
layer 1-3 26.5±1.5 22.9±1.7 23.2±1.6 23.3±1.1 22.9±2.2 
layer 5 72.6±3.6 64.1 ±2.6 64.6±3.4 62.1 ±3.2 64.2±3.9 
-----------------~l!X~~-~- §l._l_t_~:.~-.?~·Qt_~:.~_.?.7-:±t_'!:.~_.?_~._Q_;!;.~:.~-~~.:~.;t~..:l_ 
CG3 layer 1-3 44.9±4.4 40.3±2.2 41.4±4.3 40.4±3.3 37.8±3.8 
layer 5 
layer 6 
65.5±5.6 54.9±3.5 56.7±4.4 57.9±4.3 56.3±5.1 
62.5±4.5 51.6±1.8 52.1±3.3 55.0±3.8 54.8±4.6 
Hypothalamus PVNm 
PVNp 
AHN 
LH 
7.0±0.6 5.8±0.4 5.6±0.3 6.1 ±0.7 6.6±0.7 
8.3±0.7 7.3±0.4 7.2±0.4 8.0±0.7 8.6±0.6 
12.8±0.6 10.8±0.5 10.6±1.0 10.9±1.2 12.3±0.8 
4.7±0.3 4.2±0.3 4.2±0.4 4.3±0.2 4.7±0.2 
Amygdala 
VMHDM 21.6± 1.6 21.8± 1.4 21.2± 1.1 19.4±1.0 18.9± 1.0 
VMHC 32.8±2.6 32.2±2.4 31.2±2.1 27.8±1.9 29.1±1.8 
VMHVL 19.8±1.3 19.2±0.9 19.2±1.1 17.7 ±1.0 17.1 ±0.8 
DMH 10.0±0.9 9.8±0.7 10.0±0.4 8.6±0.3 9.1±0.3 
AC 6.1 ±0.4 6.5 ±0.5 6.4±0.2 6.1 ±0.3 5.4±0.3 
ALP 11.5±0.7 11.1±0.7 13.1±0.4 11.8±0.7 11.2±0.4 
ABL 17.2±1.1 16.7±0.8 17.3±0.7 17.2±0.7 16.8±0.6 
ABM 26.5±2.1 24.3±2.2 24.5±1.7 23.0±1.1 24.1±1.3 
AM 18.7±2.1 18.1±1.0 18.6±0.7 18.0±0.9 17.8±0.6 
Hippocampus CAl 62.9±1.7 49.1±5.8 51.9±3.0 43.9±4.7 59.0±4.0 
CA2 14.5±0.4 12.2±1.3 11.6±0.5 10.6±0.9 13.6±0.8 
CA3 31.6±1.1 26.5±3.2 27.3±2.0 25.2±3.2 31.9±2.3 
DG 84.1+3.0 66.5±5.5 70.7±4.4 63.2±6.4 78.3±5.2 
Mid brain DR 30.8±1.8 32.4±1.5 32.0±0.9 32.9±0.4 31.9±0.9 
MR 21.7+1.7 23.4+2.2 20.5± 1.2 20.2±1.4 18.5±0.9 
The data represent mean ± S.E.M. of 5-6 rats per group. 
Abbreviations: 
ABL: 
ABM: 
AC: 
AHN: 
ALP: 
AM: 
CAl-3: 
CG3: 
DG: 
DMH: 
DR: 
Fr2: 
LH: 
MR: 
PAR 1: 
PVNm: 
PVNp: 
VMHC: 
VMHDM: 
VMHVL: 
Basolateral amygdaloid nucleus 
Basomedial amygdaloid nucleus 
Central amygdaloid nucleus 
Anterior hypothalamic nucleus 
Lateral amygdaloid nucleus, posterior region 
Medial amygdaloid nucleus 
Field CAl, CA2 and CA3 of ammon's horn in the hippocampus 
Cingulate cortex, area 3. 
Dentate gyrus (hippocampus) 
Dorsomedial hypothalamic nucleus 
Dorsal raphe 
Frontal cortex, area 2 
Lateral hypothalamic area 
Medial raphe 
Parietal cortex, area 1 
Paraventricular hypothalamic nucleus, magnocellular region 
Paraventricular hypothalamic nucleus, parvocellular region 
Ventromedial hypothalamic nucleus, central region 
Ventromedial hypothalamic nucleus, dorsomedial region 
Ventromedial hypothalamic nucleus, ventrolateral region 
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Fi~ure 19. Paroxetine reduces the levels of G proteins in the hypothalamus. 
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi1 proteins, 
One way ANOVA: F<4• 24) =3.7267, P<0.05; B. Level of Gi2 proteins. One way 
ANOVA: F<4• 25)= 1.892, NS. C. Level of Gi3 proteins. One way ANOVA: F<4. 
27)=2.8918, P<0.05; D. Level of G0 proteins. One way ANOVA: F<4• 28) =3.3027, 
P<0.05. 
* Significant difference from the vehicle group, P < 0.05 ( Newman Keuls' multiple 
range test) 
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Fi2ure 20. Paroxetine reduces the levels of G proteins in the midbrain. The 
data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi1 proteins, One 
way ANOVA: F<4• 24l =19.55, P<0.01 B. Level of Gi2 proteins. One way ANOVA: 
F<4• 24l =12.6; P<0.01 . C. Level of Gi3 proteins. One way ANOVA: F<4• 24l=8.809, 
P<0.01. D. Level of G0 proteins. One way ANOVA: F<4• 27l=4.449; P<0.01 
* Significant difference from the vehicle group, P < 0.05 (Newman Keuls' multiple 
range test) 
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Fi2Ure 21. Paroxetine reduces the levels of G proteins in the frontal cortex. 
The data represent mean ± S.E.M. of 6-8 rats per group. A. Level of Gi1 proteins, 
One way ANOVA: F<4. 30)=12.045; P<0.01 B. Level of Gi2 proteins. One way 
ANOVA: F<4• 3l=5.189, P=0.01 . C. Level of Gi3 proteins. One way ANOVA: F<4• 
32l=0.9768, NS. D. Level of G0 proteins. One way ANOVA: Fc4. 28l=0.289, NS. 
* Significant difference from the vehicle group, P<0.05 (Newman Keuls' multiple 
range test) 
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Discussion 
The results of the present study agree with the data obtained with fluoxetine and 
suggest that sustained blockade of 5-HT uptake produces a delayed and gradual 
desensitization of 5-HT1A receptors in the hypothalamus. This desensitization of 5-HT1A 
receptors is unlikely due to a down-regulation of hypothalamic 5-HT IA receptors. Since 
the time-course of paroxetine-induced reduction in the level of Gi3 proteins in the 
hypothalamus is similar to the time-course of reduction in the hormone responses to 8-
0H-D PAT, it is possible that the reduction in the level of Gi3 proteins is involved in 
the desensitization of hypothalamic 5-HT1A receptors. 
In the present study, we examined changes in 5-HT1A receptors after 1, 3, 7 and 
14 daily injections of paroxetine. In contrast, the study on the effects of fluoxetine had 
a time-course of 0, 3, 7, 14 and 22 days. The reason for adding a one day paroxetine 
group was to determine when the desensitization of the hypothalamic 5-HT1A receptors 
would starts. We have observed that 3 daily injections of fluoxetine partially reduce 
the hormone responses to 8-0H-DPAT. In the present study, we determined whether 
the desensitization of hypothalamic 5-HT1A receptors occurs after one daily injection of 
paroxetine. We deleted the group of 22 daily injections in the present study because 
the maximal effects of fluoxetine on the 5-HT1A receptors were observed after 14 daily 
injections. Comparing the time-course of fluoxetine with that of paroxetine, these 
results suggest that the desensitization of 5-HT1A receptors in the hypothalamus requires 
more than one day of sustained inhibition of 5-HT uptake. However, one daily 
injection of paroxetine significantly decreases the levels of Gi1 proteins in the 
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hypothalamus, the levels of Gi2 and Gi3 proteins in the midbrain and the levels of Gil 
and Gi2 proteins in the frontal cortex. These results suggest that paroxetine induces 
some changes after one daily injection. These changes may not be related to the 
function of hypothalamic 5-HT1A receptors, because the neuroendocrine response is an 
amplified response to activation of the hypothalamic 5-HT1A receptors and it was not 
reduced after one daily injection of paroxetine. 
In the present study, ACTH, corticosterone and oxytocin responses to 8-0H-
DPAT were used to assess the function of hypothalamic 5-HT1A receptors. Several 
studies have demonstrated that 8-0H-DPAT-induced increases of plasma ACTH, 
corticosterone and oxytocin are dose-dependent. The ACTH and corticosterone 
responses to 8-0H-DPAT can be abolished by the 5-HTIA antagonists, pindolol, 
spiperone, NAN-190, UH-301, WAY-100135 and WAY-100635 (Cowen et al.1990; 
Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et al.1994b; Przegalinski et 
al.1989; Kelder and Ross, 1992; Vicentic et al.1996). The oxytocin response to 8-0H-
DPAT can be inhibited by WAY-100635 and NAN-190 (Vicentic et al.1996; Bagdy and 
Kalogeras, 1993). A lesion in the hypothalamic paraventricular nucleus blunted the 
ACTH, corticosterone and oxytocin responses to ipsapirone (Bagdy and Makara, 1994; 
Bagdy, 1995). These data suggest that the hormone responses to 8-0H-DPAT are 
mediated by activation of 5-HT1A receptors in the hypothalamus, likely in the 
paraventricular nucleus. Therefore, the magnitude of hormone responses to 8-0H-
DPAT can be used as a tool to assess the function of hypothalamic 5-HT1A receptors 
(Van de Kar, 1991; Van de Kar, 1989; Van de Kar and Brownfield, 1993). The results 
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of the present study show that repeated injections of paroxetine significantly decrease 
the hormone response to 8-0H-DPAT, suggesting that paroxetine produces a 
desensitization of 5-HT1A receptors in the hypothalamus. The desensitization of 
hypothalamic 5-HT1A receptors appears after 3 daily injections and reaches a maximum 
effect after 7 and 14 days. These results are consistent with those observed with 
repeated injections of fluoxetine, suggesting that the desensitization of 5-HT1A receptors 
is mediated by the blockade of 5-HT uptake sites. 
It was unexpected that the ACTH and corticosterone responses to the 500 µg/kg 
dose of 8-0H-DPAT were significantly potentiated by 3 or 7 daily injections of 
paroxetine. However, at the same time points, the ACTH and corticosterone responses 
to the low dose (50 µg/kg) of 8-0H-DPAT were decreased by daily injections of 
paroxetine. The 50 µg/kg dose of 8-0H-DPAT is close to the ED50 dose for ACTH 
and corticosterone and is more sensitive to changes in the function of 5-HT1A receptors. 
On the other hand, the 500 µg/kg dose of 8-0H-DPAT is a maximal dose for ACTH 
and corticosterone. At this high dose, 8-0H-DPAT may stimulate some other receptors 
for which 8-0H-DPAT has a relative high affinity. For example, the affinity of 8-0H-
DPAT for 5-HT7 receptors is about 10-fold lower than that for 5-HT1A receptors (Hoyer 
et al.1994). In addition, no potentiation of the effects of 8-0H-DPAT was observed 
in the oxytocin response. All together, the potentiation of the AC TH and corticosterone 
responses to the high dose of 8-0H-DPAT may not be mediated by hypothalamic 5-
HT IA receptors. 
Similar to our previous observations with fluoxetine, daily injections of 
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paroxetine decreased the ACTH and corticosterone responses to a low dose, but not a 
high dose of 8-0H-DPAT, while the decrease in the oxytocin response was observed 
at both low and high doses of 8-0H-DPAT. There is a higher 5-HT1A receptor reserve 
for ACTH and corticosterone responses than for the oxytocin response to 5-HT1A 
agonists (1994; 1994), unpublished data from Pinto and Battaglia). This difference in 
receptor reserve might explain the difference between ACTH and oxytocin. However, 
it is also possible that the lack of change in the ACTH and corticosterone responses to 
a high dose of 8-0H-DPAT is due to activation of other receptors, which increase 
ACTH and corticosterone secretion and may be sensitized by repeated injections of 
paroxetine. 
Repeated injections of paroxetine did not alter the density of 5-HT1A receptors 
in any brain regions. This observation is in agreement with our observations with 
fluoxetine and also in agreement with the data reported by other investigators (Le Poul 
et al.1995; Hensler et al.1991). Le Poul et al. (1995) showed that neither fluoxetine 
nor paroxetine altered the density of 5-HT1A receptors in the dorsal raphe nucleus and 
in the dentate gyms of the hippocampus. Hensler et al. ( 1991) found that repeated 
injections of sertraline or citalopram did not influence the density of 5-HT1A receptors 
in several brain regions. 
There are similarities but also differences between paroxetine and fluoxetine with 
respect to their effects on the levels of G proteins. Overall. paroxetine seems to 
produce a greater and earlier reduction in the levels of Gi and G() proteins, especially 
the levels of Gi1 and Gi2 proteins. For example, paroxetine reduced the level of Gi1 
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proteins in the hypothalamus after one daily injection, while fluoxetine did not 
significantly reduce the level of Gi1 proteins until 7 daily injections. Similarly, 
fluoxetine did not significantly alter the hypothalamic level of Gi2 proteins, but 
paroxetine decreased the level of Gi2 proteins after 7 daily injections. So far, there is 
no good explanation for the differential influence on the levels of Gi and G0 proteins by 
fluoxetine and paroxetine, since little is known regarding the mechanism though which 
they decrease G protein levels. 
Beside the differential effect of fluoxetine and paroxetine on levels of G 
proteins, there are some similarities which may be more important for the 
desensitization of 5-HT1A receptors. For example, the time-course of reduction in the 
hypothalamic level of Gi3 proteins is similar to the time-course of hormone responses 
to 8-0H-DPAT after repeated injections of paroxetine. This observation is consistent 
with the results observed with repeated injections of fluoxetine. Since 5-HT1A receptors 
have a high affinity for Gi3 proteins, this similarity in time-courses for reduction in the 
hypothalamic level of Gi3 proteins and the neuroendocrine resporu;es to 8-0H-DPAT 
suggests that the reduction in the level of Gi3 may be involved in the desensitization of 
hypothalamic 5-HT1A receptors. 
Repeated injections of paroxetine significantly decreased the level of Gi2 proteins 
in the midbrain. The reduction in the level of Gi2 proteins appeared after one daily 
injection and remained for 14 daily injections. Paroxetine reduced the level of G0 
proteins after 3 daily injections. These changes are similar to the results observed with 
fluoxetine injections. The level of G0 proteins returned to normal after 14 daily 
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injections of paroxetine, which is in contrast with fluoxetine-induced reduction of G0 
proteins which remained reduced during the 22 daily injections. Desensitization of 5-
HT1A autoreceptors in the dorsal raphe nucleus has been detected after 3 to 14 daily 
injections of fluoxetine or paroxetine (Le Poul et al.1995). However, no data are 
available on the effect of one daily injection of 5-HT uptake inhibitors on 5-HT1A 
autoreceptors. Therefore, it is difficult to determine which G proteins are involved in 
the desensitization of 5-HT1A autoreceptors. 
In conclusion, the results of the present of study suggest that repeated injections 
of paroxetine produce a delayed and gradual desensitization of hypothalamic 5-HT1A 
receptors. This desensitization is similar to that induced by fiuoxetine, suggesting that 
sustained blockade of 5-HT uptake sites mediates this effect. Since no change was 
detected in the density of 5-HT1A receptors in the hypothalamic nuclei, it is unlikely that 
the desensitization of hypothalamic 5-HT1A receptors is due to a down-regulation of 5-
HT1A receptors. The similarity of the time-course of the leYel of Gi3 proteins to the 
time-course of the hormone responses to 8-0H-DPAT, after repeated injections of 
paroxetine, suggests that the reduction of the level of Gll proteins may be partly 
involved in the desensitization of 5-HT1A receptors. 
CHAPTER VII 
GENERAL DISCUSSION 
The present studies demonstrate that prolonged blockade of 5-HT uptake sites 
by 5-HT uptake inhibitors produces a delayed and gradual desensitization of 
hypothalamic 5-HT1A receptors. This desensitization is not induced by blockade of 
norepinephrine uptake sites following long-term administration of desipramine. Because 
neither fluoxetine nor paroxetine changes the density and affinity of 5-HT1A receptors 
in the hypothalamus, the desensitization of hypothalamic 5-HT1A receptors is unlikely 
due to receptor down-regulation. A reduction in the level of Gi3 proteins may play a 
role in the desensitization of hypothalamic 5-HT1A receptors, because the time-course 
of the reduction in the level of Gi3 proteins is similar to the time-course of the reduction 
of the hormone responses to 8-0H-DPAT. Therefore, the results of the present studies 
support our hypothesis that repeated injections of 5-HT uptake inhibitors produce a 
delayed and gradual desensitization of hypothalamic 5-HT1A receptors that may be due 
to changes in their signal transduction mechanisms. 
The Neuroendocrine Challen1:e Test --- A Tool to Examine the Function of 
Hypothalamic 5-HT1A Receptors 
In the present studies, ACTH, corticosterone and oxytocin responses to the 5-
HT1A agonists 8-0H-DPAT and ipsapirone were used to eyaluate the function of 
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hypothalamic 5-HT1A receptors. Several studies have demonstrated that ACTH, 
corticosterone and oxytocin responses to 5-HT1A agonists are mediated by 5-HT1A 
receptors (Van de Kar, 1991; Van de Kar and Brownfield, 1993). First, several 5-HT1A 
agonists, such as 8-0H-DPAT, ipsapirone, buspirone and gepirone stimulate the 
secretion of ACTH, corticosterone and oxytocin in a dose-dependent manner (Cowen 
et al.1990; Fuller, 1992; Gilbert et al.1988a; Koenig et al.1988; Bagdy and Kalogeras, 
1993). Second, the hormone responses to 5-HT1A agonists can be inhibited by 5-HT1A 
antagonists, such as pindolol, spiperone, NAN-190, UH-301, WAY-100135 and WAY-
100635 (Cowen et al.1990; Lejeune et al.1993; Pan and Gilbert, 1992; Critchley et 
al.1994b; Przegalinski et al.1989; Kelder and Ross, 1992; Bagdy and Kalogeras, 1993; 
Vicentic et al.1996), but not by 5-HTrn, 5-HT2 , 5-HT3 and adrenoceptor antagonists 
(Przegalinski et al.1989). Third, the hormone responses to 5-HT1A agonists may be 
mediated by postsynaptic 5-HT1A receptors. A lesion in 5-HT neurons by 
intracerebroventricular injection of 5,7-DHT or depletion of 5-HT with PCPA did not 
decrease the effects of 5-HT1A agonists on the secretion of ACTH and corticosterone 
(Przegalinski et al.1989; Gilbert et al.1988b and our unpublished data). Furthermore, 
a lesion in the paraventricular nucleus of the hypothalamus blunted the corticosterone 
and oxytocin responses to ipsapirone (Bagdy and Makara, 1994; Bagdy, 1994). 
Together, these results suggest that 5-HT1A agonists increase the section of ACTH, 
corticosterone and oxytocin by activating postsynaptic 5-HT tA receptors in the 
hypothalamus. Therefore, the magnitude of the hormone responses to 5-HT1A agonists 
can be used as an index for the function of hypothalamic 5-HT 1A receptors. 
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Although it is clear that stimulation of 5-HT1A receptors in the hypothalamus 
increases the secretion of ACTH, corticosterone and oxytocin, the intracellular pathway 
of the 5-HT1A receptor-mediated regulation of hormone secretion is still unknown. For 
example, no data are available regarding which G proteins and second messengers 
mediate the increase in the secretion of hormones, and how the second messengers 
trigger the release of these hormones. Therefore, one should be aware of these 
limitation when interpreting the data in neuroendocrine challenge test. Also, it is 
possible that a change in production of a specific hormone will alter its response to a 
5-HT1A agonist. Most 5-HT1A agonists have side effects to interact with other 
receptors, which can also increase the secretion of these hormones. Therefore, a 
hormone response to a 5-HT1A agonist may not only reflect the function of 5-HT1A 
receptor systems but also of other receptors. For example, buspirone is a 5-HT1A 
agonist and a dopamine D2 antagonist. Since dopamine is a predominant controller of 
prolactin secretion, the increase in prolactin induced by buspirone may mainly represent 
the D2 antagonist effect but not the activity of 5-HT1A receptors. 
A number of approaches can be used to overcome these limitations of 
neuroendocrine challenge tests. First, it is necessary to test multiple hormone 
responses. Each hormone is differentially regulated in terms of their synthesis, their 
location and stimulation of their secretion by neurotransmitters. Therefore, the side 
effect of 5-HT1A agonists may not influence all the hormones in a same manner. For 
example, in the present studies, repeated injections of paroxetine potentiated the ACTH 
and corticosterone responses to a high dose of 8-0H-DPAT. Since potentiation was not 
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observed in the oxytocin response, it is unlikely that the paroxetine-induced potentiation 
of ACTH and corticosterone responses to 8-0H-DPAT is mediated by 5-HT1A 
receptors. Secondly, using more than one 5-HT1A agonist for the hormone challenge 
test also helps to distinguish between hormone responses mediated by 5-HT1A receptors 
and responses mediated by other receptors. Different 5-HT1A agonists may have 
different side effects which may influence the secretion of hormones. These side effects 
of 5-HT1A agonists on the hormone responses may be different between 5-HT1A 
agonists, while they share the same effects on 5-HT1A receptor-mediated hormone 
responses. Thirdly, comparing the hormone responses to 5-HT1A agonists with the 
response to other receptor agonists, such as 5-HT2Anc agonists, can rule out the 
possibility that changes in the hormone responses to 5-HT1A agonists are due to an 
alteration in the production of the hormone. For example, long-term injections of 
fluoxetine decrease the hormone responses to 5-HT1A agonists but potentiate the 
hormone responses to a 5-HT2Aizc agonist (Li et al.1993a). suggesting that the decrease 
in hormone responses to 5-HT1A agonists is not due to a reduction in the synthesis of 
these hormones. 
An advantage of hormone challenge test is that the hormone responses to 5-HT1A 
agonists amplify the changes in the 5-HT1A receptor systems. For example, activation 
of 5-HT1A receptors on parvocellular cells of the PVN increases the secretion of CRF. 
CRF further increase the secretion of ACTH from corticotrophs in the pituitary. 
ACTH will further increase corticosterone release from the adrenal cortex. Along the 
HPA axis, the signal of any change in the 5-HT1A receptors is enlarged in the each step. 
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This amplification is beneficial to monitor changes in 5-HT1A receptors. 
As we hypothesized, desensitization of hypothalamic 5-HT1A receptors may play 
a role in the therapeutic effects of SSRI's. It is possible that the changes in the 5-HT1A 
receptors occur prior to the improvement of clinical symptoms in patients receiving 
SSRI's. Therefore, neuroendocrine challenge tests can proYide early information for 
physicians to monitor and predict the therapeutic effects of SSRI's. 
Comparison of Desipramine with Fluoxetine in Neuroendocrine Challen1:e tests 
In the present studies, we compared the effect of desipramine and fluoxetine on 
the function of hypothalamic 5-HT1A receptors. Desipramine is a norepinephrine uptake 
inhibitor and a tricyclic antidepressant, while fluoxetine is a 5-HT uptake inhibitor and 
an atypical antidepressant (De Vane, 1994). The results of the present studies indicate 
that repeated injections of fluoxetine, but not desipramine, produce a desensitization of 
hypothalamic 5-HT1A receptors. These results suggest that the desensitization of 
hypothalamic 5-HT1A receptors is selectively induced by inhibition of 5-HT uptake but 
not by inhibition of norepinephrine uptake. Other studies agree with these observations. 
For example, Lesch and co-investigators (1991; 199lc) observed that long-term 
treatment with fluoxetine decreases the ACTH response to ipsapirone in patients with 
obsessive-compulsive disorder, while a tricyclic antidepressant, amitriptyline, did not 
change the ACTH response to ipsapirone in depressed patients. 
In contrast with the differential effect of fluoxetine and desipramine on the 
hypothalamic 5-HT1A receptors, both fluoxetine and desipramine potentiated the 
hormone responses to the 5-HT2 agonists DOI and MK-212 (Li et al.1993a). 
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Fluoxetine increased the density of the high affinity state 5-HT2A12c receptors in the 
hypothalamus (Li et al.1993a and our unpublished data). These observations are 
consistent with results from other studies (Li et al.1993a; Hulihan-Giblin et al.1994; 
Cadogan et al.1993; Hrdina and Vu, 1993) and suggest that both 5-HT uptake inhibitors 
and tricyclic antidepressants increase the function of 5-HT 2A 12c receptors in the 
hypothalamus, although the mechanism of the supersensitivity of 5-HT2A;2c receptors 
may be different between the two classes of antidepressants. The fact that both 5-HT 
uptake inhibitors and tricyclic antidepressants have similar therapeutic effects on 
depression suggests that the sensitization of 5-HT2A12c receptors may play a role in 
therapeutic effects of the antidepressants in the treatment of depression. 
Comparison of the Effects of Fluoxetine with Paroxetine on Hypothalamic 5-
HT lA Receptors 
To study whether the desensitization of hypothalamic 5-HT1A receptors, induced 
by repeated injections of fluoxetine, is due to blockade of 5-HT uptake sites, we 
compared the effects of fluoxetine with another 5-HT uptake inhibitor, paroxetine. 
Paroxetine has a chemical structure and pharmacokinetic profile that is different from 
fluoxetine. For example, fluoxetine has a long t112 and an active metabolite 
(norfluoxetine) which has a similar potency for 5-HT uptake sites and a longer half-life 
than fluoxetine. Paroxetine has more than 10-fold higher affinity for 5-HT uptake sites, 
a shorter half-life and no active metabolites. Also, due to difference in chemical 
structure, paroxetine and fluoxetine may have different side effects. For example, 
fluoxetine has about 20-fold higher affinity for 5-HT2A12c receptors than paroxetine, 
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while paroxetine has a much higher affinity for muscarinic receptors than fluoxetine 
(Stanford, 1996). On the other hand, both fluoxetine and paroxetine share similar 
effects in inhibiting 5-HT uptake sites. Therefore, if both fluoxetine and paroxetine 
produce a desensitization of 5-HT1A receptors, then this desensitization most likely is 
mediated by the blockade of 5-HT uptake sites. As was shown in Chapter V and VI, 
both fluoxetine and paroxetine reduced the neuroendocrine responses to 8-0H-DPAT 
and the level of Gi3 proteins in the hypothalamus, but did not alter the density of 5-HT1A 
receptors. These results suggest that the desensitization of hypothalamic 5-HT lA 
receptors is mediated by the blockade of 5-HT uptake sites. Furthermore, the 
desensitization of hypothalamic 5-HT1A receptors is not due to receptor down-
regulation, but may partly be mediated by a reduction in the hypothalamic level of Gi3 
proteins. 
The effects of fluoxetine and paroxetine on the levels of Gi and G0 proteins are 
not similar. Overall, repeated injections of paroxetine produce a greater and earlier 
reduction in the hypothalamic levels of Gi proteins, especially the levels of Gil and Gi2 
proteins, than that seen with fluoxetine. So far, there is no explanation for the 
differential effects on the levels of Gi and G0 proteins between fluoxetine and 
paroxetine. It is possible that paroxetine reduces the levels of Gi and G0 proteins not 
only because of blockade of 5-HT uptake sites, but also via stimulation of other 
receptors, such as muscarinic receptors, for which paroxetine has a higher affinity than 
fluoxetine (Stanford, 1996). 5-HT1A agonists induce a faster desensitization of 5-HT1A 
receptors than 5-HT uptake inhibitors (De V ry, 1995). If this is the case for muscarinic 
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agonists and if paroxetine acts as an agonist, then the stimulation of muscarinic 
receptors may explain the earlier effects of paroxetine on the levels of some G proteins. 
However, too little information is available on the regulation of the level of G proteins, 
and future studies are needed to clear this issue. 
Fluoxetine and paroxetine are used to treat depressed patients. The efficacy of 
the antidepressants is similar. However, paroxetine appears to have an earlier onset of 
therapeutic effect on depression than fluoxetine (Lane et al.1995; Nemeroff, 1993; 
Schone and Ludwig, 1993). This earlier onset of therapeutic effect is consistent with 
our observation that paroxetine induces an earlier reduction in the levels of G proteins. 
On the other hand, the side effects induced by fluoxetine or paroxetine are somewhat 
different. Sedation and nausea are common with paroxetine, while anxiety, agitation 
and insomnia are common with fluoxetine. Since paroxetine does not induce anxiety 
and agitation, fewer patients will drop out from the treatment. Although the mechanism 
for the difference between paroxetine and fluoxetine is still unknown, it is possible that 
the earlier onset of therapeutic effect and the fewer side effects of paroxetine are due 
to its higher selectivity for 5-HT uptake sites. 
Possible Mechanism for the Desensitization of Hypothalamic 5-HT tA Receptors 
In the present studies, we observed that repeated injections of 5-HT uptake 
inhibitors produce a delayed and gradual desensitization of hypothalamic 5-HT1A 
receptors as evidenced by a reduction in the neuroendocrine responses to 8-0H-DPAT. 
The mechanism for the desensitization is still unknown. Most evidence has shown that 
5-HT1A receptors are coupled to Gi or G0 proteins, which inhibit adenylyl cyclase, close 
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ca++ channels and open K+ channels. Therefore, any changes in the 5-HT1A receptors, 
Gi proteins and adenylyl cyclase could alter the overall function of 5-HT1A receptors. 
Few studies have investigated the regulation of hypothalamic 5-HT1A receptors. 
Newman et al. (1992) observed that repeated injections of fluoxetine for 3 weeks reduce 
the inhibitory effect of 5-HT on forskolin-stimulated adenylyl cyclase in the 
hippocampus, suggesting that chronic fluoxetine-induced desensitization could be 
mediated by changes at the receptor level, signal transduction system of 5-HT1A 
receptors, or the second messenger, adenylyl cyclase. It can be ruled out that a down-
regulation of the hypothalamic 5-HT1A receptors is involved in their desensitization, 
because the density of 5-HT1A receptors in the hypothalamus and other brain regions 
was not altered by repeated injections of either fluoxetine or paroxetine. Also, a lack 
of change in the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding suggests that 
the desensitization of 5-HT1A receptors is not due to a decrease in the ability of 5-HT1A 
receptors to couple to their G proteins. However, it is still possible that the coupling 
of 5-HT1A receptors to the G proteins that link to the release of hormones is decreased 
in living cells. There is differential affinity of 5-HT1A receptor coupling to G proteins 
(Gi3 > Gi1 > Gi2 > G0 proteins) (Mulheron et al.1994; Raymond et al.1993). 
Therefore, a reduction in the level of Gi3 proteins could alter the proportion of G 
proteins that are coupled to 5-HT1A receptors. This change can not be determined by 
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding, while it can result in a 
reduction of the function of 5-HT1A receptors. Few studies have reported on the effect 
of 5-HT uptake inhibitors on levels of G proteins that are coupled to 5-HT1A receptors. 
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Results of the present studies suggest that the decrease in the level of Gi3 proteins may 
play a role in the desensitization of the hypothalamic 5-HT1A receptors. However, since 
it is still unknown whether Gi3 proteins mediate 5-HT1A receptor-induced secretions of 
ACTH, corticosterone and oxytocin, it seems too early to conclude that the reduction 
in the level of Gi3 proteins mediates the desensitization of 5-HT 1A receptors. 
Another possible mechanism for the desensitization of the hypothalamic 5-HT1A 
receptors is their phosphorylation. Supersensitivity of 5-HT2A receptors induced by 
repeated injections of 5-HT uptake inhibitors could be a cause of desensitization of 5-
HT1A receptors. Increasing of the activity of 5-HT2A receptors will stimulate protein 
kinase C, which in tum can phosphorylate 5-HT1A receptors. 5-HT1A receptors contain 
at least three potential sites for phosphorylation by protein kinase C (Raymond et 
al.1992). Phosphorylation of 5-HT1A receptors induces a desensitization of the 5-HT1A 
receptors (Harrington et al.1994; Nebigil et al.1995; Raymond and Olsen, 1994; van 
Huizen et al.1993; Raymond, 1991). It has been reported that 5-HT1A agonist-induced 
desensitization of 5-HT1A receptors in HeLa cells can be mimicked by a protein kinase 
C activator and by forskolin, which activates adenyly 1 cyclase and consequently 
activates protein kinase A. The desensitization of 5-HT1A receptors induced by 8-0H-
DP AT can be blocked by inhibitors of protein kinase C, suggesting that protein kinase 
C can be involved in the desensitization of 5-HT1A receptors (Harrington et al.1994). 
This result is consistent with some studies (Raymond and Olsen, 1994; Raymond, 
1991), while yet other studies suggest that the phosphorylation of 5-HT1A receptors 
might be mediated by another G-protein-activated protein kinase, but not by protein 
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kinase C (Nebigil et al.1995; van Huizen et al.1993). All these data suggest that 5-
HT IA receptors can be phosphorylated and consequently be desensitized, although it is 
still unknown whether phosphorylation of 5-HT1A receptors alters their binding of 
agonists or their coupling to G proteins. However, it should be noted that most of 
these studies were performed in cells expressing cloned 5-HT IA receptors. To date, no 
data are available regarding the effect of 5-HT uptake inhibitors on the phosphorylation 
of 5-HT1A receptors. 
G proteins function as a linkage between receptors and second messengers. 
Activation of receptors by agonists induces an exchange of GDP by GTP on the a 
subunits of G proteins, resulting in a dissociation of the ex subunits from the B'Y 
complex of the G proteins and the receptors. The a subunits of G proteins then 
activate or inhibit second messenger systems. On the other hand, the dissociation of 
a subunits from their B'Y complex activates the GTPase activity of a subunits of G 
proteins and hydrolyzes the GTP to GDP, resulting in a reduced ability of G" proteins 
to interact with adenylyl cyclase and recombination of a subunits with fi)' subunits. 
Therefore, if the GTPase activity were increased, the a subunits of G proteins would 
be inactivated faster and reduce the signal transduction of receptors. An in vitro study 
has recently reported that three regulators of G protein signaling (RGS), GAIP (G 
Alpha Interacting Protein), RGS4 and RGSlO, activate the GTPase activity of a 
subunits of Gi proteins, especially of Gi3 proteins (Berman et al.1996; Watson et 
al.1996; Koelle and Horvitz, 1996; Hunt et al.1996; De Vries et al.1995). RGS4 has 
been found in the rat brain (Watson et al. 1996). If the effect of RGS proteins on the 
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GTPase activity also occurs in vivo, it can be hypothesized that desensitization of 
hypothalamic 5-HT1A receptors, induced by repeated injections of 5-HT uptake 
inhibitors, may be due to an increase of RGS4, GRSlO or GAIP in the hypothalamus. 
The increase of RGS4 and/or GAIP results in an increase in the GTPase activity of a 
subunits of Gi proteins, and consequently, increases in hydrolysis of GTP and 
inactivation of Gai proteins. This rapid inactivation of a subunits of Gi proteins will 
decrease the function of the second messenger related to 5 -HT IA receptors. This 
hypothesis can account for the results of the present studies, i.e. that repeated injections 
of 5-HT uptake inhibitors decrease the function of the hypothalamic 5-HT1A receptors 
without changing the density of 5-HT1A receptors and the coupling of 5-HT1A receptors 
to their G proteins. However, it is still unknown whether repeated exposure to 5-HT 
uptake inhibitors alters the levels of RGS4, RGSlO and/or GAJP in the hypothalamus. 
This hypothesis is currently being investigated. 
It is also possible that the desensitization of 5-HT1A receptors results from an 
interaction between 5-HT1A receptors and other receptors. 5-HT1A receptors share Gi 
proteins with several other receptors, such as D2 dopamine receptors, GABAs receptors, 
M2 muscarinic receptors and µ opiate receptors (Odagaki and Fuxe, 1995; Innis and 
Aghajanian, 1987; Innis et al.1988). However, no evidence, so far, has shown that 5-
HT uptake inhibitors influence these receptors. 
Beside the mechanisms discussed above, other regulations of the G proteins and 
second messenger systems can also induce the desensitization of 5-HT1A receptors. For 
example, alterations in the linkage between G proteins that are coupled to 5-HT1A 
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receptors and adenylyl cyclase may change the function of 5-HT1A receptors. Since Gi 
proteins are negatively coupled to adenylyl cyclase, increases in the concentration of 
cAMP may eventually decrease the function of 5-HT1A receptors. So far, no study on 
the effect of 5-HT uptake inhibitors on palmitoylation of 5-HT1A receptors has been 
reported. 
Si1mificance of the Present Studies 
Results of the present studies indicate that repeated injections of 5-HT uptake 
inhibitors produce a delayed and gradual desensitization of the hypothalamic 5-HT1A 
receptors as examined by reduction in the hormone responses to S-HT1A agonists. This 
result is consistent with report by Lesch et al. (1991c), who found that long-term 
administration of fluoxetine reduces the ACTH response to ipsa.pirone in patients with 
obsessive compulsive disorder. These results support the hypothesis that repeated 
injections of 5-HT uptake inhibitors induce an adaptive change in postsynaptic 5-HT1A 
receptors, which may play a role in the therapeutic effects of 5-HT uptake inhibitors. 
Most 5-HT uptake inhibitors produce a desensitization of 5-HT1A receptors, 
while most tricyclic antidepressants desensitize B adrenergic receptors (Bourin and 
Baker, 1996). It is still unknown what is the significance of the desensitization of 
hypothalamic 5-HT1A receptors in terms of their therapeutic effects. One possibility is 
that the desensitization of hypothalamic 5-HT1A receptors could be related to the 
treatment of a subgroup of depressed patients, whose symptoms are due to impaired 
serotonergic neurotransmission. According to the "amine hypothesis" , depression can 
be initiated by impaired adrenergic and/or serotonergic systems. It is not surprising 
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that a subgroup of depressed patients who suffer from impaired serotonergic systems 
will be more responsive to 5-HT uptake inhibitors than those who have impaired 
adrenergic systems (Leonard, 1993; Asberg and Martensson, 1993). The 
desensitization of hypothalamic 5-HT1A receptors may be a benefit for this group of 
patients. In fact, fluoxetine has been used to treat melancholia, which does not respond 
to tricyclic antidepressants (Asberg and Martensson, 1993). File and her colleagues 
(1996; 1994) reported that 5-HT1A autoreceptors in the median raphe are involved in 
the anxiolytic effect of 5-HT1A agonists, while stimulation of postsynaptic 5-HT1A 
receptors in the dorsal hippocampus produces an anxiogenic effect. So far, no clinical 
evidence supports their observation. However, if these observations are also correct 
in human, then the desensitization of postsynaptic 5-HT1A receptors by 5-HT uptake 
inhibitors may be related to the antianxiety effects of SSRI's. 
Although SSRI' s and tricyclic antidepressants have similar efficacy for 
depression, SSRI's are also used to treat other affective disorders, such as obsessive 
compulsive disorder, premenstrual syndrome, and eating disorders. Tricyclic 
antidepressants are ineffective for these disorders. The desensit1zation of hypothalamic 
5-HT1A receptors may play a role in these specific applications. Recent evidence has 
suggested that SSRI's can be used to treat schizophrenia (Breier, 1995; Costall and 
Naylor, 1992). Since D2 dopamine receptors share Gi proteins with 5-HT1A receptors, 
the decrease in the Gi proteins induced by SSRI' s may be beneficial for the treatment 
of schizophrenia. 
Another possible beneficial effect of the desensitization of 5-HT IA receptors is 
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the development of tolerance for the side effects of SSRI's (De Vry, 1995). In general, 
both tricyclic antidepressants and SSRI's have similar therapeutic effects for depression 
(Owens, 1994; Harrison, 1994; Blier and de Montigny, 1994; Montgomery, 1994; 
Wong et al.1995). However, tricyclic antidepressants have severe side effects, such 
as tachycardia, hypertension and impairment of motor and cognitive functions. An 
overdose of tricyclic antidepressants can result in cardiovascular disorders and even 
death (Blier and de Montigny, 1994; Montgomery, 1994; Wong et al.1995; Leonard, 
1993). On the other hand, SSRI's have much fewer severe side effects and are better 
tolerated. This benefit makes SSRI's have a lower dropout rate than tricyclic 
antidepressants (Lane et al.1995; Gram, 1994). One could expect that the different 
effect of SSRI's and tricyclic antidepressants on hypothalamic 5-HT1A receptors may be 
involved in the differential side effects of these two classes of antidepressants (De Vry, 
1995). 
Although both 5-HT1A agonists and 5-HT uptake inhibitors induce a 
desensitization of 5-HT1A receptors, neither group of drugs decreases the density of 5-
HT1A receptors (De Vry, 1995; Chen et al.1995; Hensler et al.1991). This suggests 
that the regulation of 5-HT1A receptor systems is usually not at the receptor level. 
Tricyclic antidepressants increase G protein activation of adenylyl cyclase (Ozawa and 
Rasenick, 1989; Chen and Rasenick, 1995a; Ozawa et al. 1994), while repeated 
injections of 5-HT uptake inhibitors reduce the levels of Gi and G0 proteins in a region-
specific manner, suggesting that G proteins and signal transduction systems may be the 
target of antidepressants. Therefore, understanding the role of signal transduction 
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systems in the treatment of affective disorders will be beneficial for the development 
of new antidepressants (Broekkamp et al .1995). 
Limitation of the Present Studies 
Several limitations should be noted when interpreting the data in the present 
studies. First, the present studies were performed with normal male rats, in which 
neurotransmission may be different from that in depressed patients. Therefore, it is 
possible that desensitization of hypothalamic 5-HT1A receptors does not occur in 
depressed patients. However, Lesch et al (1991c) observed that long-term treatment 
of obsessive compulsive disorder patients with fluoxetine reduced the ACTH response 
to ipsapirone. Furthermore, the time-course of the desensitization of hypothalamic 5-
HT IA receptors may be different from the time-course of therapeutic effect in humans, 
especially since the pharmacokinetics of 5-HT uptake inhibitors in rats are different 
from those in humans. For example, the dose of fluoxetine used in rats was much 
higher than the dose used in humans, but the half-life of f111oxetine in rats is much 
shorter than the half-life in humans (1 day vs. 5 hours) (1990). 
In the present studies, hormone responses to 5-HTM agonists were used to 
examine the function of 5-HT IA receptors. The hormone challenge test has been used 
in both experimental animals and humans to study the function of 5-HT1A receptors. 
However, these hormone responses reflect mainly 5-HT1A receptors which control 
neurons in the parvocellular and magnocellular regions of the paraventricular nucleus 
of the hypothalamus. It is still unknown whether the changes in 5-HT1A receptors in 
the neuroendocrine cells can reflect changes in other neurons in the hypothalamus or 
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even in other brain regions. So far, only a few studies have reported on the effects of 
repeated exposure to 5-HT uptake inhibitors on the function of postsynaptic 5-HT1A 
receptors (Newman et al.1992; Hensler et al.1991). Since our data suggest that the 
effects of 5-HT uptake inhibitors on the levels of G proteins are region-specific, it is 
possible that the effects of 5-HT uptake inhibitors on the 5-HT1A receptor systems are 
also region-specific. 
Signal transduction of 5-HT1A receptors was evaluated in these studies by 
examining the levels of Gi and G0 proteins. The limitations of thjs approach are, first, 
that little is known about the specific Ga proteins that are involved in 5-HT1A receptor-
induced increases in the secretion of ACTH and oxytocin. Secondly, the reduction of 
the levels of G proteins is not necessarily related to the function of 5-HT1A receptors, 
since several receptors are coupled to the same G proteins. Therefore, better methods 
should be used to determine the signal transduction of 5-HT1A receptors, such as 
agonist-stimulated [35S]-GTP')"S [35S-guanosine-5 '-0-(thiotriphosphate)] binding and 
agonist-dependent photolabeling of G protein a subunits with [32P]GTP azidoanilide. 
Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding was used to examine 
the coupling of 5-HT1A receptors to the G proteins in the present studies. Gpp(NH)p 
is a non-hydrolyzable GTP analog, which exchanges with GDP a.nd binds to a subunits 
of G proteins when agonists bind to the receptors. The binding of Gpp(NH)p to the a 
subunits of G proteins will dissociate the G proteins from the receptors and tum the 
receptors from their high affinity state to the low affinity state. Therefore, in the 
presence of Gpp(NH)p, agonist-binding will be inhibited. In the case of 5-HT1A 
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receptors, Gpp(NH)p will inhibit 3H-8-0H-DPAT binding. The percent of the 
inhibition was used to represent the degree of 5-HT1A receptors which are coupled to 
G proteins. However, it should be noted that the assay was performed in vitro in a 
frozen brain slice and only 3H-8-0H-DPATwas incubated with the brain sections. This 
is different from the normal environment surrounding 5-HT IA receptors in living cells. 
Therefore, the degree of Gpp(NH)p-induced inhibition of 3H-8-0H-DP AT binding can 
only reflect the steady-state coupling of 5-HT1A receptors to G proteins. In other 
words, Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding is more dependent on 
the ability of 5-HT1A receptors to couple to their G proteins than on the condition of 
these G proteins. For example, the degree of Gpp(NH)p-induced inhibition of 3H-8-
0H-DPAT binding may not reflect changes in the levels of Gprote:ins, but may indicate 
the ability of 5-HT1A receptors to couple to their G proteins. Therefore, a lack of 
change in the percentage of Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT binding 
suggests that fluoxetine does not alter the ability of 5-HT1A receptors to couple to their 
G proteins. 
Conclusions 
The present results suggest that prolonged blockade of 5-HT uptake sites 
produces a delayed and gradual desensitization of the hypothalamic 5-HT IA receptors. 
This desensitization is not due to a decrease in the density of S-HT1A receptors in the 
hypothalamus because no change in the density of 5-HT1A receptors has been detected 
after repeated injections of either fluoxetine or paroxetine. Farthermore, a lack of 
changes in the Gpp(NH)p-induced inhibition of 3H-8-0H-DPAT bjnding suggests that 
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the coupling of 5-HT lA receptors to G proteins is not altered by repeated injections of 
the 5-HT uptake inhibitors. However, it is possible that blockade of 5-HT uptake sites 
changes the proportion of different types of G proteins that are coupled to 5-HT1A 
receptors due to a reduction in the levels of one or two of the G proteins, resulting in 
changes in the function of 5-HT1A receptors. It has been shown that one receptor can 
couple to several types of G proteins with various affinities (Mons and Cooper, 1995; 
Rudolph et al.1996; Yung et al.1995; Kozasa and Gilman, 1995; Chan et al.1995). 
The differential coupling to G proteins can alter the efficacy of the receptor in terms 
of its function. This could be due to a different linkage between G proteins and second 
messengers. For example, Gz proteins produce more potent inhibition of type V 
adenylyl cyclase than Gi1 proteins (Kozasa and Gilman, 1995). Another possible reason 
for the alteration of efficacy is that the rate of dissociation of G proteins and receptors 
is different between the G protein subtypes (Kozasa and Gilman, 1995). In the present 
studies, we demonstrated that blockade of 5-HT uptake sites reduces the hypothalamic 
levels of Gil and Gi3 proteins, but not Gi2 proteins. Since Gi1 and Gi3 proteins have a 
higher affinity for 5-HT1A receptors than Gi2 and G0 proteins (Raymond et al.1993), one 
can expect that Gi1 and Gi3 proteins are the majority of G pmteins coupled to the 5-
HT 1A receptors in the normal condition. When the levels of Gi1 and Gi3 proteins are 
reduced, the ratio of Gi1, Gi2, Gi3 and G0 proteins coupled to j-HT1A receptors may be 
changed. This would result in an alteration in the linkage 10 second messengers or a 
reduction in the efficacy, and subsequently a decrease in the function of 5-HT1A 
receptors. The results in the present studies suggest that a reduction in the 
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hypothalamic level of Gi3 proteins may be involved in the desensitization of 5-HT1A 
receptors, because there is a similarity of the time courses in reducing the hypothalamic 
level of Gi3 proteins and the hormone responses to 5-HT11~. agonists after repeated 
injections of fluoxetine and paroxetine. 
In conclusion, the results of the present studies support our hypothesis that 
repeated injections of 5-HT uptake inhibitors produce a delayed and gradual 
desensitization of hypothalamic 5-HT lA receptors. The mechanism of the desensitization 
of hypothalamic 5-HT1A receptors may be related to a reduction in the hypothalamic 
level of Gi3 proteins. 
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